
<html lang="en"     class="pb-page"  data-request-id="84335f75-64a6-407d-96de-e58bc62f8cb7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b00447;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-14;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine" /></meta><meta name="dc.Creator" content="Reggie  Bosma" /></meta><meta name="dc.Creator" content="Zhiyong  Wang" /></meta><meta name="dc.Creator" content="Albert J.  Kooistra" /></meta><meta name="dc.Creator" content="Nick  Bushby" /></meta><meta name="dc.Creator" content="Sebastiaan  Kuhne" /></meta><meta name="dc.Creator" content="Jelle  van den Bor" /></meta><meta name="dc.Creator" content="Michael J.  Waring" /></meta><meta name="dc.Creator" content="Chris  de Graaf" /></meta><meta name="dc.Creator" content="Iwan J.  de Esch" /></meta><meta name="dc.Creator" content="Henry&#xA;F.  Vischer" /></meta><meta name="dc.Creator" content="Robert J.  Sheppard" /></meta><meta name="dc.Creator" content="Maikel  Wijtmans" /></meta><meta name="dc.Creator" content="Rob  Leurs" /></meta><meta name="dc.Description" content="Drug–target binding kinetics are an important predictor of in vivo drug efficacy, yet the relationship between ligand structures and their binding kinetics is often poorly understood. We show that ..." /></meta><meta name="Description" content="Drug–target binding kinetics are an important predictor of in vivo drug efficacy, yet the relationship between ligand structures and their binding kinetics is often poorly understood. We show that ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 20, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00447" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00447" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00447" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00447" /></link>
        
    
    

<title>Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00447" /></meta><meta property="og:title" content="Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0012.jpeg" /></meta><meta property="og:description" content="Drug–target binding kinetics are an important predictor of in vivo drug efficacy, yet the relationship between ligand structures and their binding kinetics is often poorly understood. We show that both rupatadine (1) and desloratadine (2) have a long residence time at the histamine H1 receptor (H1R). Through development of a [3H]levocetirizine radiolabel, we find that the residence time of 1 exceeds that of 2 more than 10-fold. This was further explored with 22 synthesized rupatadine and desloratadine analogues. Methylene-linked cycloaliphatic or β-branched substitutions of desloratadine increase the residence time at the H1R, conveying a longer duration of receptor antagonism. However, cycloaliphatic substituents directly attached to the piperidine amine (i.e., lacking the spacer) have decreased binding affinity and residence time compared to their methylene-linked structural analogues. Guided by docking studies, steric constraints within the binding pocket are hypothesized to explain the observed differences in affinity and binding kinetics between analogues." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00447"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00447">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00447&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00447&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00447&amp;href=/doi/10.1021/acs.jmedchem.9b00447" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6630-6644</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00454" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00537" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Route to Prolonged Residence Time at the Histamine H<sub>1</sub> Receptor: Growing from Desloratadine to Rupatadine</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Reggie Bosma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Reggie Bosma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Reggie++Bosma">Reggie Bosma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiyong Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyong++Wang">Zhiyong Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Albert J. Kooistra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Albert J. Kooistra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Albert+J.++Kooistra">Albert J. Kooistra</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5514-6021" title="Orcid link">http://orcid.org/0000-0001-5514-6021</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nick Bushby</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nick Bushby</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Operations, BioPharmaceuticals R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nick++Bushby">Nick Bushby</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sebastiaan Kuhne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sebastiaan Kuhne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sebastiaan++Kuhne">Sebastiaan Kuhne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jelle van den Bor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jelle van den Bor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jelle++van+den+Bor">Jelle van den Bor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael J. Waring</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael J. Waring</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Waring">Michael J. Waring</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9110-8783" title="Orcid link">http://orcid.org/0000-0002-9110-8783</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chris de Graaf</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chris de Graaf</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chris++de+Graaf">Chris de Graaf</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1226-2150" title="Orcid link">http://orcid.org/0000-0002-1226-2150</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Iwan J. de Esch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Iwan J. de Esch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Iwan+J.++de+Esch">Iwan J. de Esch</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Henry F. Vischer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Henry F. Vischer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Henry%0AF.++Vischer">Henry F. Vischer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0184-6337" title="Orcid link">http://orcid.org/0000-0002-0184-6337</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert J. Sheppard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert J. Sheppard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+J.++Sheppard">Robert J. Sheppard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maikel Wijtmans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maikel Wijtmans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maikel++Wijtmans">Maikel Wijtmans</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8955-8016" title="Orcid link">http://orcid.org/0000-0001-8955-8016</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rob Leurs</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rob Leurs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Amsterdam Institute for Molecules, Medicines and Systems, Division of Medicinal Chemistry, Faculty of Science, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#0f7d21636a7a7d7c4f797a216163"><span class="__cf_email__" data-cfemail="9defb3f1f8e8efeeddebe8b3f3f1">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rob++Leurs">Rob Leurs</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1354-2848" title="Orcid link">http://orcid.org/0000-0003-1354-2848</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00447&amp;href=/doi/10.1021%2Facs.jmedchem.9b00447" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6630–6644</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 20, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 March 2019</li><li><span class="item_label"><b>Published</b> online</span>20 June 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00447" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00447</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by-nc text">with CC-BY-NC-ND<a href="/page/policy/authorchoice_ccbyncnd_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00447"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3161</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00447" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Route to Prolonged Residence Time at the Histamine H1 Receptor: Growing from Desloratadine to Rupatadine&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Reggie&quot;,&quot;last_name&quot;:&quot;Bosma&quot;},{&quot;first_name&quot;:&quot;Zhiyong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;J. Kooistra&quot;},{&quot;first_name&quot;:&quot;Nick&quot;,&quot;last_name&quot;:&quot;Bushby&quot;},{&quot;first_name&quot;:&quot;Sebastiaan&quot;,&quot;last_name&quot;:&quot;Kuhne&quot;},{&quot;first_name&quot;:&quot;Jelle&quot;,&quot;last_name&quot;:&quot;van den Bor&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Waring&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;de Graaf&quot;},{&quot;first_name&quot;:&quot;Iwan&quot;,&quot;last_name&quot;:&quot;J. de Esch&quot;},{&quot;first_name&quot;:&quot;Henry\nF.&quot;,&quot;last_name&quot;:&quot;Vischer&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;J. Sheppard&quot;},{&quot;first_name&quot;:&quot;Maikel&quot;,&quot;last_name&quot;:&quot;Wijtmans&quot;},{&quot;first_name&quot;:&quot;Rob&quot;,&quot;last_name&quot;:&quot;Leurs&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6630-6644&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00447&quot;},&quot;abstract&quot;:&quot;Drug–target binding kinetics are an important predictor of in vivo drug efficacy, yet the relationship between ligand structures and their binding kinetics is often poorly understood. We show that both rupatadine (1) and desloratadine (2) have a long residence time at the histamine H1 receptor (H1R). Through development of a [3H]levocetirizine radiolabel, we find that the residence time of 1 exceeds that of 2 more than 10-fold. This was further explored with 22 synthesized rupatadine and desloratadine analogues. Methylene-linked cycloaliphatic or β-branched substitutions of desloratadine increase the residence time at the H1R, conveying a longer duration of receptor antagonism. However, cycloaliphatic substituents directly attached to the piperidine amine (i.e., lacking the spacer) have decreased binding affinity and residence time compared to their methylene-linked structural analogues. Guided by docking studies, steric constraints within the binding pocket are hypothesized to explain the observed difference&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00447&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00447" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00447&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00447" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00447&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00447" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00447&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00447&amp;href=/doi/10.1021/acs.jmedchem.9b00447" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00447" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00447" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00447%26sid%3Dliteratum%253Aachs%26pmid%3D31274307%26genre%3Darticle%26aulast%3DBosma%26date%3D2019%26atitle%3DRoute%2Bto%2BProlonged%2BResidence%2BTime%2Bat%2Bthe%2BHistamine%2BH1%2BReceptor%253A%2BGrowing%2Bfrom%2BDesloratadine%2Bto%2BRupatadine%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D14%26spage%3D6630%26epage%3D6644%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=290905" title="Kinetics">Kinetics</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/jmcmar.2019.62.issue-14/20190725/jmcmar.2019.62.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Drug–target binding kinetics are an important predictor of in vivo drug efficacy, yet the relationship between ligand structures and their binding kinetics is often poorly understood. We show that both rupatadine (<b>1</b>) and desloratadine (<b>2</b>) have a long residence time at the histamine H<sub>1</sub> receptor (H<sub>1</sub>R). Through development of a [<sup>3</sup>H]levocetirizine radiolabel, we find that the residence time of <b>1</b> exceeds that of <b>2</b> more than 10-fold. This was further explored with 22 synthesized rupatadine and desloratadine analogues. Methylene-linked cycloaliphatic or β-branched substitutions of desloratadine increase the residence time at the H<sub>1</sub>R, conveying a longer duration of receptor antagonism. However, cycloaliphatic substituents directly attached to the piperidine amine (i.e., lacking the spacer) have decreased binding affinity and residence time compared to their methylene-linked structural analogues. Guided by docking studies, steric constraints within the binding pocket are hypothesized to explain the observed differences in affinity and binding kinetics between analogues.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drugs have to bind a therapeutically relevant target to exhibit a biological effect and, as such, target binding is well characterized during the development process of many drugs. The binding affinity is an often-used parameter to measure drug binding to a target (quantified as <i>K</i><sub>D</sub> or <i>K</i><sub>i</sub> values), implicitly assuming ligand binding occurs under equilibrium conditions. However, drug pharmacodynamics can also be characterized by the drug–target binding kinetics, which provide important details about the mechanism of target binding, unexplained by solely the binding affinity.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> The drug–target residence time, which is a measure for the lifetime of a drug–target complex, is currently discussed as one of the important contributors to the biological efficacy of drugs in vivo.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10">(3−10)</a> It has been postulated that a suitably long drug–target residence time might increase the therapeutic window in vivo when clearance of the drug is faster than the dissociation of the drug from the receptor.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> In such cases, drug action would last longer than the presence of free drug plasma concentrations (i.e., hysteresis). Thus, duration of therapeutic action may not only depend on drug absorption, distribution, metabolism, and excretion (and the nature of its metabolites), but can also be a direct effect of prolonged target binding.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a></div><div class="NLM_p">As the target of 33% of all small-molecule drugs, G protein-coupled receptors (GPCRs) are an important class of proteins in drug discovery.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The histamine H<sub>1</sub> receptor (H<sub>1</sub>R) is an archetypical GPCR and is successfully targeted by antagonists for the treatment of, for example, allergic disorders.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> A long duration of action has been observed in vivo for second-generation H<sub>1</sub>R antagonists like levocetirizine and fexofenadine, which have a long residence time at the H<sub>1</sub>R.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Hysteresis was indeed observed for levocetirizine and fexofenadine.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> A strong hysteresis of H<sub>1</sub>R antagonism has also been shown for rupatadine (<b>1</b>), which antagonizes the histamine-induced flare response up to 72 h after oral administration, whereas plasma levels could only be detected up to 12 h after administration.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This might be explained by the metabolism of rupatadine to metabolites such as desloratadine (<b>2</b>), which is a known antihistamine itself with a long H<sub>1</sub>R residence time (>1 h) and a long plasma half-life in vivo (human).<a onclick="showRef(event, 'ref19 ref21 ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref19 ref21 ref22 ref23 ref24 ref25 ref26 ref27">(19,21−27)</a> Yet, a potentially long drug–target residence time of rupatadine may also be a crucial contributing factor to its observed long duration of action.</div><div class="NLM_p last">Here, we report the measurement of the residence times of rupatadine and desloratadine at the H<sub>1</sub>R. It was shown that rupatadine has a ≥10-fold longer residence time at the H<sub>1</sub>R, relative to desloratadine. As a consequence, rupatadine completely antagonized the histamine-induced calcium mobilization in HeLa cells for >2 h after removal of unbound antagonist, whereas inspected under the same conditions, desloratadine allowed a time-dependent gradual recovery of the histamine-induced response. To understand the structure–kinetics relationship (SKR) for rupatadine and desloratadine in more detail, the binding kinetics at the H<sub>1</sub>R were characterized for newly synthesized analogues (<b>3</b>–<b>24</b>) that retain the core scaffold of <b>1</b> and <b>2</b> but contain a diverse set of aromatic and aliphatic N-substituents on the piperidine ring. It was shown that relatively small aliphatic N-substitutions were sufficient for a prolonged H<sub>1</sub>R residence time compared to desloratadine, unless this was negated by steric interference in the binding pocket.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Binding Properties of Rupatadine and Desloratadine at the H<sub>1</sub>R</h3><div class="NLM_p">Based on the long duration of action of rupatadine in vivo,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> we hypothesized that it would exhibit a long residence time at the H<sub>1</sub>R. Therefore, binding of rupatadine and its structural analogue desloratadine to the human H<sub>1</sub>R was investigated, initially using [<sup>3</sup>H]mepyramine and standardized competition binding experiments.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The H<sub>1</sub>R binding affinity of desloratadine (p<i>K</i><sub>i</sub> 9.1 ± 0.1) determined in these experiments was consistent with previously reported affinity values (p<i>K</i><sub>i</sub> = 8.8–10<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a>). Rupatadine (p<i>K</i><sub>i</sub> 8.4 ± 0.1) was shown to have a 5-fold lower binding affinity for the H<sub>1</sub>R than desloratadine. To the best of our knowledge, the binding affinity of rupatadine on the human H<sub>1</sub>R has not been reported in the literature. Its H<sub>1</sub>R activity on guinea pig ileum is known, as well as that for a series of derivatives.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Competitive association experiments were subsequently performed to examine the binding kinetics of rupatadine and desloratadine at the H<sub>1</sub>R. Initially, [<sup>3</sup>H]mepyramine was selected as radioligand and experiments were performed at 25 °C with an 80 min incubation time, in the manner described previously.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> A clear initial overshoot in [<sup>3</sup>H]mepyramine binding was observed for both unlabeled ligands (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), which is indicative of the long residence times of the unlabeled ligands relative to [<sup>3</sup>H]mepyramine.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> However, since the binding curves of rupatadine and desloratadine showed similar overshoot patterns, it was difficult to discern differences in their binding kinetics using the Motulsky–Mahan analysis.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Desloratadine was found to have a residence time of 190 ± 40 min (similar to that reported in the literature<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a>), but for rupatadine, the <i>k</i><sub>off</sub> value (and thus the residence time) could not be accurately constrained by the model. To overcome this limitation, it was speculated that the residence times of desloratadine and rupatadine at the H<sub>1</sub>R might be better discriminated using a radioligand with a longer residence time, and one more closely matched to desloratadine and rupatadine than mepyramine.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(31)</a> With this in mind, levocetirizine was considered a better alternative as it is known to have a 100-fold longer residence time at the H<sub>1</sub>R than mepyramine.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Radiolabeled levocetirizine has previously been disclosed but without synthetic details for its preparation.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The radiolabel was prepared by us using a six-step sequence progressing through intermediates <b>25</b>–<b>28</b>. Separation of the enantiomers of <b>28</b>, followed by Pd-catalyzed dehalotritiation of the corresponding aryl iodide delivered the ligand with a specific activity of 956 GBq mmol<sup>–1</sup> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of [<sup><b>3</b></sup>H]Levocetirizine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Key: (a) Et<sub>2</sub>O, 0 °C to room temperature (rt), 16 h, 88 %; (b) SOCl<sub>2</sub>, dichloromethane (DCM), rt, 20 h, 95 %; (c) 2-(piperazin-1-yl)ethanol, PhMe, 80 °C, 20 h, 21 %; (d) (1) KOH, dimethylformamide (DMF), 0 °C, 90 min; (2) sodium 2-chloroacetate, DMF, 0 °C, 3 h, 57 %; (e) chiral separation; (f) T<sub>2</sub>, Pd/C (10 %), Et<sub>3</sub>N, EtOH.</p></p></figure><div class="NLM_p last">[<sup>3</sup>H]Levocetirizine was then employed in competitive association experiments to characterize the binding kinetics of rupatadine and desloratadine using an incubation time of 6 h (to ensure a steady state in [<sup>3</sup>H]levocetirizine binding). In the presence of desloratadine, [<sup>3</sup>H]levocetirizine binding to the H<sub>1</sub>R increased gradually over time, whereas in the presence of rupatadine, a clear initial overshoot in [<sup>3</sup>H]levocetirizine binding was observed (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Based on these curve shapes, it is clear that rupatadine has a longer residence time on the H<sub>1</sub>R than desloratadine. Fitting the data to the Motulsky–Mahan model<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> did not result in a precise fit of the <i>k</i><sub>off</sub> values, but indicated the <i>k</i><sub>off</sub> of desloratadine at the H<sub>1</sub>R to be >0.03 min<sup>–1</sup> (<i>P</i> = 95% in all three experiments) corresponding to a residence time of <33 min. In the case of rupatadine, the <i>k</i><sub>off</sub> value at the H<sub>1</sub>R is <0.0033 min<sup>–1</sup> (<i>P</i> = 95% in all three experiments), which corresponds to a residence time of >300 min. Thus, rupatadine has a very long residence time at the H<sub>1</sub>R, which is at least 10-fold longer than that observed for desloratadine.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design and Synthesis of Rupatadine Analogues at the H<sub>1</sub>R</h3><div class="NLM_p">To identify the structural features that drive the longer residence time of rupatadine compared to desloratadine at the H<sub>1</sub>R, various analogues were synthesized and pharmacologically characterized.</div><div class="NLM_p">Rupatadine contains a 5-methylpyridin-3-yl group connected through a methylene to the basic amine of desloratadine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). To study the SKR, we synthesized analogues with the methyl group on different positions of the pyridine ring (<b>3</b>–<b>5</b>), and the pyridine analogue without the methyl group (<b>6</b>). Two positional isomers of <b>6</b> (<b>7</b>, <b>8</b>) and two pyrimidines (<b>9</b>–<b>10</b>) were also prepared. Additionally, the pyridine ring of rupatadine was replaced by a phenyl ring with (<b>11</b>), or without (<b>12</b>), a 3-methyl group. Finally, to gradually bridge the transition to <b>2</b>, a set of analogues was synthesized, in which the basic amine of desloratadine was substituted with a range of alkyl groups (<b>13</b>–<b>24</b>), varying in size, level of constrainment, and point of attachment (with or without the one-carbon spacer). Of these, only <b>3</b>–<b>8</b>, <b>12</b>, <b>23</b>, and <b>24</b> have been reported before.<a onclick="showRef(event, 'ref28 ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref28 ref31 ref32 ref33 ref34">(28,32−35)</a></div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the investigated H<sub>1</sub>R antagonists and synthesized structural analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All rupatidine analogues were efficiently obtained in one step from commercially available desloratidine (<b>2</b>), as depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Compounds <b>4</b>–<b>8</b>, <b>11</b>–<b>12</b>, and <b>16</b> were obtained via nucleophilic substitution of the corresponding alkyl bromides in moderate to good yields (36–86%). Reductive alkylation of <b>2</b> with different aromatic aldehydes afforded <b>3</b>, <b>9</b>, and <b>10</b> (64–88% yield). Compounds <b>13</b>–<b>15</b>, <b>17</b>–<b>20</b>, <b>22</b>, and <b>23</b> were synthesized by reductive alkylation using aliphatic carbonyl compounds in acceptable to good yields (52–71%). Methyl derivative <b>24</b> was obtained as the fumarate salt from aqueous (aq) formaldehyde and NaBH(OAc)<sub>3</sub> in 60% yield. Attempted synthesis of cyclopropyl-substituted analogue <b>21</b> via alkylation of <b>2</b> with cyclopropylbromide failed. However, reductive alkylation of <b>2</b> with (1-ethoxycyclopropoxy)triethylsilane delivered the desired product, albeit in low isolated yield (17%).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(36)</a></div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Rupatadine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Key: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 18 h, 36–86%; (b) NaHB(OAc)<sub>3</sub>, dichloroethane (DCE), rt, 14 h, 64–88%; (c) NaHB(OAc)<sub>3</sub>, DCE, rt, 14 h, 52–71%; (d) NaHB(OAc)<sub>3</sub>, MeOH, DCM, AcOH, rt, 1.5 h, 60% as fumarate salt; (e) NaHB(OAc)<sub>3</sub>, AcOH, DCM, rt, 48 h, 17%.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Pharmacological Characterization</h3><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> H<sub>1</sub>R Binding Affinity</h4><div class="NLM_p last">All rupatadine analogues containing an aromatic group (<b>3</b>–<b>12</b>) had comparable binding affinities at the H<sub>1</sub>R (p<i>K</i><sub>i</sub> 7.9–8.5) as rupatadine, which were 4–16-fold lower than the binding affinity of desloratadine (p<i>K</i><sub>i</sub> = 9.1). Substituting the benzene of <b>12</b> for a cyclohexane (<b>13</b>) did not affect the binding affinity (<2-fold). However, substituting the benzene of <b>12</b> for smaller methylene-linked cycloaliphatic N substituents (<b>14</b>, <b>16</b>, and <b>17</b>) resulted in 2–6-fold higher binding affinities at the H<sub>1</sub>R, similar to the binding affinity of desloratadine. Likewise, analogues <b>22</b>–<b>24</b> with small acyclic aliphatic substituents had a high binding affinity at the H<sub>1</sub>R as well (p<i>K</i><sub>i</sub> 9.0–9.4), again similar to that of desloratadine (p<i>K</i><sub>i</sub> 9.1). Interestingly, the one-carbon linker between the basic amine and the cyclic aliphatic substituents of <b>13</b>, <b>14</b>, <b>16</b>, and <b>17</b> is important for a high-affinity binding, since a 2–8-fold reduced binding affinity is observed for analogues that lack this spacer (<b>18</b>–<b>21</b>, respectively).</div></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Analysis of Binding Kinetics</h4><div class="NLM_p">To explore the relative residence time of all analogues, a dual-point competition association was performed to determine the kinetic rate index (KRI).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This methodology is based on the initial overshoot in radioligand binding when co-incubated with an unlabeled ligand, which is an indicator of a relatively long residence time of the unlabeled ligand compared to that of the radioligand (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The overshoot is quantified by measuring the radioligand binding at two time points. The ratio in [<sup>3</sup>H]levocetirizine binding at both time points (1 and 6 h) is >1 for unlabeled ligands that cause an initial overshoot in [<sup>3</sup>H]levocetirizine binding and hence have a relatively long residence time compared to [<sup>3</sup>H]levocetirizine. Using this assay setup, a KRI value of 0.9 ± 0.1 was obtained for unlabeled levocetirizine, demonstrating that, as expected, it has a residence time essentially the same as the radioligand. Desloratadine does not cause an initial overshoot in [<sup>3</sup>H]levocetirizine binding (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) and has a KRI value of 0.82 ± 0.04. In contrast, rupatadine binds the H<sub>1</sub>R with a much longer residence time (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), which is indeed reflected by its KRI value of 2.3 ± 0.2 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The KRI values for all analogues are given in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. All analogues with an aromatic substituent (<b>3–12</b>) show KRI values >1, indicative of a consistently long residence time at the H<sub>1</sub>R (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). More notably, among the analogues with aliphatic substitutions on the piperidine ring (<b>1</b>, <b>2</b>, <b>13</b>–<b>24</b>), large differences in the KRI values were observed (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This intriguing SKR in the aliphatic series, in combination with the lack thereof in the aromatic series, led us to focus on the former series.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Radioligand association binding when co-incubated with rupatadine and desloratadine. A homogenate of HEK293T cells expressing the H<sub>1</sub>R was incubated with: (A) [<sup>3</sup>H]mepyramine (3.8 nM) alone, or in the presence of either rupatadine (130 nM) or desloratadine (4 nM) or (B) [<sup>3</sup>H]levocetirizine (6.6 nM) alone, or in the presence of either rupatadine (6 nM) or desloratadine (0.7 nM). Representative graphs of three experiments are shown depicting individual measurements with duplicate values per time point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Aliphatic substituents on the basic amine of desloratadine cause differential binding kinetics at the H<sub>1</sub>R. A homogenate of HEK293T cells expressing the H<sub>1</sub>R was incubated with [<sup>3</sup>H]levocetirizine and the respective ligands. Binding of [<sup>3</sup>H]levocetirizine was determined after 1 and 6 h, and the KRI value was determined as the ratio in [<sup>3</sup>H]levocetirizine binding at both time points (6/1 h). The bars depict the mean and SEM of ≥3 experiments. The top and bottom dotted lines represent the KRI of reference ligands 1 and 2, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. H<sub>1</sub>R Binding of Rupatadine and Desloratadine Analogues<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Fumarate salt.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Previously reported (see text for references).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Binding affinity (p<i>K</i><sub>i</sub>) values were determined by competition binding experiments using [<sup>3</sup>H]mepyramine, and KRI values were determined by dual-point competition association experiments using [<sup>3</sup>H]levocetirizine. Depicted values represent the mean ± standard error of the mean (SEM) of ≥3 experiments</p></div></div><div></div></div><div class="NLM_p last">Analogues with cycloaliphatic groups and a one-carbon spacer (<b>13</b>, <b>14</b>, <b>16</b>, and <b>17</b>) show high KRI values, also indicating a long residence time on the H<sub>1</sub>R. However, structural analogues with the same cycloaliphatic group without the one-carbon spacer (<b>18</b>–<b>21</b>) show similar KRI values to desloratadine, indicative of a shorter residence time at the H<sub>1</sub>R. Additionally, analogues with small acyclic aliphatic substituents (<b>22</b>–<b>24</b>) had an average KRI value slightly larger than 1, implying an increased residence time at the H<sub>1</sub>R compared to desloratadine. The correlation between affinity and residence time parameters of GPCR ligands and the physicochemical properties of the ligands has been investigated, including affinities for H<sub>1</sub>R receptor antagonists,<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(37,38)</a> by various research groups.<a onclick="showRef(event, 'ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45">(39−46)</a> Therefore, we investigated whether correlations exist between our p<i>K</i><sub>i</sub>/KRI values and key physicochemical parameters (log <i>D</i><sub>7.4</sub>, polar surface area, van der Waals volume, p<i>K</i><sub>a</sub> value of the conjugate acid of the piperidine nitrogen atom). However, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">Figure S1, Tables S1 and S2</a>, show that no strong correlations are evident.</div></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Duration of Functional H<sub>1</sub>R Antagonism</h4><div class="NLM_p">Since large differences were observed in the KRI values of the aliphatic rupatadine analogues, these differences were explored in more detail by measuring the kinetics of functional H<sub>1</sub>R antagonism following a preincubation with the selected analogues of interest. The functional recovery time (RecT) of the H<sub>1</sub>R was previously shown to be correlated with the residence time of antagonists.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(47)</a> As such, HeLa cells, with endogenous expression of the H<sub>1</sub>R, were preincubated with 10 times the <i>K</i><sub>i</sub> concentration of the respective compound. Unbound ligands were then depleted by washing the cells, which were subsequently stimulated after different incubation times with 10 μM histamine. The intracellular calcium mobilization following administration of histamine was determined with the calcium-sensitive fluorescent dye (Fluo4 NW).</div><div class="NLM_p">Preincubating HeLa cells with desloratadine, which has a low KRI value (<1), resulted in functional recovery of the H<sub>1</sub>R over time (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">Table S1</a>). However, cells pretreated with rupatadine were completely unresponsive to histamine, for at least 2 h after removing unbound rupatadine, suggesting very persistent target engagement by rupatadine. In <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B, the functional recovery of the H<sub>1</sub>R is compared after pretreating the cells with analogues containing cycloaliphatic N substituents on the piperidine with or without a one-carbon spacer. Analogues with a one-carbon spacer (<b>14</b>, <b>16</b>, and <b>17</b>) completely abolished the histamine-induced calcium response for at least 2 h, similarly to rupatadine. In contrast, and in line with the measured KRI values, removing the one-carbon spacer (<b>19</b>–<b>21</b>), allowed a relatively fast functional recovery of the histamine response.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Functional recovery of histamine-induced calcium mobilization after a preincubation with ligands that bind the H<sub>1</sub>R. HeLa cells were preincubated for 18–20 h with the respective H<sub>1</sub>R ligand, reaching stable and high (±90%) occupancy of the endogenously expressed H<sub>1</sub>R. The cells were then labeled with Fluo4 NW in the presence of the respective ligands for 1 h. All excess Fluo4 NW and unbound ligands were removed by wash steps and the cells were subsequently stimulated with histamine (10<sup>–5</sup> M) after different incubation times. Representative graphs of ≥3 experiments are shown, which depict the normalized calcium mobilization that was measured at each time point after washout. (A) Cells were preincubated with the reference H<sub>1</sub>R antagonists: rupatadine (1) and desloratadine (2). (B) Cells were preincubated with compounds having various cycloalkyl substituents on the basic amine with (<b>14</b>, <b>16</b>, <b>17</b>) or without (<b>19</b>, <b>20</b>, <b>21</b>) a one-carbon spacer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The differences in the combined kinetic/affinity binding profiles of the compounds were further explored on a structural level with docking studies. Using the X-ray crystal structure of the H<sub>1</sub>R with the structurally related ligand doxepin bound,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(48)</a> reference compounds desloratadine, rupatadine, as well as all analogues (<b>3</b>–<b>24</b>) were docked using PLANTS.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(49)</a><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> shows the postulated binding modes of desloratadine, rupatadine, and the representative pair <b>14</b>/<b>19</b>, in comparison to the binding mode of the co-crystallized ligand doxepin. Desloratadine likely adopts a similar binding pose to doxepin in the H<sub>1</sub>R crystal structure (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Rupatadine was also found to adopt a similar binding mode to doxepin, but its (5-methylpyridin-3-yl)methyl moiety targets an additional area of the H<sub>1</sub>R binding pocket toward the extracellular vestibule (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Since the available space in the H<sub>1</sub>R pocket next to the amine-binding region is limited by I454<sup>7.39</sup> and Y458<sup>7.43</sup>, it is postulated that the cyclopentyl substituent of <b>19</b> encounters greater steric hindrance than the cyclopentylmethyl substituent of <b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C), in line with the altered H<sub>1</sub>R binding characteristics of <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). This steric hindrance results in a tilted binding mode compared to desloratadine, which is not observed for optimal binding of analogues with a methylene spacer between the desloratadine scaffold and the cyclopentyl group (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). The spacer allows the aliphatic group to turn toward the extracellular vestibule (in the direction of H450<sup>7.35</sup>), where more room is available, possibly preventing a steric clash with I454<sup>7.39</sup> and Y458<sup>7.43</sup> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proposed binding modes of (A) desloratadine (yellow), (B) rupatadine (salmon), and (C, D) compound <b>19</b> (orange) in comparison to compound <b>14</b> (blue) based on docking<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(49)</a> into the crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE">3RZE</a><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(48)</a>) of the H<sub>1</sub>R in complex with doxepin [magenta; see (A)]. The clipped molecular surface of H<sub>1</sub>R highlights the limited space for growing from the amine of desloratadine due to I454<sup>7.39</sup> and Y458<sup>7.43</sup>. To highlight the fit of the substituents of rupatadine (<b>2</b>, B), <b>19</b> (C), and <b>14</b> (D) compared to desloratadine in the H<sub>1</sub>R binding pocket, they are shown as transparent surfaces.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03780" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03780" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A long drug–target residence time has been postulated to benefit the in vivo efficacy of several drugs for a broad number of drug targets, among which is the H<sub>1</sub>R.<a onclick="showRef(event, 'ref3 ref4 ref7 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref7 ref49 ref50">(3,4,7,50,51)</a> Affinity-based optimization of drug binding does not necessarily reflect differences in target residence time,<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(52,53)</a> and a discrepancy between affinity and residence time at the H<sub>1</sub>R was previously described. Moreover, in the case of ligands that do not reach a binding equilibrium within the time frame of a binding experiment, i.e., ligands with a very slow off rate like rupatadine, p<i>K</i><sub>i</sub> will be underestimated.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(54)</a> The drug–target residence time can therefore provide additional information for the optimization of drugs that would be lost by focusing on only the binding affinity. Since the residence time is not routinely incorporated in drug development, design strategies for optimizing the drug–target residence time of lead compounds are not widely available. Since rupatadine is shown here to have a much longer residence time at the H<sub>1</sub>R than its close structural analogue desloratadine, despite a reduced binding affinity, it provides an opportunity for a detailed investigation of the SKR for this GPCR. Toward this end, we synthesized [<sup>3</sup>H]levocetirizine, which proved to be a useful tool to map the differences in the KRIs between the two antihistamines. It was therefore employed to determine the relative residence times of structural analogues <b>3</b>–<b>24</b>. Several analogues of rupatadine were designed to replace the (5-methylpyridin-3-yl)methyl group with other aromatic moieties (<b>3</b>–<b>12</b>). Interestingly, the <i>K</i><sub>i</sub> values of <b>3</b>–<b>12</b> are within 4-fold of the <i>K</i><sub>i</sub> value of rupatadine. Additionally, all aromatic analogues have a long apparent residence time, as is reflected by the KRI > 1. Removing the aromatic character of the functional group of <b>12</b> by replacing it with a cyclohexyl group (<b>13</b>) does not affect the observed H<sub>1</sub>R binding properties either. Hence, the strong effect on the residence time by the (5-methylpyridin-3-yl)methyl group of rupatadine (compared to desloratadine) cannot be explained by the aromatic character, nor by the pyridine nitrogen atom and the methyl substituent.</div><div class="NLM_p">To further probe the SKR between rupatadine and desloratadine, a series of analogues were characterized that had different aliphatic substituents on the piperidine group (<b>13</b>–<b>24</b>). Strikingly, most aliphatic moieties afford an increase in the KRI compared to desloratadine, whereas the binding affinity remains similar or even decreases. For example, <b>13</b>–<b>15</b> contain relatively large aliphatic substituents (≥6 carbons) and have a slightly reduced binding affinity (p<i>K</i><sub>i</sub> 8.6–8.9) and a high KRI (>1.4) compared to desloratadine. Moreover, analogues with small (≤3 carbons) acyclic aliphatic substituents (<b>22</b>–<b>24</b>) have a similar binding affinity but still a slightly higher KRI compared to desloratadine. This suggests that growing an aliphatic group from the piperidine increases the residence time at the H<sub>1</sub>R. This trend is disrupted, however, for analogues that contain cycloaliphatic groups directly substituted on the amine (<b>18</b>–<b>21</b>) instead of being separated from the amine by a one-carbon spacer (<b>13</b>, <b>14</b>, <b>16</b>, and <b>17</b>). Analogues without the methylene spacer (<b>18</b>–<b>21</b>) are marked by a diminished KRI and binding affinity compared to analogues with a methylene spacer, whereas the KRI values are of the same magnitude as desloratadine.</div><div class="NLM_p">This cliff in the SKR trend was validated for a subset of analogues by studying the kinetics of functional H<sub>1</sub>R antagonism, which is known to reflect differential residence times at the H<sub>1</sub>R.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(47)</a> Representative analogues in which the cycloaliphatic group is substituted with a one-carbon spacer (<b>14</b>, <b>16</b>, and <b>17</b>) completely inhibits the functional response of the H<sub>1</sub>R for at least 2 h after removal of unbound ligands, as was observed for rupatadine. In contrast, analogues with the same cycloaliphatic groups without a one-carbon spacer (<b>19</b>–<b>21</b>) allowed a clear recovery of the H<sub>1</sub>R functional response, as was also observed for desloratadine. Hence, the relevance of the methylene spacer for the binding kinetics of analogues with relatively large N substituents was confirmed by the duration of functional H<sub>1</sub>R inhibition.</div><div class="NLM_p">The observed residence time/affinity cliff correlated with the binding poses of the representative pair <b>14</b> and <b>19</b> in the H<sub>1</sub>R binding pocket. Our docking studies suggest that the reduced flexibility of the cycloaliphatic group without a spacer (<b>19</b>) might lead to a suboptimal fit due to steric hindrance (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). The increase in ligand residence time at the H<sub>1</sub>R, as was observed for most analogues with an aliphatic group on the basic amine of desloratadine (vide supra), seems therefore to be mitigated when the shape of the H<sub>1</sub>R binding pocket, i.e., the steric constraints imposed by residues I454<sup>7.39</sup> and Y458<sup>7.43</sup>, is interfering with the binding position of the desloratadine scaffold.</div><div class="NLM_p">Recently, it has been shown that N-methylation of H<sub>1</sub>R ligands with a primary or secondary amine increased the binding affinity at the H<sub>1</sub>R by displacing a water molecule near I454<sup>7.39</sup>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(43)</a> However, this effect on the binding affinity was not observed for analogues with a chlorine moiety on the aromatic rings. Consistent with this finding, N-methylation of desloratadine (which contains a chlorine group), affording <b>24</b>, had only modest effects on the H<sub>1</sub>R binding affinity. Interestingly, <b>24</b> did have a higher KRI compared to desloratadine but not to the same extent as was observed for larger aliphatic substituents (for example, <b>13</b>–<b>17</b>). Substitution with aliphatic or aromatic groups on the piperidine possibly reduces the resolvation of both the ligand and binding site during a dissociation event. For ligand dissociation from the CRF<sub>1</sub>R, for example, a low degree of ligand solvation during egress from the pocket was related to a long residence time at the receptor.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(41)</a> Moreover, hydrophobic shielding of H bonds can increase the lifetime of such interactions and consequently result in an increased residence time.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(40)</a> This is corroborated by the fact that ligands with a relatively high KRI (>1.5) were relatively lipophilic (log <i>D</i><sub>7.4</sub>, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">Figure S1</a>). Considering that N substitution of H<sub>1</sub>R ligands was shown to interfere with the water network in the binding site<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(43)</a> and that the salt bridge between the basic amine of ligands and D107<sup>3.32</sup> is crucial for a high binding affinity at the receptor,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(42)</a> shielding this interaction pair might prevent a rapid egress of the ligands from the binding site.</div><div class="NLM_p last">In conclusion, compared to desloratadine, rupatadine has an extremely long residence time at the H<sub>1</sub>R despite an apparent loss in binding affinity, resulting in a longer duration of functional H<sub>1</sub>R antagonism. Development of a [<sup>3</sup>H]levocetirizine radiolabel allowed a detailed SKR study, which shows that aliphatic N substitution of the piperidine ring from desloratadine is enough to obtain antagonists with a long residence time at the H<sub>1</sub>R without increasing the observed binding affinity. Analogues with large flexible cycloaliphatic or aromatic substituents, like the (5-methylpyridin-3-yl)methyl substituent of rupatadine, have a long residence time at the H<sub>1</sub>R. Notably, analogues with cycloaliphatic substituents required an additional methylene spacer on the amine for an optimal binding of the H<sub>1</sub>R. Modeling studies suggest that the combined affinity/kinetics profiles of analogues without a methylene spacer are possibly linked to the steric complementarity in the ligand–H<sub>1</sub>R complex. Aliphatic N substitution of H<sub>1</sub>R antagonists is a new potential strategy to optimize the residence time at the receptor. The presented SKR highlights that subtle structural changes of small-molecule ligands can have a profound effect on the binding kinetics at GPCRs.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pharmacological Assays</h3><div class="NLM_p last">All compounds that were tested in pharmacological assays (<b>1</b>–<b>24</b>, <b>28</b>) are confirmed to pass a publicly available pan-assay interference compounds filter.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Radioligand Binding Experiments</h3><div class="NLM_p">Radioligand binding experiments were performed as described before, with minor alterations.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Cell pellets were produced from HEK293T cells expressing the N-terminally HA-tagged H<sub>1</sub>R, and the pellets were stored at −20 °C. Upon experimentation, the cells were thawed, resuspended in radioligand binding buffer [Na<sub>2</sub>HPO<sub>4</sub> (50 mM) and KH<sub>2</sub>PO<sub>4</sub> (50 mM), pH 7.4], and homogenized with a Branson Sonifier 250 (Branson Ultrasonics, Danbury, CT). Cell homogenates (0.5–3 μg per well) were then incubated with the respective ligands under gentle agitation, as specified for the various assay formats below. After the incubation time, binding reactions were terminated with the cell harvester (PerkinElmer) using rapid filtration and wash steps over polyethyleneimine-coated GF/C filter plates. Filter bound radioligand was then quantified by scintillation counting using MicroScint-O and the Wallac MicroBeta counter (PerkinElmer).</div><div class="NLM_p">In competition binding experiments, cell homogenates were incubated for 4 h at 25 °C with a single concentration of [<sup>3</sup>H]mepyramine (1.5–4 nM) and increasing concentrations unlabeled ligands (10<sup>–5</sup>–10<sup>–13</sup> M). IC<sub>50</sub> values were obtained by analyzing the displacement curves with GraphPad Prism 7.03 (GraphPad Software, San Diego) and were converted to <i>K</i><sub>i</sub> values using the Cheng–Prusoff equation.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">The binding rate constants of [<sup>3</sup>H]levocetirizine were determined using the previously described methodology, by using four different concentrations of [<sup>3</sup>H]levocetirizine (1–35 nM) for a total incubation time of 360 min, with an incubation temperature of 37 °C (data not shown).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This resulted in a <i>k</i><sub>on</sub> of 3.7 ± 0.4 10<sup>6</sup> min<sup>–1</sup> M<sup>–1</sup> and a <i>k</i><sub>off</sub> of 0.022 ± 0.003 min<sup>–1</sup>. In competitive association experiments with [<sup>3</sup>H]levocetirizine as radioligand, cell homogenates were incubated at 37 °C for various incubation times with a single concentration of [<sup>3</sup>H]levocetirizine (5–8 nM) in the absence of unlabeled ligand as well as with three different concentrations of either desloratadine (2–60 nM) or rupatadine (0.1–7 nM). The <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub> values for the binding of [<sup>3</sup>H]levocetirizine are constrained during the analysis of the H<sub>1</sub>R binding kinetics of desloratadine and rupatadine. Kinetic binding rate constants as well as their asymmetrical 95% confidence intervals (95% CI) were determined using GraphPad Prism 7.03. Since the 95% CI values were very broad, the values are depicted to be higher or lower than the 95% CI boundary value observed over all individually performed experiments. Graphs depict a representative graph with mean and standard deviation of duplicate values showing, for clarity, only a single concentration unlabeled ligand.</div><div class="NLM_p">Competitive association experiments with [<sup>3</sup>H]mepyramine as radioligand were performed as described before, with minor alterations.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Briefly, cell homogenates were incubated at 25 °C for various incubation times with a single concentration of [<sup>3</sup>H]mepyramine (2.5–5.5 nM) in the absence or presence of a single concentration unlabeled ligand [desloratadine (4–8 nM) or rupatadine (80–250 nM)].</div><div class="NLM_p last">In dual-point competition association experiments, the kinetic rate index (KRI) value at the H<sub>1</sub>R is determined. Cell homogenates were incubated on a 96-well plate for 1 and 6 h at 37 °C, with a single concentration of [<sup>3</sup>H]levocetirizine (4–11 nM) together with a single concentration of unlabeled ligand that equals the respective <i>K</i><sub>i</sub> value of that ligand at the H<sub>1</sub>R. All conditions were measured in triplicate per experiment (<i>n</i> = 3). Additionally, for each 96-well plate, [<sup>3</sup>H]levocetirizine was incubated with a large excess of mianserin (10<sup>–5</sup> M) to determine nonspecific binding levels of the radioligand (<i>n</i> = 6) and, as a positive control, [<sup>3</sup>H]levocetirizine binding was determined in the absence of competitor (maximal binding, <i>n</i> = 6). [<sup>3</sup>H]levocetirizine binding levels were baseline-corrected by subtracting nonspecific binding levels, and KRI values were then calculated by the ratio of [<sup>3</sup>H]levocetirizine binding after a 1 h incubation time over the [<sup>3</sup>H]levocetirizine binding after a 6 h incubation time. KRI is a quantitative measure for the overshoot in radioligand binding, which results from incubating the radioligand with an unlabeled ligand that has a relatively low <i>k</i><sub>off</sub>.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> It is therefore crucial that the concentrations of unlabeled ligands are comparable and lead to a submaximal inhibition of the radioligand binding. Therefore KRI values were only accepted when the % inhibition of [<sup>3</sup>H]levocetirizine binding (compared to the maximal [<sup>3</sup>H]levocetirizine binding) was (1) less than 80% after either 1 or 6 h and (2) more than 20% inhibition after 6 h. In the case that data points had to be excluded, the concentration unlabeled ligands were attenuated (ranging from 1 × <i>K</i><sub>i</sub> to 3 × <i>K</i><sub>i</sub> concentrations). All experiments were performed in triplicate or more.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Intracellular Calcium Mobilization Assay</h3><div class="NLM_p last">The functional recovery of the H<sub>1</sub>R following antagonism was measured as described before.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(47)</a> In short, HeLa cells, endogenously expressing the H<sub>1</sub>R, were seeded 2 × 10<sup>4</sup> cells per well in a clear bottom 96-well plate, which were preincubated overnight with a concentration antagonist corresponding to 10 times the respective <i>K</i><sub>i</sub> at the H<sub>1</sub>R (24 wells per antagonist). After 18–20 h, the cells were labeled with the Fluo-4NW dye in the presence of the respective concentration antagonist for an hour. Both the excess dye solution and the unbound antagonists were removed by washing the cells two times, and the cells were then reconstituted in Hank’s balanced salt solution buffer supplemented with probenecid (2.5 mM) (<i>t</i><sub>0</sub>). Following the wash step, the cells were stimulated every 5 min by histamine injection, into a single well, using the NOVOstar plate reader (BMG Labtech, Ortenberg, Germany), while simultaneously detecting the calcium-mediated Fluo4 NW fluorescence (λ<sub>excitation</sub> = 494 nm and λ<sub>emission</sub> = 516 nm). For each well stimulated with histamine, a consecutive Triton X-100 injection after 65 s was used to lyse the cells leading to saturation of the Fluo4 NW with calcium. The histamine-induced peak response was then normalized to basal levels of fluorescence (prior to histamine injection; 0) and saturated Fluo4 NW fluorescence (following Triton X-100 injection; 1). This led to a reproducible histamine-induced response over time for HeLa cells pretreated with vehicle condition, which was set to 100%. Histamine-induced peak responses were plotted against the difference in time between <i>t</i><sub>0</sub> and the subsequent histamine injection. The recovery time (RecT) was determined for antagonists by nonlinear regression using the one-phase association model in GraphPad Prism 7.03.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Modeling</h3><div class="NLM_p last">Simplified molecular-input line-entry system for compounds <b>1</b>–<b>24</b> were obtained from ChemBioDraw Ultra (version 16.0.1.4) and were subsequently used as input for ChemAxon’s calculator for protonation (pH = 7.4). A three-dimensional conformation was then generated using Molecular Networks’ CORINA (version 3.49) and stored in Tripos MOL2 format (gold extension). The doxepin-bound H<sub>1</sub>R structure was obtained from the protein data bank (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE">3RZE</a>), after which the fused T4-lysozyme was removed from the structure. The complex was further prepared for docking using Molecular Operating Environment (Chemical Computing Group, version 2016.0802). Using PLANTS (version 1.2),<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(49)</a> each compound was docked into the H<sub>1</sub>R binding pocket three times with the following settings: search speed, 1; cluster root-mean-square deviation, 1.0; cluster structures, 10; and scored using the ChemPLP scoring function. The binding site was defined by the center of the co-crystallized ligand doxepin with a radius of 11 Å. The resulting docking poses were visually inspected, and the poses with the best overlap with each other as well as the doxepin reference compound were selected, which were also the highest-ranking poses for each compound. Moreover, using an interaction fingerprint similarity analysis,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> all docking poses were compared to the binding mode of the co-crystallized compound doxepin. All selected docking poses have an interaction fingerprint similarity of at least 0.72 compared to the binding mode of doxepin and are depicted in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">Figures S2 and S3</a>). The binding mode figures were created with PyMol (version 1.8.0).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedures</h4><div id="sec4_5_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> Synthesis of Rupatadine Analogues <b>3</b>–<b>24</b></h5><div class="NLM_p">Anhydrous tetrahydrofuran, DCM, DMF, and Et<sub>2</sub>O were obtained by elution through an activated alumina column prior to use. All other solvents and chemicals were acquired from commercial suppliers and were used as received. ChemBioDraw Ultra 16.0.1.4 was used to generate systematic names for all molecules. All reactions were performed under an inert atmosphere (N<sub>2</sub>). Thin-layer chromatography analyses were carried out with alumina silica plates (Merck F<sub>254</sub>) using staining and/or UV visualization. Column purifications were performed manually using SiliCycle UltraPure silica gel or automatically using Biotage equipment. NMR spectra (<sup>1</sup>H, <sup>13</sup>C, and two-dimensional) were recorded on a Bruker 300 (300 MHz), Bruker 500 (500 MHz), or Bruker 600 (600 MHz) spectrometer. Chemical shifts are reported in parts per million (ppm) (δ), and the residual solvent was used as internal standard (δ <sup>1</sup>H NMR: CDCl<sub>3</sub> 7.26; dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub> 2.50; CD<sub>3</sub>OD 3.31; δ <sup>13</sup>C NMR: CDCl<sub>3</sub> 77.16; DMSO-<i>d</i><sub>6</sub> 39.52; CD<sub>3</sub>OD 49.00). Data are reported as follows: chemical shift (integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad signal, m = multiplet, app = apparent), and coupling constants (Hz)). A Bruker microTOF mass spectrometer using electrospray ionization (ESI) in positive-ion mode was used to record high-resolution mass spectrometry (HRMS) images. A Shimadzu LC-20AD liquid chromatograph pump system linked to a Shimadzu SPD-M20A diode array detector with MS detection using a Shimadzu LC-MS-2010EV mass spectrometer was used to perform liquid chromatography–mass spectrometry (LC–MS) analyses. An Xbridge (C18) 5 μm column (50 mm, 4.6 mm) was used. The solvents that were used were the following: solvent B (acetonitrile with 0.1% formic acid) and solvent A (water with 0.1% formic acid), flow rate of 1.0 mL min<sup>–1</sup>, start 5% B, linear gradient to 90% B in 4.5 min, then 1.5 min at 90% B, then linear gradient to 5% B in 0.5 min, then 1.5 min at 5% B; and total run time of 8 min. All compounds have a purity of ≥95% (unless specified otherwise), calculated as the percentage peak area of the analyzed compound by UV detection at 254 nm (values are rounded). Reverse-phase column chromatography purifications were performed using Buchi PrepChrom C-700 equipment with a discharge deuterium lamp ranging from 200 to 600 nm to detect compounds using solvent B (acetonitrile with 0.1% formic acid), solvent A (water with 0.1% formic acid), flow rate of 15.0 mL min<sup>–1</sup>, and a gradient (start 95% A for 3.36 min, then linear gradient to 5% A in 30 min, then at 5% A for 3.36 min, then linear gradient to 95% A in 0.5 min, and then 1.5 min at 95% A).</div><div class="NLM_p last">The <a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">Supporting Information</a> lists <sup>1</sup>H NMR and <sup>13</sup>C NMR spectroscopy data as well as high-resolution mass spectroscopy and LC–MS images (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">Figures S4–S69</a>).</div></div><div id="sec4_5_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> Synthesis of [<sup>3</sup>H]Levocetirizine (<b>25</b>–<b>28</b>)</h5><div class="NLM_p last">Column chromatography was carried out using prepacked silica gel cartridges (SiliCycle, Quebec, Canada) on an Isco Companion (Teledyne Isco, NE). <sup>1</sup>H NMR spectra were recorded on a Bruker (600 or 400 MHz) using the stated solvent. Chemical shifts (δ) in ppm are quoted relative to CDCl<sub>3</sub> (δ 7.26 ppm) and DMSO-<i>d</i><sub>6</sub> (δ 2.50 ppm). Liquid chromatography–mass spectrometry (LC–MS) data were collected using a Waters Alliance LC (Waters Corporation, MA) with Waters ZQ mass detector. Analytical high-performance liquid chromatography (HPLC) data were recorded using Agilent 1200 HPLC system with a β-Ram Flow Scintillation Analyser, using the following conditions: Waters Sunfire C<sub>18</sub>, 3.5 μm, 4.6 × 100 mm<sup>2</sup> column at 40 °C, eluting with 5% acetonitrile/water + 0.1% trifluoroacetic acid (TFA) to 95% acetonitrile/water + 0.1% TFA over a 32 min gradient. Specific activities were determined gravimetrically with a Packard Tri-Carb 2100CA Liquid Scintillation Analyser (Packard Instrument Company Inc., IL) using Ultima Gold cocktail. Reactions with tritium gas were carried out on a steel manifold obtained from RC Tritec AG (Teufen, Switzerland). Specific activity was calculated by comparison of the ratio of tritium/hydrogen or carbon-14/carbon-12 for the tracer against the unlabeled reference. [<sup>3</sup>H]Methyl nosylate was obtained from Quotient Bioresearch as a solution in toluene at 3150 GBq mmol<sup>–1</sup>. Tritium gas was supplied and absorbed onto a depleted uranium bed by RC Tritec AG (). All other reagents and solvents obtained from Sigma-Aldrich and Fisher and were used without further purification.</div></div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Detailed Experimental Procedures</h4><div id="sec4_5_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 8-Chloro-11-(1-((4-methylpyridin-3-yl)methyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>3</b>)</h5><div class="NLM_p">A mixture of 4-methylnicotinaldehyde (93 mg, 0.77 mmol), desloratadine (200 mg, 0.643 mmol), and NaBH(OAc)<sub>3</sub> (218 mg, 1.027 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH). The product fraction was evaporated, extracted with DCM/satd. aq Na<sub>2</sub>CO<sub>3</sub> solution, dried (MgSO<sub>4</sub>), and concentrated to yield the title compound as a pink foam (170 mg, 64% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.42–8.22 (m, 3H), 7.39 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.15–6.97 (m, 5H), 3.48–3.25 (m, 4H), 2.87–2.60 (m, 4H), 2.51–2.20 (m, 7H), 2.19–2.04 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.46, 150.18, 148.22, 147.40, 146.49, 139.49, 138.86, 137.76, 137.35, 133.43, 132.62, 132.56, 132.41, 130.79, 128.94, 125.98, 125.43, 122.13, 57.98, 54.80, 54.71, 31.79, 31.40, 30.97, 30.76, 18.81. HRMS: C<sub>26</sub>H<sub>27</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> calcd: 416.1894, found: 416.1883. LC–MS: <i>t</i><sub>R</sub> = 3.0 min, purity >96% (254 nm), <i>m</i>/<i>z</i>: 416.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 8-Chloro-11-(1-((2-methylpyridin-3-yl)methyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>4</b>)</h5><div class="NLM_p">A mixture of desloratadine (155 mg, 0.50 mmol), 3-(chloromethyl)-2-methylpyridine hydrochloride (116 mg, 0.65 mmol), and K<sub>2</sub>CO<sub>3</sub> (180 mg, 1.30 mmol) in DMF (10 mL) was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with water (2×) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH) to yield the title compound as a pink foam (120 mg, 58% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.42–8.31 (m, 2H), 7.59 (d, <i>J</i> = 7.0 Hz, 1H), 7.42 (d, <i>J</i> = 7.6 Hz, 1H), 7.16–7.02 (m, 5H), 3.49–3.29 (m, 4H), 2.88–2.65 (m, 4H), 2.60–2.45 (m, 4H), 2.45–2.26 (m, 3H), 2.23–2.06 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.62, 157.44, 147.40, 146.61, 139.50, 138.78, 137.76, 137.32, 137.01, 133.37, 132.69, 132.59, 131.89, 130.78, 128.92, 125.98, 122.11, 121.00, 59.61, 54.92, 54.84, 31.77, 31.41, 30.95, 30.72, 22.26. HRMS: C<sub>26</sub>H<sub>27</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> calcd: 416.1888, found: 416.1906. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >98% (254 nm), <i>m</i>/<i>z</i>: 416.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 8-Chloro-11-(1-((6-methylpyridin-3-yl)methyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>5</b>)</h5><div class="NLM_p">A mixture of desloratadine (200 mg, 0.643 mmol), 5-(bromomethyl)-2-methylpyridine hydrobromide (224 mg, 0.836 mmol), and K<sub>2</sub>CO<sub>3</sub> (231 mg, 1.67 mmol) in DMF (10 mL) was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with water (2×) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH). The product fraction was evaporated, extracted with DCM/satd. aq Na<sub>2</sub>CO<sub>3</sub> solution, dried (MgSO<sub>4</sub>), and concentrated to yield the title compound as a pink foam (170 mg, 64% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.41–8.33 (m, 2H), 7.60 (d, <i>J</i> = 7.3 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.16–7.02 (m, 5H), 3.50 (s, 2H), 3.42–3.28 (m, 2H), 2.86–2.68 (m, 4H), 2.57–2.48 (m, 4H), 2.47–2.12 (m, 5H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.41, 157.37, 149.71, 146.60, 139.51, 138.20, 137.70, 137.42, 137.32, 133.38, 133.00, 132.69, 130.70, 130.1, 128.95, 126.01, 123.01, 122.14, 59.62, 54.56, 54.45, 31.76, 31.42, 30.64, 30.39, 24.10. HRMS: C<sub>26</sub>H<sub>27</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> calcd: 416.1894, found: 416.1886. LC–MS: <i>t</i><sub>R</sub> = 3.0 min, purity >98% (254 nm), <i>m</i>/<i>z</i>: 416.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 8-Chloro-11-(1-(pyridin-3-ylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>6</b>)</h5><div class="NLM_p">A mixture of desloratadine (500 mg, 1.61 mmol), 3-(bromomethyl)-pyridine hydrobromide (529 mg, 2.09 mmol), and K<sub>2</sub>CO<sub>3</sub> (579 mg, 4.19 mmol) in DMF (10 mL) was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with water (2×) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH) to yield the title compound as a pink foam (430 mg, 66% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.54–8.43 (m, 2H), 8.37 (d, <i>J</i> = 4.6 Hz, 1H), 7.67 (d, <i>J</i> = 7.7 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.25–7.20 (m, 1H), 7.15–7.02 (m, 4H), 3.49 (s, 2H), 3.43–3.27 (m, 2H), 2.88–2.64 (m, 4H), 2.55–2.46 (m, 1H), 2.45–2.25 (m, 3H), 2.21–2.02 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.44, 150.40, 148.60, 146.63, 139.51, 138.60, 137.73, 137.34, 136.81, 133.63, 133.40, 132.79, 132.63, 130.81, 128.96, 126.01, 123.37, 122.15, 60.04, 54.73, 54.66, 31.80, 31.42, 30.89, 30.65. HRMS: C<sub>25</sub>H<sub>25</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> calcd: 402.1737, found: 402.1733. LC–MS: <i>t</i><sub>R</sub> = 3.0 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 402.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 8-Chloro-11-(1-(pyridin-4-ylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>7</b>)</h5><div class="NLM_p">A mixture of desloratadine (500 mg, 1.61 mmol), 4-(bromomethyl)-pyridine hydrobromide (529 mg, 2.09 mmol), and K<sub>2</sub>CO<sub>3</sub> (579 mg, 4.19 mmol) in DMF (10 mL) was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with water (2×) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH) to yield the title compound as a pink foam (229 mg, 36% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.49 (d, <i>J</i> = 5.6 Hz, 2H), 8.35 (d, <i>J</i> = 4.6 Hz, 1H), 7.39 (d, <i>J</i> = 7.6 Hz, 1H), 7.24 (d, <i>J</i> = 5.4 Hz, 2H), 7.16–7.00 (m, 4H), 3.46 (s, 2H), 3.42–3.24 (m, 2H), 2.85–2.60 (m, 4H), 2.57–2.23 (m, 4H), 2.20–2.04 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.38, 149.64, 147.76, 146.58, 139.50, 138.46, 137.69, 137.38, 133.41, 132.82, 132.63, 130.78, 128.96, 126.00, 123.89, 122.18, 61.56, 54.85, 54.82, 31.77, 31.40, 30.89, 30.67. HRMS: C<sub>25</sub>H<sub>25</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> calcd: 402.1737, found: 402.1741. LC–MS: <i>t</i><sub>R</sub> = 3.0 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 402.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 8-Chloro-11-(1-(pyridin-2-ylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>8</b>)</h5><div class="NLM_p">A mixture of desloratadine (500 mg, 1.61 mmol), 2-(bromomethyl)-pyridine hydrobromide (529 mg, 2.09 mmol), and K<sub>2</sub>CO<sub>3</sub> (579 mg, 4.19 mmol) in DMF (10 mL) was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with water (2×) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH) to yield the title compound as a pink foam (399 mg, 62% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.52 (d, <i>J</i> = 4.5 Hz, 1H), 8.36 (d, <i>J</i> = 4.6 Hz, 1H), 7.62 (t, <i>J</i> = 7.6 Hz, 1H), 7.40 (d, <i>J</i> = 7.2 Hz, 2H), 7.18–6.98 (m, 5H), 3.63 (s, 2H), 3.45–3.27 (m, 2H), 2.87–2.68 (m, 4H), 2.59–2.40 (m, 2H), 2.40–2.27 (m, 2H), 2.26–2.10 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.54, 157.56, 149.24, 146.60, 139.52, 138.86, 137.75, 137.28, 136.44, 133.43, 132.62, 132.57, 130.87, 128.96, 125.97, 123.22, 122.11, 122.06, 64.46, 55.07, 55.05, 31.82, 31.40, 30.94, 30.71. HRMS: C<sub>25</sub>H<sub>25</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> calcd: 402.1737, found: 402.1738. LC–MS: <i>t</i><sub>R</sub> = 3.1 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 402.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 8-Chloro-11-(1-(pyrimidin-2-ylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>9</b>)</h5><div class="NLM_p">A mixture of pyrimidine-2-carbaldehyde (91 mg, 0.84 mmol), desloratadine (218 mg, 0.7 mmol), and NaBH(OAc)<sub>3</sub> (237 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (EtOAc/MeOH/triethylamine (TEA) = 94:4:2, v/v/v) to yield the title compound as a pink foam (240 mg, 85% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.71 (d, <i>J</i> = 4.9 Hz, 2H), 8.37 (dd, <i>J</i> = 4.7, 1.4 Hz, 1H), 7.41 (dd, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.17 (t, <i>J</i> = 4.9 Hz, 1H), 7.14–7.02 (m, 4H), 3.86–3.74 (m, 2H), 3.44–3.30 (m, 2H), 2.89–2.71 (m, 4H), 2.65–2.47 (m, 2H), 2.42–2.25 (m, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.63, 157.64, 157.20, 146.59, 139.48, 138.78, 137.73, 137.20, 133.43, 132.61, 132.59, 130.89, 128.96, 125.97, 122.07, 119.32, 65.09, 55.25, 55.21, 31.85, 31.40, 30.75, 30.50. HRMS: C<sub>24</sub>H<sub>24</sub>ClN<sub>4</sub> (M + H)<sup>+</sup> calcd: 403.1684, found: 403.1680. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 403.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 8-Chloro-11-(1-(pyrimidin-4-ylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>10</b>)</h5><div class="NLM_p">A mixture of pyrimidine-4-carbaldehyde (91 mg, 0.84 mmol), desloratadine (218 mg, 0.7 mmol), and NaBH(OAc)<sub>3</sub> (237 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (EtOAc/MeOH/TEA = 94:4:2, v/v/v) to yield the title compound as a pink foam (248 mg, 88% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.11 (s, 1H), 8.67 (d, <i>J</i> = 5.2 Hz, 1H), 8.38 (dd, <i>J</i> = 4.7, 1.2 Hz, 1H), 7.53 (d, <i>J</i> = 5.0 Hz, 1H), 7.42 (dd, <i>J</i> = 8.8, 1.2 Hz, 2H), 7.17–7.02 (m, 4H), 3.62 (s, 2H), 3.44–3.31 (m, 2H), 2.87–2.71 (m, 4H), 2.61–2.52 (m, 1H), 2.51–2.42 (m, 1H), 2.41–2.31 (m, 2H), 2.30–2.19 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 167.86, 158.57, 157.38, 157.09, 146.59, 139.52, 138.13, 137.71, 137.37, 133.42, 133.05, 132.71, 130.74, 128.96, 126.03, 122.17, 120.13, 63.36, 55.10, 31.79, 31.44, 30.92, 30.70, one signal overlapping or not visible. HRMS: C<sub>24</sub>H<sub>24</sub>ClN<sub>4</sub> (M + H)<sup>+</sup> calcd: 403.1684, found: 403.1681. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 403.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 8-Chloro-11-(1-(3-methylbenzyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>11</b>)</h5><div class="NLM_p">Desloratadine (500 mg, 1.61 mmol) was added to 3-methylbenzyl bromide (387 mg, 2.09 mmol) and TEA (326 mg, 3.22 mmol) in DCM (10 mL). The resulting mixture was stirred at room temperature for 18 h. The solution was then diluted with DCM, washed with a 5% NaHCO<sub>3</sub> solution, then with H<sub>2</sub>O, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH). The product fraction was evaporated, extracted with DCM/satd. aq Na<sub>2</sub>CO<sub>3</sub> solution, dried (MgSO<sub>4</sub>), and concentrated to yield the title compound as a pink foam (432 mg, 65% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 7.41 (d, <i>J</i> = 7.7 Hz, 1H), 7.22–6.99 (m, 8H), 3.53–3.28 (m, 4H), 2.90–2.68 (m, 4H), 2.58–2.25 (m, 7H), 2.21–2.04 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.69, 146.64, 139.52, 139.18, 138.09, 137.84, 137.78, 137.23, 133.42, 132.57, 132.49, 130.92, 129.97, 128.97, 128.06, 127.79, 126.33, 125.99, 122.08, 62.99, 54.89, 54.85, 31.87, 31.44, 30.99, 30.75, 21.46. HRMS: C<sub>27</sub>H<sub>28</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 415.1941, found: 415.1938. LC–MS: <i>t</i><sub>R</sub> = 3.6 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 415.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 11-(1-Benzylpiperidin-4-ylidene)-8-chloro-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>12</b>)</h5><div class="NLM_p">Desloratadine (500 mg, 1.61 mmol) was added to benzyl bromide (358 mg, 2.09 mmol) and TEA (326 mg, 3.22 mmol) in DCM (10 mL). The resulting mixture was stirred at room temperature for 18 h. The solution was then diluted with DCM and H<sub>2</sub>O and extraction was performed. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and filtered. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH). The product fraction was evaporated, extracted with DCM/satd. aq Na<sub>2</sub>CO<sub>3</sub> solution, dried (MgSO<sub>4</sub>), and concentrated to yield the title compound as a pink foam (484 mg, 75% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.38 (dd, <i>J</i> = 4.8, 1.2 Hz, 1H), 7.42 (dd, <i>J</i> = 7.3, 1.1 Hz, 1H), 7.33–7.20 (m, <i>5H</i>), 7.17–7.00 (m, 4H), 3.51 (s, 2H), 3.45–3.28 (m, 2H), 2.87–2.69 (m, 4H), 2.58–2.26 (m, 4H), 2.23–2.07 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.64, 146.62, 139.51, 139.04, 138.09, 137.81, 137.26, 133.42, 132.58, 132.54, 130.89, 129.23, 128.96, 128.21, 127.06, 125.99, 122.10, 62.91, 54.79, 54.74, 31.85, 31.42, 30.94, 30.71. HRMS: C<sub>26</sub>H<sub>26</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 401.1785, found: 401.1779. LC–MS: <i>t</i><sub>R</sub> = 3.4 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 401.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 8-Chloro-11-(1-(cyclohexylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>13</b>)</h5><div class="NLM_p">A mixture of cyclohexanecarbaldehyde (95 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (180 mg, 63% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 4.6 Hz, 1H), 7.42 (d, <i>J</i> = 7.6 Hz, 1H), 7.16–7.09 (m, 3H), 7.07 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.46–3.29 (m, 2H), 2.86–2.74 (m, 2H), 2.74–2.63 (m, 2H), 2.55–2.46 (m, 1H), 2.44–2.25 (m, 3H), 2.14–1.97 (m, 4H), 1.80–1.60 (m, 5H), 1.50–1.38 (m, 1H), 1.26–1.07 (m, 3H), 0.91–0.78 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.77, 146.74, 139.66, 137.96, 137.35, 133.54, 132.70, 132.55, 130.96, 129.07, 126.10, 122.18, 65.45, 55.51, 55.41, 35.32, 32.16, 32.13, 31.94, 31.55, 30.87, 30.62, 26.82, 26.25, one aromatic signal overlapping or not visible. HRMS: C<sub>26</sub>H<sub>32</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 407.2249, found: 407.2231. LC–MS: <i>t</i><sub>R</sub> = 3.6 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 407.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 8-Chloro-11-(1-(cyclopentylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>14</b>)</h5><div class="NLM_p">A mixture of cyclopentanecarbaldehyde (83 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (162 mg, 59% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 4.6 Hz, 1H), 7.41 (d, <i>J</i> = 7.7 Hz, 1H), 7.15–7.08 (m, 3H), 7.06 (dd, <i>J</i> = 7.6, 4.9 Hz, 1H), 3.45–3.29 (m, 2H), 2.86–2.69 (m, 4H), 2.55–2.45 (m, 1H), 2.44–2.27 (m, 3H), 2.25 (d, <i>J</i> = 7.2 Hz, 2H), 2.16–1.96 (m, 3H), 1.77–1.67 (m, 2H), 1.61–1.43 (m, 4H), 1.22–1.12 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.87, 146.72, 139.60, 137.98, 137.26, 133.50, 132.63, 132.30, 131.03, 129.03, 126.06, 122.11, 64.50, 55.36, 55.30, 37.60, 31.96, 31.77, 31.52, 31.09, 30.85, 25.30, one aromatic signal overlapping or not visible. HRMS: C<sub>25</sub>H<sub>30</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 393.2092, found: 393.2091. LC–MS: <i>t</i><sub>R</sub> = 3.2 min, purity >98% (254 nm), <i>m</i>/<i>z</i>: 393.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 8-Chloro-11-(1-(2-ethylbutyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>15</b>)</h5><div class="NLM_p">A mixture of 2-ethylbutanal (85 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (186 mg, 67% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (dd, <i>J</i> = 4.9, 1.7 Hz, 1H), 7.42 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.16–7.11 (m, 3H), 7.08 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.46–3.29 (m, 2H), 2.88–2.69 (m, 4H), 2.61–2.03 (br m, 8H), 1.49–1.24 (m, 5H), 0.84 (t, <i>J</i> = 7.4 Hz, 6H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.95, 146.74, 139.83, 139.63, 138.06, 137.25, 133.51, 132.64, 132.27, 131.04, 129.04, 126.06, 122.10, 62.44, 55.60, 55.52, 38.06, 31.99, 31.56, 31.15, 30.92, 24.33, 10.99. HRMS: C<sub>25</sub>H<sub>32</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 395.2249, found: 395.2244. LC–MS: <i>t</i><sub>R</sub> = 3.3 min, purity >98% (254 nm), <i>m</i>/<i>z</i>: 395.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 8-Chloro-11-(1-(cyclobutylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>16</b>)</h5><div class="NLM_p">A mixture of (bromomethyl)cyclobutane (208 mg, 1.40 mmol), desloratadine (218 mg, 0.70 mmol), and 60% NaH dispersion (41.6 mg, 1.05 mmol) in DMF (10 mL) was stirred at room temperature for 10 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (150 mg, 56% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 4.9, 1.4 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.15–7.08 (m, 3H), 7.06 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.44–3.30 (m, 2H), 2.85–2.73 (m, 2H), 2.74–2.66 (m, 2H), 2.56–2.44 (m, 2H), 2.43–2.25 (m, 5H), 2.12–1.96 (m, 4H), 1.92–1.80 (m, 1H), 1.79–1.70 (m, 1H), 1.69–1.58 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.78, 146.73, 139.60, 139.24, 137.93, 137.29, 133.49, 132.66, 132.46, 130.99, 129.03, 126.07, 122.13, 65.28, 55.13, 55.07, 34.36, 31.94, 31.53, 31.05, 30.80, 28.32, 18.93. HRMS: C<sub>24</sub>H<sub>28</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 379.1936, found: 379.1923. LC–MS: <i>t</i><sub>R</sub> = 3.1 min, purity >96% (254 nm), <i>m</i>/<i>z</i>: 379.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 8-Chloro-11-(1-(cyclopropylmethyl)piperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>17</b>)</h5><div class="NLM_p">A mixture of cyclopropanecarboxaldehyde (59 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (132 mg, 52% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 7.42 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.16–7.09 (m, 3H), 7.07 (dd, <i>J</i> = 7.6, 4.7 Hz, 1H), 3.44–3.30 (m, 2H), 2.93–2.73 (m, 4H), 2.59–2.50 (m, 1H), 2.48–2.31 (m, 3H), 2.24 (d, <i>J</i> = 6.5 Hz, 2H), 2.21–2.12 (m, 2H), 0.92–0.79 (m, 1H), 0.53–0.43 (m, 2H), 0.06 (app q, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.78, 146.76, 139.61, 139.24, 137.94, 137.32, 133.51, 132.70, 132.58, 131.01, 129.05, 126.10, 122.17, 63.74, 55.10, 55.05, 31.96, 31.55, 31.05, 30.80, 8.52, 4.11, 4.09. HRMS: C<sub>23</sub>H<sub>26</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 365.1779, found: 365.1773. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 365.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 8-Chloro-11-(1-cyclohexylpiperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>18</b>)</h5><div class="NLM_p">A mixture of cyclohexanone (82 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (192 mg, 70% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 7.42 (d, <i>J</i> = 7.6, 1H), 7.16–7.09 (m, 3H), 7.06 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.44–3.30 (m, 2H), 2.86–2.71 (m, 4H), 2.53–2.44 (m, 1H), 2.44–2.23 (m, 6H), 1.88–1.69 (m, 4H), 1.60 (app d, <i>J</i> = 13.6 Hz, 1H), 1.27–1.12 (m, 4H), 1.12–1.00 (m, 1H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.92, 146.74, 139.86, 139.60, 137.96, 137.25, 133.52, 132.64, 132.24, 131.10, 129.05, 126.06, 122.12, 63.76, 50.71, 50.59, 32.00, 31.64, 31.54, 31.38, 29.05, 28.91, 26.47, 26.17. HRMS: C<sub>25</sub>H<sub>30</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 393.2092, found: 393.2083. LC–MS: <i>t</i><sub>R</sub> = 3.1 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 393.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 8-Chloro-11-(1-cyclopentylpiperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>19</b>)</h5><div class="NLM_p">A mixture of cyclopentanone (70 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (189 mg, 71% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 4.8, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.15–7.08 (m, 3H), 7.06 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.44–3.29 (m, 2H), 2.87–2.72 (m, 4H), 2.57–2.39 (m, 3H), 2.38–2.29 (m, 2H), 2.19–2.07 (m, 2H), 1.87–1.74 (m, 2H), 1.70–1.59 (m, 2H), 1.55–1.45 (m, 2H), 1.45–1.33 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.81, 146.73, 139.59, 139.45, 137.87, 137.26, 133.52, 132.66, 132.27, 131.05, 129.04, 126.07, 122.13, 67.41, 54.13, 54.10, 31.98, 31.53, 31.13, 30.85, 30.70, 24.34. HRMS: C<sub>24</sub>H<sub>28</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 379.1936, found: 379.1921. LC–MS: <i>t</i><sub>R</sub> = 3.0 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 379.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 8-Chloro-11-(1-cyclobutylpiperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>20</b>)</h5><div class="NLM_p">A mixture of cyclobutanone (59 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (145 mg, 57% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 4.6 Hz, 1H), 7.42 (d, <i>J</i> = 7.6 Hz, 1H), 7.15–7.09 (m, 3H), 7.09–7.05 (m, 1H), 3.45–3.30 (m, 2H), 2.87–2.74 (m, 2H), 2.74–2.60 (m, 3H), 2.55–2.46 (m, 1H), 2.46–2.28 (m, 3H), 2.05–1.86 (m, 6H), 1.74–1.57 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.78, 146.77, 139.60, 139.01, 137.89, 137.33, 133.53, 132.78, 132.74, 130.99, 129.09, 126.12, 122.21, 60.32, 51.24, 51.23, 31.97, 31.53, 30.65, 30.38, 27.42, 14.35. HRMS: C<sub>23</sub>H<sub>26</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 365.1779, found: 365.1772. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 365.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 8-Chloro-11-(1-cyclopropylpiperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>21</b>)</h5><div class="NLM_p">A mixture of (1-ethoxycyclopropoxy)trimethylsilane (347 mg, 2.00 mmol), desloratadine (622 mg, 2.00 mmol), AcOH (111 mg, 2.00 mmol), and sodium triacetoxyborohydride (604 mg, 3.20 mmol) in DCM (10 mL) was stirred at room temperature for 48 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by reverse-phase column chromatography (H<sub>2</sub>O/MeCN/HCOOH). The product fraction was evaporated, extracted with DCM/satd. aq Na<sub>2</sub>CO<sub>3</sub> solution, dried (MgSO<sub>4</sub>), and concentrated to yield the title compound as a pink foam (124 mg, 17% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (dd, <i>J</i> = 4.9, 1.5 Hz, 1H), 7.43 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.16–7.10 (m, 3H), 7.08 (dd, <i>J</i> = 7.7, 4.7 Hz, 1H), 3.45–3.32 (m, 2H), 2.92–2.74 (m, 4H), 2.50–2.42 (m, 1H), 2.40–2.26 (m, 5H), 1.60–1.50 (m, 1H), 0.47–0.35 (m, 4H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.85, 146.75, 139.58, 139.35, 137.95, 137.30, 133.51, 132.69, 132.66, 131.01, 129.08, 126.10, 122.17, 55.16, 38.39, 31.97, 31.52, 31.00, 30.74, 6.09, one aliphatic signal overlapping or not visible. HRMS: C<sub>22</sub>H<sub>24</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 351.1623, found: 351.1610. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >98% (254 nm), <i>m</i>/<i>z</i>: 351.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 8-Chloro-11-(1-isopropylpiperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>22</b>)</h5><div class="NLM_p">A mixture of propan-2-one (49 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (101 mg, 41% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.39 (dd, <i>J</i> = 4.8, 1.7 Hz, 1H), 7.43 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.16–7.10 (m, 3H), 7.08 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 3.45–3.32 (m, 2H), 2.87–2.69 (m, 5H), 2.55–2.47 (m, 1H), 2.46–2.22 (m, 5H), 1.04 (d, <i>J</i> = 6.6 Hz, 3H), 1.03 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.87, 146.76, 139.62, 137.93, 137.30, 133.55, 132.70, 132.43, 131.08, 129.08, 126.10, 122.17, 54.57, 50.34, 50.19, 32.01, 31.56, 31.40, 31.13, 18.60, 18.45, one aromatic signal overlapping or not visible. HRMS: C<sub>22</sub>H<sub>26</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 353.1779, found: 353.1770. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >95% (254 nm), <i>m</i>/<i>z</i>: 353.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 8-Chloro-11-(1-ethylpiperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine (<b>23</b>)</h5><div class="NLM_p">A mixture of acetaldehyde (37 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and NaBH(OAc)<sub>3</sub> (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at room temperature for 12 h. The resulting solution was diluted with water and extracted with DCM. The organic phase was washed with satd. aq NaHCO<sub>3</sub> solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The crude mixture was purified by column chromatography (cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink foam (65 mg, 27% yield).</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.40 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 7.43 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.19–7.11 (m, 3H), 7.08 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 3.48–3.29 (m, 2H), 2.91–2.70 (m, 4H), 2.62–2.50 (m, 1H), 2.50–2.29 (m, 5H), 2.24–2.05 (m, 2H), 1.09 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.76, 146.78, 139.64, 139.14, 137.93, 137.36, 133.54, 132.75, 132.66, 131.01, 129.08, 126.13, 122.21, 54.65, 54.59, 52.31, 31.97, 31.57, 31.05, 30.79, 12.23. HRMS: C<sub>21</sub>H<sub>24</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 339.1623, found: 339.1608. LC–MS: <i>t</i><sub>R</sub> = 2.7 min, purity >97% (254 nm), <i>m</i>/<i>z</i>: 339.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 8-Chloro-11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridine fumarate (<b>24</b>)</h5><div class="NLM_p">To a solution of desloratadine (5.00 g, 16.1 mmol) in DCM (150 mL) were added MeOH (75 mL), aq formaldehyde solution (ca. 13.4 M, 2.40 mL, 32.2 mmol) and AcOH (1.29 mL, 22.5 mmol), and the resulting mixture was stirred at room temperature for 15 min. Subsequently, NaBH(OAc)<sub>3</sub> (5.11 g, 24.1 mmol) was added and the resulting mixture was stirred for 1.5 h at room temperature. The reaction mixture was diluted with 1 M aqueous NaOH (600 mL) and extracted with DCM (2 × 200 mL). The combined organic phases were washed with brine (200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. Purification by flash column chromatography (DCM/MeOH/TEA 190:5:5) gave the free base (3.96 g), which was subsequently converted to the fumaric acid salt to obtain the title compound as a white solid (4.27 g, 60%).</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36–8.32 (m, 1H), 7.57 (d, <i>J</i> = 7.6 Hz, 1H), 7.31 (d, <i>J</i> = 2.0 Hz, 1H), 7.24–7.17 (m, 2H), 7.09 (d, <i>J</i> = 8.2 Hz, 1H), 6.55 (s, 2H), 3.37–3.24 (m, 2H), 2.89–2.77 (m, 4H), 2.48–2.38 (m, 4H), 2.36 (s, 3H), 2.31–2.22 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.0, 156.7, 146.4, 140.2, 137.8, 137.5, 135.3, 134.6, 133.3, 133.2, 131.6, 130.7, 129.0, 125.7, 122.4, 55.1, 44.2, 30.9, 30.6, 29.2, 29.1. HRMS: C<sub>20</sub>H<sub>22</sub>ClN<sub>2</sub> (M + H)<sup>+</sup> calcd: 325.1466, found 325.1452. LC–MS: <i>t</i><sub>R</sub> = 2.9 min, purity >99% (254 nm), <i>m</i>/<i>z</i>: 324.9 (M + H)<sup>+</sup>.</div></div><div id="sec4_5_2_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (4-Chlorophenyl)(4-iodophenyl)methanol (<b>25</b>)</h5><div class="NLM_p">(4-Chlorophenyl)magnesium bromide (1.0 M in Et<sub>2</sub>O) (3.23 mL, 3.23 mmol) was added dropwise over 15 min to a stirred solution of 4-iodobenzaldehyde (500 mg, 2.16 mmol) in Et<sub>2</sub>O (4 mL) at 0 °C under nitrogen. The mixture was allowed to warm to room temperature and stirred for a further 16 h. Satd. aq NH<sub>4</sub>Cl (1 mL) was added carefully (CAUTION! Exotherm and vigorous bubbling). After bubbling had ceased, the mixture was partitioned between Et<sub>2</sub>O (10 mL) and satd. aq NH<sub>4</sub>Cl (5 mL). The organic phase was washed with brine (5 mL), dried (MgSO<sub>4</sub>), filtered, and evaporated to give the title compound (655 mg, 88%) as a cream solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.59 (d, <i>J</i> = 8.62 Hz, 2H), 7.27–7.13 (m, 4H), 7.02 (d, <i>J</i> = 8.36 Hz, 2H), 5.68 (s, 1H).</div></div><div id="sec4_5_2_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 1-Chloro-4-(chloro(4-iodophenyl)methyl)benzene (<b>26</b>)</h5><div class="NLM_p">SOCl<sub>2</sub> (0.138 mL, 1.89 mmol) was added dropwise to a stirred solution of <b>25</b> (0.65 g, 1.89 mmol) in DCM (9.29 mL) at room temperature. After 20 h, the solvent was evaporated under vacuum to give the product (0.653 g, 1.799 mmol, 95%) as a purple solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.63–7.58 (m, 2H), 7.27–7.16 (m, 4H), 7.07–7.02 (m, 2H), 5.94 (s, 1H).</div></div><div id="sec4_5_2_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 2-(4-((4-Chlorophenyl)(4-iodophenyl)methyl)piperazin-1-yl)ethanol (<b>27</b>)</h5><div class="NLM_p">A solution of 2-(piperazin-1-yl)ethanol (0.206 g, 1.58 mmol) in toluene (1 mL) was added to <b>26</b> (0.637 g, 1.75 mmol) and the mixture was stirred at 80 °C under nitrogen for 20 h. The mixture was diluted with DCM and purified by ion-exchange chromatography (strong cation exchange) eluting with 1 M NH<sub>3</sub>/MeOH. Fractions containing product were purified by flash silica chromatography (elution gradient 0–5% MeOH–NH<sub>3</sub> (3.5 M) in DCM) to afford the product (165 mg, 0.361 mmol, 21%) as a white solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) 7.65 (d, <i>J</i> = 8.1 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (d, <i>J</i> = 8.2 Hz, 2H), 4.15 (s, 1H), 4.32 (s, 1H), 3.5–3.42 (m, 2H), 2.48–2.41 (m, 4H), 2.38 (t, <i>J</i> = 6.0 Hz, 2H), 2.33–2.24 (m, 4H). LC–MS (ESI) <i>m</i>/<i>z</i> 457.</div></div><div id="sec4_5_2_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>S</i>)-2-(2-(4-((4-Chlorophenyl)(4-iodophenyl)methyl)piperazin-1-yl)ethoxy)acetic Acid (<b>28</b>)</h5><div class="NLM_p">KOH (79 mg, 1.41 mmol) was added to a stirred solution of <b>27</b> (161 mg, 0.35 mmol) in DMF (641 μL) at 0 °C and the mixture was stirred for 90 min. Sodium 2-chloroacetate (82 mg, 0.70 mmol) was added and the mixture was stirred for 3 h. Water (3 mL) was added and the pH was adjusted to 9–10 with aq HCl (1 M). The mixture was washed with EtOAc (2 × 1 mL) and the pH was adjusted to 4–5 with aq HCl (1 M). The mixture was extracted with DCM (3 × 2 mL). The combined DCM phases were washed with brine (2 mL), dried (MgSO<sub>4</sub>), filtered, and evaporated to give, after trituration with Et<sub>2</sub>O, racemic product (103 mg, 0.200 mmol, 57%) as an off-white solid.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) 7.69–7.65 (m, 2H), 7.44–7.4 (m, 2H), 7.38–7.34 (m, 2H), 7.22 (d, <i>J</i> = 8.4 Hz, 2H), 3.87 (s, 2H), 4.39 (s, 1H), 3.62 (t, <i>J</i> = 5.5 Hz, 2H), 2.85–2.63 (m, 6H), 2.46–2.27 (m, 4H). LC–MS (ESI) <i>m</i>/<i>z</i> 515.</div><div class="NLM_p last">The stereoisomers were separated by chromatography using a Chiralpak OD column, 5 μm silica, 20 mm diameter, 250 mm length, eluting with 95/05/0.2/0.1 mixture of MeCN/MeOH/AcOH/TEA to give the desired isomer (first eluted) (<i>S</i>)-2-(2-(4-((4-chlorophenyl)(4-iodophenyl)methyl)piperazin-1-yl)ethoxy)acetic acid (<i>S</i>)-<b>28</b> (7.8 mg)</div></div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>R</i>)-5-(4-((4-Chlorophenyl)([4-<sup>3</sup>H]phenyl)methyl)piperazin-1-yl)pentanoic Acid ([<sup>3</sup>H]Levocetirizine)</h4><div class="NLM_p">Precursor (<i>S</i>)-<b>28</b> (0.8 mg, 1.55 μmol), Pd (10% on carbon, 0.5 mg, 0.47 μmol), and Et<sub>3</sub>N (5 μL, 0.04 mmol) were mixed in EtOH (200 μL). The flask was fitted to the tritium manifold. The mixture was freeze–pump–thaw degassed and was then stirred under tritium gas (63.5 GBq) at 162 mbar for 2.5 h. The reaction mixture was filtered through a poly(tetrafluoroethylene) filter (Whatman 0.45 μm) and washed thoroughly with more EtOH (5 mL). The solution was lyophilized to remove labile tritium, more EtOH (5 mL) was addeAmyloid Inhbitorsd, and the mixture was again lyophilized. Purification by preparative HPLC (Waters XBridge C18 column, 5 μm, 4.6 × 150 mm<sup>2</sup>) using decreasingly polar mixtures of water (containing 0.1% TFA) and MeCN as eluents followed by further preparative HPLC (Waters XBridge C18 column, 5 μm, 4.6 × 150 mm<sup>2</sup>), using decreasingly polar mixtures of water (containing 0.1% ammonia) and MeCN as eluents, afforded [<sup>3</sup>H]levocetirizine (728 MBq), which was dissolved in EtOH (10 mL) for storage as a colorless solution.</div><div class="NLM_p last">Radiochemical purity >98% by HPLC. Chiral purity 93% enantiomeric excess by HPLC (obtained on ethyl ester derivative by standing in ethanol with TFA for 3 days). LC–MS (ESI) <i>m</i>/<i>z</i> 391 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (640 MHz, DMSO-<i>d</i><sub>6</sub>) 7.20 (t, <i>J</i> = 7.8). Specific activity by mass spectrometry: 956 GBq mmol<sup>–1</sup>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00447" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81100" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81100" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00447" class="ext-link">10.1021/acs.jmedchem.9b00447</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Characterization of the kinetics of binding and functional inhibition for H<sub>1</sub>R antagonists (Table S1); correlations between key physicochemical properties of rupatadine analogues (<b>1</b>–<b>24</b>) vs the respective p<i>K</i><sub>i</sub> and KRI values at the H<sub>1</sub>R (Figure S1); physicochemical properties of <b>1</b>–2<b>4</b> (Table S2); docked binding poses of <b>1</b>–<b>24</b> in the H<sub>1</sub>R binding pocket (Figures S2 and S3); and <sup>1</sup>H NMR and <sup>13</sup>C NMR spectroscopy data as well as high-resolution mass spectroscopy and LC–MS chromatograms (Figures S4–S69) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biochemical data of <b>1</b>–<b>24</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf">jm9b00447_si_001.pdf (6.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_002.csv">jm9b00447_si_002.csv (2.23 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00447" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rob Leurs</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1354-2848" title="Orcid link">http://orcid.org/0000-0003-1354-2848</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e99bc7858c9c9b9aa99f9cc78785"><span class="__cf_email__" data-cfemail="97e5b9fbf2e2e5e4d7e1e2b9f9fb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reggie Bosma</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyong Wang</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert J. Kooistra</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span>; 
    <span>Present Address:
                        Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark (A.J.K.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5514-6021" title="Orcid link">http://orcid.org/0000-0001-5514-6021</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nick Bushby</span> - <span class="hlFld-Affiliation affiliation">Operations,
BioPharmaceuticals R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sebastiaan Kuhne</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jelle van den Bor</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Waring</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry, Research and Early
Development, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom</span>; 
    <span>Present Address:
                        Northern Institute for Cancer Research, School of Natural and Environmental Sciences, Newcastle University, Bedson Building, Newcastle upon Tyne NE1 7RU, United Kingdom (M.J.W.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9110-8783" title="Orcid link">http://orcid.org/0000-0002-9110-8783</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris de Graaf</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span>; 
    <span>Present Address:
                        Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom (C.d.G.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1226-2150" title="Orcid link">http://orcid.org/0000-0002-1226-2150</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iwan J. de Esch</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Henry
F. Vischer</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0184-6337" title="Orcid link">http://orcid.org/0000-0002-0184-6337</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert J. Sheppard</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Cardiovascular, Renal and
Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maikel Wijtmans</span> - <span class="hlFld-Affiliation affiliation">Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, VU University
Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8955-8016" title="Orcid link">http://orcid.org/0000-0001-8955-8016</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.B. and Z.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4171-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85385" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85385" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Hans Custers is thanked for technical assistance. This research was financially supported by the EU/EFPIA Innovative Medicines Initiative (IMI) Joint Undertaking, K4DD (grant no. 115366) as well as by the China Scholarship Council (CSC) (grant no. 201506270163).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">H<sub>1</sub>R</td><td class="NLM_def"><p class="first last">histamine H<sub>1</sub> receptor</p></td></tr><tr><td class="NLM_term">KRI</td><td class="NLM_def"><p class="first last">kinetic rate index</p></td></tr><tr><td class="NLM_term">RecT</td><td class="NLM_def"><p class="first last">recovery time</p></td></tr><tr><td class="NLM_term">SKR</td><td class="NLM_def"><p class="first last">structure–kinetics relationship</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14276" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14276" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Biochemical mechanisms of drug action: what does it take for success?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1038/nrd1500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd1500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=15340390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=801-808&author=D.+C.+Swinney&title=Biochemical+mechanisms+of+drug+action%3A+what+does+it+take+for+success%3F&doi=10.1038%2Fnrd1500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Biochemical mechanisms of drug action: what does it take for success?</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">801-808</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Drug discovery is extremely difficult.  There are many unanticipated scientific, medical and business challenges to every drug discovery program.  It is important to increase our understanding of the fundamental properties of effective drugs so that we can anticipate potential problems in developing new agents.  This article addresses potential drug discovery and development risks assocd. with the biochem. mechanism of drug action, and proposes simple rules to minimize these risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXhyDgozFUdrVg90H21EOLACvtfcHk0lhyhwgqUOKGDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D&md5=b06bdc6ace3168dcb011679b43b72aed</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd1500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1500%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DBiochemical%2520mechanisms%2520of%2520drug%2520action%253A%2520what%2520does%2520it%2520take%2520for%2520success%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D801%26epage%3D808%26doi%3D10.1038%2Fnrd1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.2174/156802606776743093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.2174%2F156802606776743093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16719803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtV2jurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=461-478&author=D.+C.+Swinney&title=Biochemical+mechanisms+of+new+molecular+entities+%28NMEs%29+approved+by+United+States+FDA+during+2001-2004%3A+mechanisms+leading+to+optimal+efficacy+and+safety&doi=10.2174%2F156802606776743093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">461-478</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The United States FDA approved 85 New Mol. Entities (NMEs) during the period from Jan. 2001 to Nov. 2004 of which 60 were pharmaceuticals with known mol. targets.  The majority targeted enzymes (48%) or G-protein coupled receptors (GPCRs) (33%).  Eighty percent of the NMEs interacted at the same site as endogenous effector; either as competitive inhibitor/antagonist (67%) or agonist (13%).  Three biochem. operations defined the modes of action of the NMEs: (1) mass action competition (equil.), (2) a drug stabilized conformational change in the target that is important to the response (conformational), and(or) (3) drug action is less-responsive to mass action competition with effectors due to non-equil. kinetics (non-equil. kinetic).  Approx. 80% of the NMEs elicit a response utilizing conformational and(or) non-equil. kinetic mechanisms.  The remaining 20% of NMEs find mass action competition with the endogenous substrate or ligand sufficient for therapeutic utility.  These observations indicate that for the majority of drug targets, mass action-driven equil. binding alone may not be sufficient for maximal therapeutic utility.  A key determinant of the biochem. mode of action for these NMEs was to minimize the potential for toxicity, either by providing a maximal response at a low dose to minimize off-target toxicities, or by providing a mechanism to minimize the incidence of mechanism-based toxicity while retaining a sufficiently efficacious response.  This principle appears to be independent of target class and provides insight as to intrinsic biochem. features and approaches required for a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7meEijEZ3GrVg90H21EOLACvtfcHk0lhyhwgqUOKGDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtV2jurs%253D&md5=091dc5bf90bf465ccf21160bd9140067</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F156802606776743093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606776743093%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DBiochemical%2520mechanisms%2520of%2520new%2520molecular%2520entities%2520%2528NMEs%2529%2520approved%2520by%2520United%2520States%2520FDA%2520during%25202001-2004%253A%2520mechanisms%2520leading%2520to%2520optimal%2520efficacy%2520and%2520safety%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D461%26epage%3D478%26doi%3D10.2174%2F156802606776743093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0ljWovVBMCwe8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Applications of binding kinetics to drug discovery</span>. <i>Pharm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1007/BF03256679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2FBF03256679" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=23-34&author=D.+C.+Swinney&title=Applications+of+binding+kinetics+to+drug+discovery&doi=10.1007%2FBF03256679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2FBF03256679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03256679%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DApplications%2520of%2520binding%2520kinetics%2520to%2520drug%2520discovery%26jtitle%3DPharm.%2520Med.%26date%3D2008%26volume%3D22%26spage%3D23%26epage%3D34%26doi%3D10.1007%2FBF03256679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">The drug–target residence time model: a 10-year retrospective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd.2015.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=26678621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=87-95&author=R.+A.+Copeland&title=The+drug%E2%80%93target+residence+time+model%3A+a+10-year+retrospective&doi=10.1038%2Fnrd.2015.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The drug-target residence time model: a 10-year retrospective</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The drug-target residence time model was first introduced in 2006 and has been broadly adopted across the chem. biol., biotechnol. and pharmaceutical communities.  While traditional in vitro methods view drug-target interactions exclusively in terms of equil. affinity, the residence time model takes into account the conformational dynamics of target macromols. that affect drug binding and dissocn.  The key tenet of this model is that the lifetime (or residence time) of the binary drug-target complex, and not the binding affinity per se, dictates much of the in vivo pharmacol. activity.  Here, this model is revisited and key applications of it over the past 10 years are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNrhp9U8kwLVg90H21EOLACvtfcHk0ljWovVBMCwe8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE&md5=23f4a6973d77804292ff0af6c81358c0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.18%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520drug%25E2%2580%2593target%2520residence%2520time%2520model%253A%2520a%252010-year%2520retrospective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D87%26epage%3D95%26doi%3D10.1038%2Fnrd.2015.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span> <span> </span><span class="NLM_article-title">Ligand residence time at G-protein-coupled receptors-why we should take our time to study it</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1124/mol.115.099671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1124%2Fmol.115.099671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=26152198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCgs77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=552-560&author=C.+Hoffmannauthor=M.+Castroauthor=A.+Rinkenauthor=R.+Leursauthor=S.+J.+Hillauthor=H.+F.+Vischer&title=Ligand+residence+time+at+G-protein-coupled+receptors-why+we+should+take+our+time+to+study+it&doi=10.1124%2Fmol.115.099671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand residence time at G-protein-coupled receptors-why we should take our time to study it</span></div><div class="casAuthors">Hoffmann, C.; Castro, M.; Rinken, A.; Leurs, R.; Hill, S. J.; Vischer, H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">552-560</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Over the past decade the kinetics of ligand binding to a receptor have received increasing interest.  The concept of drug-target residence time is becoming an invaluable parameter for drug optimization.  It holds great promise for drug development, and its optimization is thought to reduce off-target effects.  The success of long-acting drugs like tiotropium support this hypothesis.  Nonetheless, we know surprisingly little about the dynamics and the mol. detail of the drug binding process.  Because protein dynamics and adaptation during the binding event will change the conformation of the protein, ligand binding will not be the static process that is often described.  This can cause problems because simple math. models often fail to adequately describe the dynamics of the binding process.  In this minireview we will discuss the current situation with an emphasis on G-protein-coupled receptors.  These are important membrane protein drug targets that undergo conformational changes upon agonist binding to communicate signaling information across the plasma membrane of cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulpr-SkEipLVg90H21EOLACvtfcHk0ljy4biTQLZtzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCgs77P&md5=c675935da015aa4a590c75a4be65d01a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.099671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.099671%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DCastro%26aufirst%3DM.%26aulast%3DRinken%26aufirst%3DA.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26atitle%3DLigand%2520residence%2520time%2520at%2520G-protein-coupled%2520receptors-why%2520we%2520should%2520take%2520our%2520time%2520to%2520study%2520it%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D552%26epage%3D560%26doi%3D10.1124%2Fmol.115.099671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time-a case for G protein-coupled receptors</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/med.21307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1002%2Fmed.21307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=24549504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=856-892&author=D.+Guoauthor=J.+M.+Hillgerauthor=A.+P.+IJzermanauthor=L.+H.+Heitman&title=Drug-target+residence+time-a+case+for+G+protein-coupled+receptors&doi=10.1002%2Fmed.21307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Target Residence Time-A Case for G Protein-Coupled Receptors</span></div><div class="casAuthors">Guo, Dong; Hillger, Julia M.; Ijzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">856-892</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A vast no. of marketed drugs act on G protein-coupled receptors (GPCRs), the most successful category of drug targets to date.  These drugs usually possess high target affinity and selectivity, and such combined features have been the driving force in the early phases of drug discovery.  However, attrition has also been high.  Many investigational new drugs eventually fail in clin. trials due to a demonstrated lack of efficacy.  A retrospective assessment of successfully launched drugs revealed that their beneficial effects in patients may be attributed to their long drug-target residence times (RTs).  Likewise, for some other GPCR drugs short RT could be beneficial to reduce the potential for on-target side effects.  Hence, the compds.' kinetics behavior might in fact be the guiding principle to obtain a desired and durable effect in vivo.  We therefore propose that drug-target RT should be taken into account as an addnl. parameter in the lead selection and optimization process.  This should ultimately lead to an increased no. of candidate drugs moving to the preclin. development phase and on to the market.  This review contains examples of the kinetics behavior of GPCR ligands with improved in vivo efficacy and summarizes methods for assessing drug-target RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN5vhWI93LMbVg90H21EOLACvtfcHk0ljy4biTQLZtzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D&md5=af48cdedf3c60ecb608d5c9ad03a0bbe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.21307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21307%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHillger%26aufirst%3DJ.%2BM.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DDrug-target%2520residence%2520time-a%2520case%2520for%2520G%2520protein-coupled%2520receptors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D856%26epage%3D892%26doi%3D10.1002%2Fmed.21307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, P. J.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time: critical information for lead optimization</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2010.06.176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.cbpa.2010.06.176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=20663707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=467-474&author=H.+Luauthor=P.+J.+Tonge&title=Drug-target+residence+time%3A+critical+information+for+lead+optimization&doi=10.1016%2Fj.cbpa.2010.06.176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time: Critical information for lead optimization</span></div><div class="casAuthors">Lu, Hao; Tonge, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-474</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics.  Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug-target binding are flawed, since this approach ignores the fluctuations in drug concn. that occur in vivo.  Instead the lifetime of the drug-target complex must also be considered, since drugs only act when they are bound to their targets.  Consequently, to improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug-target residence time must be incorporated into the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodk2kN_txuMLVg90H21EOLACvtfcHk0ljy4biTQLZtzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr4%253D&md5=3189f56032106db858cfb4269d3fc11f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.176%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26atitle%3DDrug-target%2520residence%2520time%253A%2520critical%2520information%2520for%2520lead%2520optimization%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D467%26epage%3D474%26doi%3D10.1016%2Fj.cbpa.2010.06.176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fj.1476-5381.2010.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=20880390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=488-508&author=G.+Vauquelinauthor=S.+J.+Charlton&title=Long-lasting+target+binding+and+rebinding+as+mechanisms+to+prolong+in+vivo+drug+action&doi=10.1111%2Fj.1476-5381.2010.00936.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span></div><div class="casAuthors">Vauquelin, Georges; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-508</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  An increasing no. of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding.  The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent.  Simulations reveal that these latter phenomena become esp. influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy.  There is not always a direct link between slow dissocn. and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor.  Local phenomena that hinder the diffusion of free drug mols. away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concn. in the bulk phase has already dropped to insignificant levels.  The micro-anat. properties of many effect compartments are likely to intensify this phenomenon.  By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiol. relevant conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSGNmKeaTzrVg90H21EOLACvtfcHk0ljyKuBHyClVMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE&md5=bd91e09a0fd79a2de6bf9ef0cfd3443e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DLong-lasting%2520target%2520binding%2520and%2520rebinding%2520as%2520mechanisms%2520to%2520prolong%2520in%2520vivo%2520drug%2520action%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D488%26epage%3D508%26doi%3D10.1111%2Fj.1476-5381.2010.00936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folmer, R. H. A.</span></span> <span> </span><span class="NLM_article-title">Drug target residence time: a misleading concept</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.drudis.2017.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=28782685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=12-16&author=R.+H.+A.+Folmer&title=Drug+target+residence+time%3A+a+misleading+concept&doi=10.1016%2Fj.drudis.2017.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug target residence time: a misleading concept</span></div><div class="casAuthors">Folmer, Rutger H. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-16</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Since the importance of drug target residence time was first highlighted more 10 years ago, slow binding kinetics has received much attention in the drug discovery literature, and indeed within pharmaceutical research.  However, the residence concept as presented in most papers is supported by rather misleading simulations and arguments, and by examples where compds. are taken out of their pharmacokinetic context.  Moreover, fast assocn. is typically more desirable than slow, and advantages of long residence time, notably a potential disconnect between pharmacodynamics (PD) and pharmacokinetics (PK), would be partially or completely offset by slow on-rate.  Therefore, plain potency is likely a better predictor of drug development success than is residence time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5NQgx9uuufLVg90H21EOLACvtfcHk0ljyKuBHyClVMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitbjI&md5=61f68447e7f8eaf6b93c4b09fc5afeda</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DFolmer%26aufirst%3DR.%2BH.%2BA.%26atitle%3DDrug%2520target%2520residence%2520time%253A%2520a%2520misleading%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2018%26volume%3D23%26spage%3D12%26epage%3D16%26doi%3D10.1016%2Fj.drudis.2017.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerud, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and the drug-target residence time concept</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.drudis.2013.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23500610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=697-707&author=G.+Dahlauthor=T.+Akerud&title=Pharmacokinetics+and+the+drug-target+residence+time+concept&doi=10.1016%2Fj.drudis.2013.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and the drug-target residence time concept</span></div><div class="casAuthors">Dahl, Goeran; Akerud, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of drug-target residence time has been in focus in recent drug discovery literature.  However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug.  Using a simple model that takes both PK and BK into account, we found that prolongation of binding owing to a long drug-target residence time can only occur when the binding dissocn. is slower than the PK elimination.  Data for several drugs and/or drug candidates in the literature indicate that the opposite is obsd., i.e., they have a slower elimination compared with dissocn.  These observations greatly reduce the usability of drug-target residence times for estg. the duration of effect of a drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2xZ9fJkTybVg90H21EOLACvtfcHk0ljyKuBHyClVMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D&md5=73b190a44d359f55ee19af9099846505</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DAkerud%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520the%2520drug-target%2520residence%2520time%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.drudis.2013.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span> <span> </span><span class="NLM_article-title">In vivo target residence time and kinetic selectivity: the association rate constant as determinant</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.tips.2016.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27394919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=831-842&author=W.+E.+A.+de%0AWitteauthor=M.+Danhofauthor=P.+H.+van+der+Graafauthor=E.+C.+M.+de+Lange&title=In+vivo+target+residence+time+and+kinetic+selectivity%3A+the+association+rate+constant+as+determinant&doi=10.1016%2Fj.tips.2016.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant</span></div><div class="casAuthors">de Witte, Wilhelmus E. A.; Danhof, Meindert; van der Graaf, Piet H.; de Lange, Elizabeth C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">831-842</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">It is generally accepted that, in conjunction with pharmacokinetics, the first-order rate const. of target dissocn. is a major determinant of the time course and duration of in vivo target occupancy.  Here we show that the second-order rate const. of target assocn. can be equally important.  On the basis of the commonly used math. models for drug-target binding, it is shown that a high target assocn. rate const. can increase the (local) concn. of the drug, which decreases the rate of decline of target occupancy.  The increased drug concn. can also lead to increased off-target binding and decreased selectivity.  Therefore, the kinetics of both target assocn. and dissocn. need to be taken into account in the selection of drug candidates with optimal pharmacodynamic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri0cm4NKLv-7Vg90H21EOLACvtfcHk0liHK7dQPBeVPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE&md5=e2c077f2c8636214e2f8a77ee5734ad4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.06.008%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DDanhof%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26atitle%3DIn%2520vivo%2520target%2520residence%2520time%2520and%2520kinetic%2520selectivity%253A%2520the%2520association%2520rate%2520constant%2520as%2520determinant%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26spage%3D831%26epage%3D842%26doi%3D10.1016%2Fj.tips.2016.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Louizos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yáñez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. M.</span></span> <span> </span><span class="NLM_article-title">Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships</span>. <i>J. Pharm. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.18433/J3GP53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.18433%2FJ3GP53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=24735761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADC%252BC2cnkt1OjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=34-91&author=C.+Louizosauthor=J.+A.+Y%C3%A1%C3%B1ezauthor=M.+L.+Forrestauthor=N.+M.+Davies&title=Understanding+the+hysteresis+loop+conundrum+in+pharmacokinetic%2Fpharmacodynamic+relationships&doi=10.18433%2FJ3GP53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships</span></div><div class="casAuthors">Louizos Christopher; Yanez Jaime A; Forrest M Laird; Davies Neal M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hysteresis loops are phenomena that sometimes are encountered in the analysis of pharmacokinetic and pharmacodynamic relationships spanning from pre-clinical to clinical studies.  When hysteresis occurs it provides insight into the complexity of drug action and disposition that can be encountered.  Hysteresis loops suggest that the relationship between drug concentration and the effect being measured is not a simple direct relationship, but may have an inherent time delay and disequilibrium, which may be the result of metabolites, the consequence of changes in pharmacodynamics or the use of a non-specific assay or may involve an indirect relationship.  Counter-clockwise hysteresis has been generally defined as the process in which effect can increase with time for a given drug concentration, while in the case of clockwise hysteresis the measured effect decreases with time for a given drug concentration.  Hysteresis loops can occur as a consequence of a number of different pharmacokinetic and pharmacodynamic mechanisms including tolerance, distributional delay, feedback regulation, input and output rate changes, agonistic or antagonistic active metabolites, uptake into active site, slow receptor kinetics, delayed or modified activity, time-dependent protein binding and the use of racemic drugs among other factors.  In this review, each of these various causes of hysteresis loops are discussed, with incorporation of relevant examples of drugs demonstrating these relationships for illustrative purposes.  Furthermore, the effect that pharmaceutical formulation has on the occurrence and potential change in direction of the hysteresis loop, and the major pharmacokinetic / pharmacodynamic modeling approaches utilized to collapse and model hysteresis are detailed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSC0uKaIdi8tLjnyZkbE8yXfW6udTcc2eYKEKz4iwGmybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnkt1OjsA%253D%253D&md5=7e58b87eebafb814d7ed9fe01c5218af</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18433%2FJ3GP53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ3GP53%26sid%3Dliteratum%253Aachs%26aulast%3DLouizos%26aufirst%3DC.%26aulast%3DY%25C3%25A1%25C3%25B1ez%26aufirst%3DJ.%2BA.%26aulast%3DForrest%26aufirst%3DM.%2BL.%26aulast%3DDavies%26aufirst%3DN.%2BM.%26atitle%3DUnderstanding%2520the%2520hysteresis%2520loop%2520conundrum%2520in%2520pharmacokinetic%252Fpharmacodynamic%2520relationships%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D17%26spage%3D34%26epage%3D91%26doi%3D10.18433%2FJ3GP53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span> <span> </span><span class="NLM_article-title">Effects of target binding kinetics on in vivo drug efficacy: <i>k</i><sub>off</sub>, <i>k</i><sub>on</sub> and rebinding</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">2319</span>– <span class="NLM_lpage">2334</span>, <span class="refDoi"> DOI: 10.1111/bph.13504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fbph.13504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27129075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSiurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=2319-2334&author=G.+Vauquelin&title=Effects+of+target+binding+kinetics+on+in+vivo+drug+efficacy%3A+koff%2C+kon+and+rebinding&doi=10.1111%2Fbph.13504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of target binding kinetics on in vivo drug efficacy: koff, kon and rebinding</span></div><div class="casAuthors">Vauquelin, Georges</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2319-2334</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Optimal drug therapy often requires continuing high levels of target occupancy.  Besides the traditional pharmacokinetic contribution, target binding kinetics is increasingly considered to play an important role as well.  While most attention has been focused on the dissocn. rate of the complex, recent reports expressed doubt about the unreserved translatability of this pharmacodynamic property into clin. efficacy. 'Micro'-pharmacokinetic mechanisms like drug rebinding and partitioning into the cell membrane may constitute a potential fix.  Exptl. Approach : Simulations were based on solving differential equations.  Key Results : Based on a selected range of assocn. and dissocn. rate consts., kon and koff, and rebinding potencies of the drugs as variables, their effects on the temporal in vivo occupancy profile of their targets, after one or multiple repetitive dosings, have here been simulated.  Conclusions and Implications : Most strikingly, the simulations show that, when rebinding is also taken into account, increasing kon may produce closely the same outcome as decreasing koff when dosing is performed in accordance with the therapeutically most relevant const. [Lmax]/KD ratio paradigm.  Also, under certain conditions, rebinding may produce closely the same outcome as invoking slow diffusion of the drug between the plasma compartment and a target-contg. 'effect' compartment.  Although the present simulations should only be regarded as a 'proof of principle', these findings may help pharmacologists and medicinal chemists to devise ex vivo and in vitro binding kinetic assays that are more relevant and translatable to in vivo settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5-dbZNJetv7Vg90H21EOLACvtfcHk0lhY44mBc1b0pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSiurvI&md5=5d1b13ef5786a0c661118ce9be503d50</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fbph.13504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13504%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DEffects%2520of%2520target%2520binding%2520kinetics%2520on%2520in%2520vivo%2520drug%2520efficacy%253A%2520koff%252C%2520kon%2520and%2520rebinding%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D2319%26epage%3D2334%26doi%3D10.1111%2Fbph.13504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span> <span> </span><span class="NLM_article-title">The influence of drug distribution and drug-target binding on target occupancy: the rate-limiting step approximation</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">S83</span>– <span class="NLM_lpage">S89</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.ejps.2017.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotFyntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=S83-S89&author=W.+E.+A.+de%0AWitteauthor=G.+Vauquelinauthor=P.+H.+van+der+Graafauthor=E.+C.+M.+de+Lange&title=The+influence+of+drug+distribution+and+drug-target+binding+on+target+occupancy%3A+the+rate-limiting+step+approximation&doi=10.1016%2Fj.ejps.2017.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation</span></div><div class="casAuthors">de Witte, W. E. A.; Vauquelin, G.; van der Graaf, P. H.; de Lange, E. C. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Suppl.</span>),
    <span class="NLM_cas:pages">S83-S89</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The influence of drug-target binding kinetics on target occupancy can be influenced by drug distribution and diffusion around the target, often referred to as "rebinding" or "diffusion-limited binding".  This gives rise to a decreased decline of the drug-target complex concn. as a result of a locally higher drug concn. that arises around the target, which leads to prolonged target exposure to the drug.  This phenomenon has been approximated by the steady-state approxn., assuming a steady-state concn. around the target.  Recently, a rate-limiting step approxn. of drug distribution and drug-target binding has been published.  However, a comparison between both approaches has not been made so far.  In this study, the rate-limiting step approxn. has been rewritten into the same math. format as the steady-state approxn. in order to compare the performance of both approaches for the investigation of the influence of drug-target binding kinetics on target occupancy.  While both approxns. clearly indicated the importance of kon and high target concns., it was shown that the rate-limiting step approxn. is more accurate than the steady-state approxn., esp. when dissocn. is fast compared to assocn. and distribution out of the binding compartment.  It is therefore concluded that the new rate-limiting step approxn. is to be preferred for assessing the influence of binding kinetics on local target site concns. and target occupancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFE8powQy5Q7Vg90H21EOLACvtfcHk0lhY44mBc1b0pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotFyntLo%253D&md5=f3fdcef1a3d40690eb41e8d0e37ed71a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.05.024%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26atitle%3DThe%2520influence%2520of%2520drug%2520distribution%2520and%2520drug-target%2520binding%2520on%2520target%2520occupancy%253A%2520the%2520rate-limiting%2520step%2520approximation%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D109%26spage%3DS83%26epage%3DS89%26doi%3D10.1016%2Fj.ejps.2017.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0lhY44mBc1b0pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simons, F. E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, K. J.</span></span> <span> </span><span class="NLM_article-title">Histamine and H1-antihistamines: celebrating a century of progress</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2011.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.jaci.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=22035879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKnu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2011&pages=1139-1150&author=F.+E.+R.+Simonsauthor=K.+J.+Simons&title=Histamine+and+H1-antihistamines%3A+celebrating+a+century+of+progress&doi=10.1016%2Fj.jaci.2011.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine and H1-antihistamines: Celebrating a century of progress</span></div><div class="casAuthors">Simons, F. Estelle R.; Simons, Keith J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1139-1150.e4</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this review we celebrate a century of progress since the initial description of the physiol. and pathol. roles of histamine and 70 years of progress since the introduction of H1-antihistamines for clin. use.  We discuss histamine and clin. relevant information about the mol. mechanisms of action of H1-antihistamines as inverse agonists (not antagonists or blockers) with immunoregulatory effects.  Unlike first (old)-generation H1-antihistamines introduced from 1942 to the mid-1980s, most of the second (new)-generation H1-antihistamines introduced subsequently have been investigated extensively with regard to clin. pharmacol., efficacy, and safety; moreover, they are relatively free from adverse effects and not causally linked with fatalities after overdose.  Important advances include improved nasal and ophthalmic H1-antihistamines with rapid onset of action (in minutes) for allergic rhinitis and allergic conjunctivitis treatment, resp., and effective and safe use of high (up to 4-fold) doses of oral second-generation H1-antihistamines for chronic urticaria treatment.  New H1-antihistamines introduced for clin. use include oral formulations (bilastine and rupatadine), and ophthalmic formulations (alcaftadine and bepotastine).  Clin. studies of H3-antihistamines with enhanced decongestant effects have been conducted in patients with allergic rhinitis.  Addnl. novel compds. being studied include H4-antihistamines with anti-inflammatory effects in allergic rhinitis, atopic dermatitis, and other diseases.  Antihistamines have a storied past and a promising future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXBww6BOAHrVg90H21EOLACvtfcHk0lix0REkIvHAgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKnu7%252FL&md5=974702e4d5d97dc67acebfcd6cb61ca7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DF.%2BE.%2BR.%26aulast%3DSimons%26aufirst%3DK.%2BJ.%26atitle%3DHistamine%2520and%2520H1-antihistamines%253A%2520celebrating%2520a%2520century%2520of%2520progress%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2011%26volume%3D128%26spage%3D1139%26epage%3D1150%26doi%3D10.1016%2Fj.jaci.2011.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoepke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span> <span> </span><span class="NLM_article-title">The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy caucasian and japanese volunteers</span>. <i>Acta Derm. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.2340/00015555-1490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.2340%2F00015555-1490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23147964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ekurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=286-293&author=N.+Schoepkeauthor=M.+Churchauthor=M.+Maurer&title=The+inhibition+by+levocetirizine+and+fexofenadine+of+the+histamine-induced+wheal+and+flare+response+in+healthy+caucasian+and+japanese+volunteers&doi=10.2340%2F00015555-1490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers</span></div><div class="casAuthors">Schoepke, Nicole; Church, Martin K.; Maurer, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-293, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">1651-2057</span>.
    
            (<span class="NLM_cas:orgname">Acta Dermato-Venereologica</span>)
        </div><div class="casAbstract">This randomized, double-blind, placebo-controlled cross-over study compared inhibition by one 5 mg dose of levocetirizine with two 60 mg doses of fexofenadine sepd. by 12 h of histamine-induced wheal and flare responses in 9 Caucasian and 9 Japanese healthy male volunteers.  Levocetirizine was more inhibitory than fexofenadine on wheal, flare and pruritus (p<0.005).  Variability, evaluated from the std. deviation of inhibition, ranged from 14% to 23.2% for levocetirizine and 65.4% to 112.4% for fexofenadine.  Levocetirizine had a faster onset of action (30-90 min vs. 2 h), shorter time to max. effect (3-4 vs. 3-6 h) and longer duration of action (at least 24 h vs. ∼12 h) than fexofenadine.  The plasma levels of levocetirizine rose more quickly, reached higher levels, were more consistent and decreased slower than those of fexofenadine.  There were no clin. significant ethnic differences in responsiveness to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU3pstGQuc8bVg90H21EOLACvtfcHk0lix0REkIvHAgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ekurnK&md5=8b85c352f07576c8426cc80f6cb2e72c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2340%2F00015555-1490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2340%252F00015555-1490%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepke%26aufirst%3DN.%26aulast%3DChurch%26aufirst%3DM.%26aulast%3DMaurer%26aufirst%3DM.%26atitle%3DThe%2520inhibition%2520by%2520levocetirizine%2520and%2520fexofenadine%2520of%2520the%2520histamine-induced%2520wheal%2520and%2520flare%2520response%2520in%2520healthy%2520caucasian%2520and%2520japanese%2520volunteers%26jtitle%3DActa%2520Derm.%2520Venereol.%26date%3D2013%26volume%3D93%26spage%3D286%26epage%3D293%26doi%3D10.2340%2F00015555-1490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Perren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moguilevsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massingham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, P.</span></span> <span> </span><span class="NLM_article-title">Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1124/mol.61.2.391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1124%2Fmol.61.2.391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=11809864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1OnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2002&pages=391-399&author=M.+Gillardauthor=C.+Van+Der+Perrenauthor=N.+Moguilevskyauthor=R.+Massinghamauthor=P.+Chatelain&title=Binding+characteristics+of+cetirizine+and+levocetirizine+to+human+H1+histamine+receptors%3A+contribution+of+Lys191+and+Thr194&doi=10.1124%2Fmol.61.2.391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194</span></div><div class="casAuthors">Gillard, Michel; Van Der Perren, Christy; Moguilevsky, Nicole; Massingham, Roy; Chatelain, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-399</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Competition expts. with [3H]mepyramine showed that cetirizine and its enantiomers, levocetirizine and (S)-cetirizine, bound with high affinity and stereoselectivity to human H1 histamine receptors (Ki values of 6, 3, and 100 nM, resp.).  Cetirizine and levocetirizine were 600-fold more selective for H1 receptors compared with a panel of receptors and channels.  Binding results indicated that the interaction between cetirizine, its enantiomers, and histamine is compatible with a competitive behavior, in contrast with the noncompetitive profile of cetirizine and levocetirizine obsd. in isolated organs.  Binding kinetics provided a suitable explanation for this observation, because levocetirizine dissocd. from H1 receptors with a half-time of 142 min; that of (S)-cetirizine was only 6 min, implying that the former could act as a pseudo-irreversible antagonist in functional studies.  The carboxylic function of levocetirizine seemed responsible for its long dissocn. time.  Indeed, hydroxyl or Me ester analogs dissocd. more rapidly from H1 receptors, with half-times of 31 min and 7 min, resp.  The importance of the carboxylic function of levocetirizine for the interaction with the H1 receptor was further supported by the results from the mutation of Lys191 to Ala191.  This mutation decreased the dissocn. half-time of levocetirizine from 142 to 13 min and reduced its affinity from 3 to 12 nM, whereas the affinity and dissocn. kinetics of hydroxyl and Me ester analogs were hardly affected.  The mutation of Thr194 reduced the binding stereoselectivity by selectively enhancing the affinity of the distomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUA4hyZN6ibVg90H21EOLACvtfcHk0ljtrwrGzmdHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1OnsQ%253D%253D&md5=92af3601b619f4f3dc876dc9fd1ab999</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fmol.61.2.391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.61.2.391%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DVan%2BDer%2BPerren%26aufirst%3DC.%26aulast%3DMoguilevsky%26aufirst%3DN.%26aulast%3DMassingham%26aufirst%3DR.%26aulast%3DChatelain%26aufirst%3DP.%26atitle%3DBinding%2520characteristics%2520of%2520cetirizine%2520and%2520levocetirizine%2520to%2520human%2520H1%2520histamine%2520receptors%253A%2520contribution%2520of%2520Lys191%2520and%2520Thr194%26jtitle%3DMol.%2520Pharmacol.%26date%3D2002%26volume%3D61%26spage%3D391%26epage%3D399%26doi%3D10.1124%2Fmol.61.2.391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span> <span> </span><span class="NLM_article-title">Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1007/s00011-011-0373-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2Fs00011-011-0373-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=21874559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSju73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=1107-1112&author=M.+K.+Church&title=Comparative+inhibition+by+bilastine+and+cetirizine+of+histamine-induced+wheal+and+flare+responses+in+humans&doi=10.1007%2Fs00011-011-0373-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans</span></div><div class="casAuthors">Church, Martin K.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1107-1112</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Comparison of bilastine and cetirizine in inhibiting skin wheal and flare responses over 24 h.  Twenty-one healthy male volunteers (aged 19-44 years).  Volunteers were randomized to receive single oral doses of 20 or 50 mg bilastine, 10 mg cetirizine or placebo before provocation of wheal and flare responses to 100 mg/mL histamine by skin prick 1.5, 4, 8, 12, and 24 h later.  There were no significant differences between overall inhibitions of wheal or flare by 20 mg bilastine and 10 mg cetirizine.  Bilastine was faster in onset than cetirizine, inhibitions of wheal and flare at 1.5 h being 89 vs. 44% and 85 vs. 45%, resp. (Student's t test).  At 1.5 h, both wheals and flares were inhibited by >70% in 11/12 volunteers taking bilastine and 3/11 taking cetirizine.  There were no significant differences between the drugs at later times.  Bilastine 50 mg had a longer duration of action than bilastine 20 mg.  Both 20 mg bilastine and 10 mg cetirizine are effective and of long duration in reducing histamine-induced wheal and flare responses, the major difference between the 2 drugs being the more rapid onset of action of bilastine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXAVx6mYGjXrVg90H21EOLACvtfcHk0ljtrwrGzmdHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSju73P&md5=c4bfdb3b3f1c3279e3c70ebd6e13b93b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00011-011-0373-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-011-0373-y%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26atitle%3DComparative%2520inhibition%2520by%2520bilastine%2520and%2520cetirizine%2520of%2520histamine-induced%2520wheal%2520and%2520flare%2520responses%2520in%2520humans%26jtitle%3DInflammation%2520Res.%26date%3D2011%26volume%3D60%26spage%3D1107%26epage%3D1112%26doi%3D10.1007%2Fs00011-011-0373-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1330</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.2010.10029.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fj.1365-2133.2010.10029.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=20819087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFGltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2010&pages=1330-1332&author=M.+K.+Church&title=Efficacy+and+tolerability+of+rupatadine+at+four+times+the+recommended+dose+against+histamine-+and+platelet-activating+factor-induced+flare+responses+and+ex+vivo+platelet+aggregation+in+healthy+males&doi=10.1111%2Fj.1365-2133.2010.10029.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males</span></div><div class="casAuthors">Church, M. K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1330-1332</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">European guidelines recommend increasing H1-antihistamine doses up to fourfold in poorly responding patients with urticaria.  To assess the efficacy and tolerability of high-dose rupatadine (40 mg) against platelet-activating factor (PAF)- and histamine-induced flare responses in human skin and to verify its anti-PAF activity by assessing its inhibition of PAF-induced platelet aggregation in the blood of subjects receiving rupatadine 40 mg.  In the flare study, six male volunteers received a single dose of rupatadine 40 mg.  Flares were induced before dosing and up to 96 h afterwards by intradermal PAF and histamine.  In the ex vivo study, four male volunteers received an oral dose of rupatadine 40 mg and blood samples were taken 4 h afterwards.  Platelet aggregation was assessed in platelet-rich plasma by incubation for 5 min with PAF.  Rupatadine 40 mg reached maximal plasma levels of 15.1 ± 4.4 ng/mL-1 at 1 h and its metabolite, desloratadine, 5.2 ± 0.9 ng/mL-1 at 2 h.  Neither was detectable at 12 h.  Inhibition of histamine- and PAF-induced flares was significant within 2 h, maximal at 6 h (87.8 ± 3.1% and 87.1 ± 2.5% inhibition, resp., P < 0.0001) and still statistically significant at 72 h.  Rupatadine 40 mg inhibited PAF-induced platelet aggregation ex vivo by 82 ± 9% (P = 0.023).  A single oral dose of rupatadine 40 mg was well tolerated with mild transient somnolence being reported.  A single dose of rupatadine at four times the recommended dose is well tolerated, highly effective for up to 72 h against PAF- and histamine-induced dermal flares and has demonstrable PAF-receptor antagonism ex vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ5Sj9vLAfyrVg90H21EOLACvtfcHk0ljtrwrGzmdHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFGltw%253D%253D&md5=fcfdafe8d0cf308f358d026bb7fb20df</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2010.10029.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2010.10029.x%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520rupatadine%2520at%2520four%2520times%2520the%2520recommended%2520dose%2520against%2520histamine-%2520and%2520platelet-activating%2520factor-induced%2520flare%2520responses%2520and%2520ex%2520vivo%2520platelet%2520aggregation%2520in%2520healthy%2520males%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2010%26volume%3D163%26spage%3D1330%26epage%3D1332%26doi%3D10.1111%2Fj.1365-2133.2010.10029.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span> <span> </span><span class="NLM_article-title">Development of a highly sensitive LC–MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: application to a clinical pharmacokinetic study</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2015.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.jpba.2015.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=25890211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtFSisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2015&pages=163-168&author=C.+Sunauthor=Q.+Liauthor=L.+Panauthor=B.+Liuauthor=P.+Guauthor=J.+Zhangauthor=L.+Dingauthor=C.+Wu&title=Development+of+a+highly+sensitive+LC%E2%80%93MS%2FMS+method+for+simultaneous+determination+of+rupatadine+and+its+two+active+metabolites+in+human+plasma%3A+application+to+a+clinical+pharmacokinetic+study&doi=10.1016%2Fj.jpba.2015.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study</span></div><div class="casAuthors">Sun, Chenglong; Li, Qian; Pan, Liping; Liu, Bing; Gu, Pan; Zhang, Junying; Ding, Li; Wu, Chungyong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-168</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An easy LC-ESI-MS/MS method was developed and validated for simultaneous detn. of rupatadine (RT) and its two active metabolites, namely desloratadine (DT) and 3-hydroxydesloratadine (3-OH-DT), in human plasma.  The chromatog. sepn. was carried out on a C18 column with gradient elution by using methanol and 10 mM ammonium acetate contg. 0.1% (vol./vol.) formic acid.  The lower limit of quantification (LLOQ) was 0.05, 0.035 and 0.035 ng/mL for RT, DT and 3-OH-DT, resp.  The intra- and inter-day precision of analytes were within the range of 1.0-4.7% and 2.2-12.1%, resp.  The intra- and inter-day accuracy of analytes were within the range of -7.7% to 5.2% and -4.1% to 4.8%, resp.  The method was successfully applied to a pharmacokinetic study of RT and its two metabolite DT and 3-OH-DT in healthy volunteers following single (10, 20, 40 mg) and multiple (10 mg) oral doses of rupatadine fumarate tablets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsb0tOdskDQ7Vg90H21EOLACvtfcHk0liNyf-xgehQFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtFSisrc%253D&md5=0a5816dea760df564cd2cd2dd6f8c251</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2015.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2015.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DC.%26atitle%3DDevelopment%2520of%2520a%2520highly%2520sensitive%2520LC%25E2%2580%2593MS%252FMS%2520method%2520for%2520simultaneous%2520determination%2520of%2520rupatadine%2520and%2520its%2520two%2520active%2520metabolites%2520in%2520human%2520plasma%253A%2520application%2520to%2520a%2520clinical%2520pharmacokinetic%2520study%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2015%26volume%3D111%26spage%3D163%26epage%3D168%26doi%3D10.1016%2Fj.jpba.2015.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonijoan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peña, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbó, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbanoj, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1650</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2008.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.clinthera.2008.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=18840369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWqs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=1639-1650&author=A.+Solansauthor=I.+Izquierdoauthor=E.+Donadoauthor=R.+Antonijoanauthor=J.+Pe%C3%B1aauthor=T.+Nadalauthor=M.-L.+Carb%C3%B3author=M.+Merlosauthor=M.+Barbanoj&title=Pharmacokinetic+and+safety+profile+of+rupatadine+when+coadministered+with+azithromycin+at+steady-state+levels%3A+a+randomized%2C+open-label%2C+two-way%2C+crossover%2C+Phase+I+study&doi=10.1016%2Fj.clinthera.2008.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, phase I study</span></div><div class="casAuthors">Solans, Anna; Izquierdo, Inaki; Donado, Esther; Antonijoan, Rosa; Pena, Juana; Nadal, Teresa; Carbo, Marcel-li; Merlos, Manuel; Barbanoj, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1639-1650</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">Background: Rupatadine is an oral active antihistamine and platelet-activating factor antagonist indicated for the management of allergic rhinitis and chronic urticaria in Europe.  Objective: The purpose of this study was to describe the effect of the concomitant administration of azithromycin and rupatadine on the pharmacokinetics of rupatadine and its metabolites after repeated doses.  Methods: This was a multiple-dose, randomized, open-label, 2-way, crossover, Phase I study in which healthy male and female volunteers received rupatadine 10 mg once a day for 6 days either alone or with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6.  Treatments were administered after a fasting period of 10 h with 240 mL of water, and fasting conditions were kept until 3 h postmedication.  A washout period of at least 21 days between the 2 active periods was obsd.  Blood samples were collected and plasma concns. of rupatadine and its metabolites desloratadine and 3-hydroxydesloratadine were detd. by liq. chromatog. tandem mass spectrometry.  Tolerability was based on the recording of adverse events (AEs), phys. examn., electrocardiograms, and lab. screen controls at baseline and the final study visit.  Results: Twenty-four healthy volunteers (15 males, 9 females; mean [SD] age, 25.67 [5.58] years; wt., 65.96 [8.57] kg) completed the study.  Except for max. obsd. concn. during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on av., there were no statistically significant differences in mean plasma concns. in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone.  The Cmax,ss ratio was 111 (90% CI, 91-136) and area under the plasma concn.-time curve during a dosing interval (AUC0-*au) ratio had a value of 103 (90% CI, 91-117).  The corresponding ratios for the rupatadine metabolites were 109 (90% CI, 100-120) for Cmax,ss and 103 (90% CI, 96-110) for AUC0-*au for desloratadine and 109 (90% CI, 103-115) for Cmax,ss and 104 (90% CI, 100-108) for AUC0-*au for 3-hydroxydesloratadine.  Point ests. for Cmax,ss ratios using paired data were 111% for rupatadine, 109% for desloratadine, and 109% for 3-hydroxydesloratadine.  The 90% CIs were included in the interval 80% to 125% for desloratadine and 3-hydroxydesloratadine, whereas 90% CI for rupatadine was shifted to the right of the interval used for comparing bioavailability of the drugs.  A total of 5 subjects reported 9 AEs; 5 of these were thought to be related to the drug administration and all were categorized as mild or moderate.  The reported AEs were somnolence (1/24 in the rupatadine group and 1/24 in the rupatadine plus azithromycin group), diarrhea (1/24 in the rupatadine plus azithromycin group), and gastric discomfort (2/24 in the rupatadine plus azithromycin group).  Four AEs were considered not to be related (2 episodes of headache, 1 anemia, 1 cheilitis).  All were resolved spontaneously.  No serious AEs were reported.  Conclusions: The results of this study in these healthy volunteers found no significant differences in pharmacokinetic parameters other than Cmax,ss of 3-hydroxydesloratadine between rupatadine 10 mg administered alone or with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6.  The administration of rupatadine compared with rupatadine plus azithromycin met the regulatory definition of bioequivalence in terms of exposure and rate parameters; however, Cmax,ss of rupatadine was outside the conventional confidence interval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppr5FtFXMpCrVg90H21EOLACvtfcHk0liNyf-xgehQFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWqs7zP&md5=f20f2743d03a0c72a03755c811ce1dab</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2008.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2008.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DSolans%26aufirst%3DA.%26aulast%3DIzquierdo%26aufirst%3DI.%26aulast%3DDonado%26aufirst%3DE.%26aulast%3DAntonijoan%26aufirst%3DR.%26aulast%3DPe%25C3%25B1a%26aufirst%3DJ.%26aulast%3DNadal%26aufirst%3DT.%26aulast%3DCarb%25C3%25B3%26aufirst%3DM.-L.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBarbanoj%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520and%2520safety%2520profile%2520of%2520rupatadine%2520when%2520coadministered%2520with%2520azithromycin%2520at%2520steady-state%2520levels%253A%2520a%2520randomized%252C%2520open-label%252C%2520two-way%252C%2520crossover%252C%2520Phase%2520I%2520study%26jtitle%3DClin.%2520Ther.%26date%3D2008%26volume%3D30%26spage%3D1639%26epage%3D1650%26doi%3D10.1016%2Fj.clinthera.2008.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anthes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrest, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. E.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>449</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(02)02049-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2FS0014-2999%2802%2902049-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=12167464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVWltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2002&pages=229-237&author=J.+C.+Anthesauthor=H.+Gilchrestauthor=C.+Richardauthor=S.+Eckelauthor=D.+Heskauthor=R.+E.+Westauthor=S.+M.+Williamsauthor=S.+Greenfederauthor=M.+Billahauthor=W.+Kreutnerauthor=R.+E.+Egan&title=Biochemical+characterization+of+desloratadine%2C+a+potent+antagonist+of+the+human+histamine+H1+receptor&doi=10.1016%2FS0014-2999%2802%2902049-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor</span></div><div class="casAuthors">Anthes, John C.; Gilchrest, Helen; Richard, Christian; Eckel, Stephen; Hesk, Dave; West, Robert E.; Williams, Shirley M.; Greenfeder, Scott; Billah, Motasim; Kreutner, William; Egan, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">449</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-237</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">We have characterized desloratadine (5H-benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene), CAS 100643-71-8) as a potent antagonist of the human histamine H1 receptor.  [3H]Desloratadine bound to membranes expressing the recombinant human histamine H1 receptor in Chinese hamster ovary cells (CHO-H1) in a specific and saturable manner with a Kd of 1.1±0.2 nM, a Bmax of 7.9±2.0 pmol/mg protein, and an assocn. rate const. of 0.011 nM-1 min-1.  The Kd calcd. from the kinetic measurements was 1.5 nM.  Dissocn. of [3H]desloratadine from the human histamine H1 receptor was slow, with only 37% of the binding reversed at 6 h in the presence of 5 μM unlabeled desloratadine.  Seventeen histamine H1-receptor antagonists were evaluated in competition-binding studies.  Desloratadine had a Ki of 0.9±0.1 nM in these competition studies.  In CHO-H1 cells, histamine stimulation resulted in a concn.-dependent increase in [Ca2+]i with an EC50 of 170±30 nM.  After a 90-min preincubation with desloratadine, the histamine-stimulated increase in [Ca2+]i was shifted to the right, with a depression of the maximal response at higher concns. of antagonist.  The apparent Kb value was 0.2±0.14 nM with a slope of 1.6±0.1.  The slow dissocn. from the receptor and noncompetitive antagonism suggests that desloratadine may be a pseudoirreversible antagonist of the human histamine H1 receptor.  The mechanism of desloratadine antagonism of the human histamine H1 receptor may help to explain the high potency and 24-h duration of action obsd. in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6H8IJZE7hrbVg90H21EOLACvtfcHk0lheUhL_vtU-kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVWltbo%253D&md5=cd55fee981b04e2ec5ee45c339f4a37c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2902049-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252902049-6%26sid%3Dliteratum%253Aachs%26aulast%3DAnthes%26aufirst%3DJ.%2BC.%26aulast%3DGilchrest%26aufirst%3DH.%26aulast%3DRichard%26aufirst%3DC.%26aulast%3DEckel%26aufirst%3DS.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DWest%26aufirst%3DR.%2BE.%26aulast%3DWilliams%26aufirst%3DS.%2BM.%26aulast%3DGreenfeder%26aufirst%3DS.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DKreutner%26aufirst%3DW.%26aulast%3DEgan%26aufirst%3DR.%2BE.%26atitle%3DBiochemical%2520characterization%2520of%2520desloratadine%252C%2520a%2520potent%2520antagonist%2520of%2520the%2520human%2520histamine%2520H1%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D449%26spage%3D229%26epage%3D237%26doi%3D10.1016%2FS0014-2999%2802%2902049-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, P.</span></span> <span> </span><span class="NLM_article-title">Changes in pH differently affect the binding properties of histamine H1 receptor antagonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2005.11.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.ejphar.2005.11.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16388798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvVCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2006&pages=205-214&author=M.+Gillardauthor=P.+Chatelain&title=Changes+in+pH+differently+affect+the+binding+properties+of+histamine+H1+receptor+antagonists&doi=10.1016%2Fj.ejphar.2005.11.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in pH differently affect the binding properties of histamine H1 receptor antagonists</span></div><div class="casAuthors">Gillard, Michel; Chatelain, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors investigated the effect of acidic pH, a condition that can be encountered during inflammation accompanying allergic reaction, on the binding properties of histamine H1 receptor antagonists, including levocetirizine ((2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; Xyzal), fexofenadine (rac-2-[4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl) piperidin-1-yl]butyl]phenyl]-2-methylpropionic acid hydrochloride; Allegra) and desloratadine (8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Clarinex).  Lowering the pH from 7.4 to 5.8 decreased the affinity of [3H]mepyramine for histamine H1 receptors from 1.7 to 7.5 nM while the opposite was obsd. with [3H]levocetirizine, whose affinity increased from 4.1 to 1.5 nM.  Competition curves with [3H]mepyramine indicated that decreasing the pH from 7.4 to 5.8 led to a 2- to 5-fold increase in the affinity of fexofenadine and levocetirizine, no change in affinity for desloratadine and a 5- to 10-fold decrease in affinity for mepyramine and histamine.  Kinetic expts. showed that the increase in affinity of levocetirizine and, to a lesser extent, fexofenadine were totally attributable to a lower dissocn. rate at acidic pH (t1/2 increasing from 77 to 266 min and from 71 to 135 min, resp.).  Although the affinity of desloratadine remained unchanged, lowering the pH caused a decrease in its dissocn. rate (t1/2 of 50 and 256 min at pH 7.5 and 5.8, resp.) accompanied by a concomitant 3.5-fold decrease in its assocn. rate const.  The loss of affinity of mepyramine at acidic pH was driven by a decrease in its assocn. rate const.  Interaction between the carboxylic moiety of levocetirizine and Lys191 is responsible for its slow dissocn. rate from the receptor.  The authors found that the magnitude of the pH effect on the dissocn. rate of levocetirizine was maintained after mutating Lys191 into alanine, suggesting that a tighter interaction of levocetirizine with Lys191 at lower pH is not the cause of its even slower dissocn. rate from the receptor.  Although these changes may seem limited in amplitude, the authors show that they may have substantial effects on receptor occupancy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FEmST1QTYbVg90H21EOLACvtfcHk0lheUhL_vtU-kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvVCnsA%253D%253D&md5=314247a18386e3a7dc851b50c5e1044e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.11.051%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DChatelain%26aufirst%3DP.%26atitle%3DChanges%2520in%2520pH%2520differently%2520affect%2520the%2520binding%2520properties%2520of%2520histamine%2520H1%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D530%26spage%3D205%26epage%3D214%26doi%3D10.1016%2Fj.ejphar.2005.11.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span> <span> </span><span class="NLM_article-title">BRET-based β-arrestin2 recruitment to the histamine H1 receptor for investigating antihistamine binding kinetics</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.phrs.2016.07.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27468652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=679-687&author=R.+Bosmaauthor=R.+Moritaniauthor=R.+Leursauthor=H.+F.+Vischer&title=BRET-based+%CE%B2-arrestin2+recruitment+to+the+histamine+H1+receptor+for+investigating+antihistamine+binding+kinetics&doi=10.1016%2Fj.phrs.2016.07.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">BRET-based β-arrestin 2 recruitment to the histamine H1 receptor for investigating antihistamine binding kinetics</span></div><div class="casAuthors">Bosma, Reggie; Moritani, Ryo; Leurs, Rob; Vischer, Henry F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">679-687</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ligand residence time is thought to be a crit. parameter for optimizing the in vivo efficacy of drug candidates.  For the histamine H1 receptor (H1R) and other G protein-coupled receptors, the kinetics of ligand binding are typically measured by low throughput radioligand binding expts. using homogenized cell membranes expressing the target receptor.  In this study, a real-time proximity assay between H1R and β-arrestin 2 in living cells was established to investigate the dynamics of antihistamine binding to the H1R.  No receptor reserve was found for the histamine-induced recruitment of β-arrestin 2 to the H1R and the transiently recruited β-arrestin 2 therefore reflected occupancy of the receptor by histamine.  Antihistamines displayed similar kinetic signatures on antagonizing histamine-induced β-arrestin 2 recruitment as compared to displacing radioligand binding from the H1R.  This homogeneous functional method unambiguously detd. the fifty-fold difference in the dissocn. rate const. between mepyramine and the long residence time antihistamines levocetirizine and desloratadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXXu1vQbacy7Vg90H21EOLACvtfcHk0lj2pLuDk7NjqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr%252FN&md5=e18f2dc0c4a3bd9712976c1768a7139e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DMoritani%26aufirst%3DR.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26atitle%3DBRET-based%2520%25CE%25B2-arrestin2%2520recruitment%2520to%2520the%2520histamine%2520H1%2520receptor%2520for%2520investigating%2520antihistamine%2520binding%2520kinetics%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.phrs.2016.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strolin Benedetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltes, E.</span></span> <span> </span><span class="NLM_article-title">Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1007/s00011-005-1368-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2Fs00011-005-1368-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16273334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFOntL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=367-369&author=M.+Gillardauthor=M.+Strolin+Benedettiauthor=P.+Chatelainauthor=E.+Baltes&title=Histamine+H1+receptor+occupancy+and+pharmacodynamics+of+second+generation+H1-antihistamines&doi=10.1007%2Fs00011-005-1368-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines</span></div><div class="casAuthors">Gillard, M.; Benedetti, M. Strolin; Chatelain, P.; Baltes, E.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">367-369</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">The predictive efficacy of drugs in humans is frequently estd. from both a high affinity for their receptor as measured in vitro and a long plasmatic half-life.  This is grossly misleading since one key parameter is missing: drug concn. at the receptor site in vivo.  As a case study we compared the efficacies of three H1 antihistamines in inhibiting histamine-induced wheal and flare in humans at two different time points with the above mentioned parameters.  It is concluded that estg. in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concn., is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHk5Wn7LujrVg90H21EOLACvtfcHk0lj2pLuDk7NjqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFOntL3K&md5=7364f734d156d1d6aea8585814c9770a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00011-005-1368-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-005-1368-3%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DStrolin%2BBenedetti%26aufirst%3DM.%26aulast%3DChatelain%26aufirst%3DP.%26aulast%3DBaltes%26aufirst%3DE.%26atitle%3DHistamine%2520H1%2520receptor%2520occupancy%2520and%2520pharmacodynamics%2520of%2520second%2520generation%2520H1-antihistamines%26jtitle%3DInflammation%2520Res.%26date%3D2005%26volume%3D54%26spage%3D367%26epage%3D369%26doi%3D10.1007%2Fs00011-005-1368-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carceller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balsa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartroli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Rafanell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forn, J.</span></span> <span> </span><span class="NLM_article-title">(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2697</span>– <span class="NLM_lpage">2703</span>, <span class="refDoi"> DOI: 10.1021/jm00043a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00043a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1Cmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2697-2703&author=E.+Carcellerauthor=M.+Merlosauthor=M.+Giralauthor=D.+Balsaauthor=C.+Almansaauthor=J.+Bartroliauthor=J.+Garcia-Rafanellauthor=J.+Forn&title=%283-Pyridylalkyl%29piperidylidene%5Dbenzocycloheptapyridine+Derivatives+as+Dual+Antagonists+of+PAF+and+Histamine&doi=10.1021%2Fjm00043a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine</span></div><div class="casAuthors">Carceller, Elena; Merlos, Manuel; Giral, Marta; Balsa, Dolors; Almansa, Carmen; Bartroli, Javier; Garcia-Rafanell, Julian; Forn, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2697-703</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of [(3-pyridylalkyl)piperidylidene]- and (nicotinoylpiperidylidene)benzocycloheptapyridine derivs. were prepd. and evaluated for PAF antagonist and H1 antihistamine activity.  PAF antagonist activity was investigated by the in vitro PAF-induced platelet aggregation assay (PPA) and the in vivo PAF-induced hypotension test in rats (PH) and mortality test in mice (PM).  For the evaluation of H1 antihistamine activity, the in vitro histamine-induced contraction of the guinea-pig ileum assay (HC) and the in vivo histamine-induced hypotension test (HH) in normotensive rats were used.  The potential antiallergic activity of the compds. was evaluated using the active anaphylactic shock test in mice.  These compds. are structurally related to loratadine (1) and were generated by replacement of the ethoxycarbonyl group of 1 with substituted 3-pyridylmethyl and nicotinoyl moieties.  Both anti-PAF and H1 antihistamine activities have shown a high dependence on the exact nature and position of the substituent in the pyridine ring.  The optimum structure, incorporating a (5-methyl-3-pyridyl)methyl radical, displayed an unique dual activity inhibiting both PAF-induced effects (PPA, IC50 = 3.7 μM; PH, ID50 = 0.44 mg/kg i.v.; PM, ID50 = 1.9 mg/kg po) and histamine-induced effects (HC, IC50 = 3.9 nM; HH, ID50 = 1.4 mg/kg i.v.).  Furthermore, this compd. was highly active in the passive cutaneous anaphylactic shock in rats (ID50 = 1.2 mg/kg po) and strongly protected mice and rats from mortality induced by endotoxin (ID50 = 1.2 and 0.5 mg/kg i.v., resp.).  It showed itself to be devoid of CNS depressant effects, neither modifying spontaneous motor activity nor prolonging barbiturate-sleeping time in mice at a dose of 100 mg/kg po, and is now under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1hihmTS3DPrVg90H21EOLACvtfcHk0ljSjKKWICpR3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1Cmu7k%253D&md5=294559c3d02dfab86deb09a8b9d52243</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm00043a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00043a009%26sid%3Dliteratum%253Aachs%26aulast%3DCarceller%26aufirst%3DE.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGiral%26aufirst%3DM.%26aulast%3DBalsa%26aufirst%3DD.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DBartroli%26aufirst%3DJ.%26aulast%3DGarcia-Rafanell%26aufirst%3DJ.%26aulast%3DForn%26aufirst%3DJ.%26atitle%3D%25283-Pyridylalkyl%2529piperidylidene%255Dbenzocycloheptapyridine%2520Derivatives%2520as%2520Dual%2520Antagonists%2520of%2520PAF%2520and%2520Histamine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2697%26epage%3D2703%26doi%3D10.1021%2Fjm00043a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dorp, E. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhoven, J. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brussee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1177/1087057112464776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1177%2F1087057112464776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23093571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Ogtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=309-320&author=D.+Guoauthor=E.+J.+H.+van+Dorpauthor=T.+Mulder-Kriegerauthor=J.+P.+D.+van+Veldhovenauthor=J.+Brusseeauthor=A.+P.+Ijzermanauthor=L.+H.+Heitman&title=Dual-point+competition+association+assay%3A+a+fast+and+high-throughput+kinetic+screening+method+for+assessing+ligand-receptor+binding+kinetics&doi=10.1177%2F1087057112464776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics</span></div><div class="casAuthors">Guo, Dong; van Dorp, Erika J. H.; Mulder-Krieger, Thea; van Veldhoven, Jacobus P. D.; Brussee, Johannes; Ijzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-320, 12</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The concept of ligand-receptor binding kinetics is emerging as an important parameter in the early phase of drug discovery.  Since the currently used kinetic assays are laborious and low throughput, we developed a method that enables fast and large format screening.  It is a so-called dual-point competition assocn. assay, which measures radioligand binding at two different time points in the absence or presence of unlabeled competitors.  Specifically, this assay yields the kinetic rate index (KRI), which is a measure for the binding kinetics of the unlabeled ligands screened.  As a prototypical drug target, the adenosine A1 receptor (A1R) was chosen for assay validation and optimization.  A screen with 35 high-affinity A1R antagonists yielded seven compds. with a KRI value above 1.0, which indicated a relatively slow dissocn. from the target.  All other compds. had a KRI value below or equal to 1.0, predicting a relatively fast dissocn. rate.  Several compds. were selected for follow-up kinetic quantifications in classical kinetic assays and were shown to have kinetic rates that corresponded to their KRI values.  The dual-point assay and KRI value may have general applicability at other G-proteincoupled receptors, as well as at drug targets from other protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQTc5G9SVmrVg90H21EOLACvtfcHk0ljSjKKWICpR3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Ogtb%252FK&md5=8b43f2fbfdaf41ce30181acb06c12404</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F1087057112464776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057112464776%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3Dvan%2BDorp%26aufirst%3DE.%2BJ.%2BH.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3Dvan%2BVeldhoven%26aufirst%3DJ.%2BP.%2BD.%26aulast%3DBrussee%26aufirst%3DJ.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DDual-point%2520competition%2520association%2520assay%253A%2520a%2520fast%2520and%2520high-throughput%2520kinetic%2520screening%2520method%2520for%2520assessing%2520ligand-receptor%2520binding%2520kinetics%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2013%26volume%3D18%26spage%3D309%26epage%3D320%26doi%3D10.1177%2F1087057112464776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motulsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, L.</span></span> <span> </span><span class="NLM_article-title">The kinetics of competitive radioligand binding predicted by the law of mass action</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=6708928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=1-9&author=H.+Motulskyauthor=L.+Mahan&title=The+kinetics+of+competitive+radioligand+binding+predicted+by+the+law+of+mass+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of competitive radioligand binding predicted by the law of mass action</span></div><div class="casAuthors">Motulsky H J; Mahan L C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored.  The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time.  This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions.  Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments.  Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached.  Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time.  The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above.  When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI.  At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved.  When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCXDwvoK7MbN1QT_1O5WBYfW6udTcc2eZEG9vWRzP-6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D&md5=f0c09a16d7f8947fe0d72c256e2e4914</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotulsky%26aufirst%3DH.%26aulast%3DMahan%26aufirst%3DL.%26atitle%3DThe%2520kinetics%2520of%2520competitive%2520radioligand%2520binding%2520predicted%2520by%2520the%2520law%2520of%2520mass%2520action%26jtitle%3DMol.%2520Pharmacol.%26date%3D1984%26volume%3D25%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouzo-Lorenzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inkoom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briddon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Montalván, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7906</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-44025-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fs41598-019-44025-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=31133718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gt1Cksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7906&issue=1&author=R.+Bosmaauthor=L.+A.+Stoddartauthor=V.+Georgiauthor=M.+Bouzo-Lorenzoauthor=N.+Bushbyauthor=L.+Inkoomauthor=M.+J.+Waringauthor=S.+J.+Briddonauthor=H.+F.+Vischerauthor=R.+J.+Sheppardauthor=A.+Fern%C3%A1ndez-Montalv%C3%A1nauthor=S.+J.+Hillauthor=R.+Leurs&title=Probe+dependency+in+the+determination+of+ligand+binding+kinetics+at+a+prototypical+G+protein-coupled+receptor&doi=10.1038%2Fs41598-019-44025-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor</span></div><div class="casAuthors">Bosma Reggie; Inkoom Loretta; Vischer Henry F; Leurs Rob; Stoddart Leigh A; Bouzo-Lorenzo Monica; Briddon Stephen J; Hill Stephen J; Stoddart Leigh A; Bouzo-Lorenzo Monica; Briddon Stephen J; Hill Stephen J; Georgi Victoria; Fernandez-Montalvan Amaury; Bushby Nick; Waring Michael J; Waring Michael J; Sheppard Robert J; Fernandez-Montalvan Amaury</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7906</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-target binding kinetics are suggested to be important parameters for the prediction of in vivo drug-efficacy.  For G protein-coupled receptors (GPCRs), the binding kinetics of ligands are typically determined using association binding experiments in competition with radiolabelled probes, followed by analysis with the widely used competitive binding kinetics theory developed by Motulsky and Mahan.  Despite this, the influence of the radioligand binding kinetics on the kinetic parameters derived for the ligands tested is often overlooked.  To address this, binding rate constants for a series of histamine H1 receptor (H1R) antagonists were determined using radioligands with either slow (low koff) or fast (high koff) dissociation characteristics.  A correlation was observed between the probe-specific datasets for the kinetic binding affinities, association rate constants and dissociation rate constants.  However, the magnitude and accuracy of the binding rate constant-values was highly dependent on the used radioligand probe.  Further analysis using recently developed fluorescent binding methods corroborates the finding that the Motulsky-Mahan methodology is limited by the employed assay conditions.  The presented data suggest that kinetic parameters of GPCR ligands depend largely on the characteristics of the probe used and results should therefore be viewed within the experimental context and limitations of the applied methodology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTifAO8Ecm0p0wlCcfExbvbfW6udTcc2eZEG9vWRzP-6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gt1Cksg%253D%253D&md5=718e9db4fe44af49f445fde232139bf8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44025-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44025-5%26sid%3Dliteratum%253Aachs%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DGeorgi%26aufirst%3DV.%26aulast%3DBouzo-Lorenzo%26aufirst%3DM.%26aulast%3DBushby%26aufirst%3DN.%26aulast%3DInkoom%26aufirst%3DL.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DBriddon%26aufirst%3DS.%2BJ.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DSheppard%26aufirst%3DR.%2BJ.%26aulast%3DFern%25C3%25A1ndez-Montalv%25C3%25A1n%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DProbe%2520dependency%2520in%2520the%2520determination%2520of%2520ligand%2520binding%2520kinetics%2520at%2520a%2520prototypical%2520G%2520protein-coupled%2520receptor%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D7906%26doi%3D10.1038%2Fs41598-019-44025-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutner, W.</span></span> <span> </span><span class="NLM_article-title">Dual antagonists of platelet-activating factor and histamine: identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1021/jm00105a069</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00105a069" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1Ghtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=457-461&author=J.+J.+Piwinskiauthor=J.+K.+Wongauthor=M.+J.+Greenauthor=A.+K.+Gangulyauthor=M.+M.+Billahauthor=R.+E.+Westauthor=W.+Kreutner&title=Dual+antagonists+of+platelet-activating+factor+and+histamine%3A+identification+of+structural+requirements+for+dual+activity+of+N-acyl-4-%285%2C6-dihydro-11H-benzo%5B5%2C6%5Dcyclohepta%5B1%2C2-b%5Dpyridin-11-ylidene%29piperidines&doi=10.1021%2Fjm00105a069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual antagonists of platelet-activating factor and histamine.  Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines</span></div><div class="casAuthors">Piwinski, John J.; Wong, Jesse K.; Green, Michael J.; Ganguly, Ashit K.; Billah, M. Motasim; West, Robert E., Jr.; Kreutner, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">457-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title compds. I (R = H, Me, OMe, OH, Br, Cl, F; R1 = H, Cl, F; R2 = H, Me, Et, Pr, CMe3, OEt, Ph) were prepd. from the N-Me derivs. by demethylation-acylation.  I are dual antagonists of platelet activating factor (PAF) and histamine.  A no. of structural features are identified which are necessary for PAF antagonist activity.  Acylation of the piperidine N is required for appreciable activity with small acyl groups being optimal.  Less conformationally constrained analogs and those lacking either N atom exhibit little or no anti-PAF activity.  The H1-antihistamine activity can be adjusted utilizing substitution in the benzo ring.  I (R = Cl, R1 = H, R2 = Me) was selected for clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0fYNFCTXNV7Vg90H21EOLACvtfcHk0lixJI5II2Isfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1Ghtw%253D%253D&md5=84020e411a1008bc9ab1f9052b27d038</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm00105a069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00105a069%26sid%3Dliteratum%253Aachs%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DWong%26aufirst%3DJ.%2BK.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DGanguly%26aufirst%3DA.%2BK.%26aulast%3DBillah%26aufirst%3DM.%2BM.%26aulast%3DWest%26aufirst%3DR.%2BE.%26aulast%3DKreutner%26aufirst%3DW.%26atitle%3DDual%2520antagonists%2520of%2520platelet-activating%2520factor%2520and%2520histamine%253A%2520identification%2520of%2520structural%2520requirements%2520for%2520dual%2520activity%2520of%2520N-acyl-4-%25285%252C6-dihydro-11H-benzo%255B5%252C6%255Dcyclohepta%255B1%252C2-b%255Dpyridin-11-ylidene%2529piperidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D457%26epage%3D461%26doi%3D10.1021%2Fjm00105a069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume, H.</span></span> <span> </span><span class="NLM_article-title">HPLC-determination of loratadine and its active metabolite descarboethoxyloratadine in human plasma</span>. <i>Pharmazie</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=7816900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaK2cXmslWitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1994&pages=736-739&author=D.+Zhongauthor=H.+Blume&title=HPLC-determination+of+loratadine+and+its+active+metabolite+descarboethoxyloratadine+in+human+plasma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">HPLC-determination of loratadine and its active metabolite descarboethoxyloratadine in human plasma</span></div><div class="casAuthors">Zhong, D.; Blume, H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmazie</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">736-9</span>CODEN:
                <span class="NLM_cas:coden">PHARAT</span>;
        ISSN:<span class="NLM_cas:issn">0031-7144</span>.
    </div><div class="casAbstract">The quant. detn. of loratidine and its active metabolite descarboethoxyloratadine is described.  Because of the high difference in polarity between loratidine and descarboethoxyloratadine, the two analytes were detd. in two HPLC-systems sep.  As internal stds. propyl-4-(8-chloro-5,6-dihydro-11 H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridin-11-ylidin)-1-piperidinecarboxylate and 1-ethyl-4-(8-chloro-5,6-dihydro-11 H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridin-11-ylidin)-piperidine were used for loratidine and descarboethoxyloratadine, resp.  After extn. with org. solvents from 1 mL plasma, loratidine and descarboethoxyloratadine were re-extd. with dild. phosphoric acid from the org. phase.  Chromatog. sepn. on a RP-18 column and fluorescence detection allowed a sufficiently sensitive detn. of loratidine and descarboethoxyloratadine in plasma with a lower limit of quantitation of 0.5 ng/mL for both analytes.  The method was successfully applied to human plasma samples from 16 subjects after oral administration of 20 mg loratidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodu1qELsGm2rVg90H21EOLACvtfcHk0lixJI5II2Isfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmslWitr8%253D&md5=066f8eb34de0630222fa2884be6bf1b1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DD.%26aulast%3DBlume%26aufirst%3DH.%26atitle%3DHPLC-determination%2520of%2520loratadine%2520and%2520its%2520active%2520metabolite%2520descarboethoxyloratadine%2520in%2520human%2520plasma%26jtitle%3DPharmazie%26date%3D1994%26volume%3D49%26spage%3D736%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span>; <span class="NLM_string-name">Hasumi, K.</span>; <span class="NLM_string-name">Nishimoto, T.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Ishitani, K.</span>; <span class="NLM_string-name">Aotsuka, T.</span>; <span class="NLM_string-name">Kanazawa, H.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compound and H1 Receptor Antagonist</span>. <span class="NLM_patent">US20130085127</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Okada&author=K.+Hasumi&author=T.+Nishimoto&author=M.+Yoshida&author=K.+Ishitani&author=T.+Aotsuka&author=H.+Kanazawa&title=Heterocyclic+Compound+and+H1+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DM.%26atitle%3DHeterocyclic%2520Compound%2520and%2520H1%2520Receptor%2520Antagonist%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanoli, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramzan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, U.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and bioevaluation of tricyclic fused ring system as dual binding site acetylcholinesterase inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.bioorg.2018.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=30399465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2019&pages=336-347&author=S.+T.+Tanoliauthor=M.+Ramzanauthor=A.+Hassanauthor=A.+Sadiqauthor=M.+S.+Janauthor=F.+A.+Khanauthor=F.+Ullahauthor=H.+Ahmadauthor=M.+Bibiauthor=T.+Mahmoodauthor=U.+Rashid&title=Design%2C+synthesis+and+bioevaluation+of+tricyclic+fused+ring+system+as+dual+binding+site+acetylcholinesterase+inhibitors&doi=10.1016%2Fj.bioorg.2018.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and bioevaluation of tricyclic fused ring system as dual binding site acetylcholinesterase inhibitors</span></div><div class="casAuthors">Tanoli, Saba Tahir; Ramzan, Muhammad; Hassan, Abbas; Sadiq, Abdul; Jan, Muhammad Saeed; Khan, Farhan A.; Ullah, Farhat; Ahmad, Haseen; Bibi, Maria; Mahmood, Tariq; Rashid, Umer</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">336-347</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Due to recently discovered non-classical acetylcholinesterase (AChE) function, dual binding-site AChE inhibitors have acquired a paramount attention of drug designing researchers.  The unique structural arrangements of AChE peripheral anionic site (PAS) and catalytic site (CAS) joined by a narrow gorge, prompted us to design the inhibitors that can interact with dual binding sites of AChE.  Eighteen homo- and heterodimers of desloratadine and carbazole (already available tricyclic building blocks) were synthesized and tested for their inhibition potential against elec. eel acetylcholinesterase (eeAChE) and equine serum butyrylcholinesterase (eqBChE).  We identified a six-carbon tether heterodimer of desloratadine and indanedione based tricyclic dihydropyrimidine (4c) as potent and selective inhibitor of eeAChE with IC50 value of 0.09 ± 0.003 μM and 1.04 ± 0.08 μM (for eqBChE) with selectivity index of 11.1.  Binding pose anal. of potent inhibitors suggest that tricyclic ring is well accommodated into the AChE active site through hydrophobic interactions with Trp84 and Trp279.  The indanone ring of most active heterodimer 4b is stabilized into the bottom of the gorge and forms hydrogen bonding interactions with the important catalytic triad residue Ser200. bis-desloratadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ei_NOFNjZLVg90H21EOLACvtfcHk0lhxcSaYnHOvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qt7bP&md5=73eb9e4b923302d4aa1cbd4f58a82c78</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DTanoli%26aufirst%3DS.%2BT.%26aulast%3DRamzan%26aufirst%3DM.%26aulast%3DHassan%26aufirst%3DA.%26aulast%3DSadiq%26aufirst%3DA.%26aulast%3DJan%26aufirst%3DM.%2BS.%26aulast%3DKhan%26aufirst%3DF.%2BA.%26aulast%3DUllah%26aufirst%3DF.%26aulast%3DAhmad%26aufirst%3DH.%26aulast%3DBibi%26aufirst%3DM.%26aulast%3DMahmood%26aufirst%3DT.%26aulast%3DRashid%26aufirst%3DU.%26atitle%3DDesign%252C%2520synthesis%2520and%2520bioevaluation%2520of%2520tricyclic%2520fused%2520ring%2520system%2520as%2520dual%2520binding%2520site%2520acetylcholinesterase%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D83%26spage%3D336%26epage%3D347%26doi%3D10.1016%2Fj.bioorg.2018.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span>; <span class="NLM_string-name">Flohr, A.</span>; <span class="NLM_string-name">Jolidon, S.</span>; <span class="NLM_string-name">Knust, H.</span>; <span class="NLM_string-name">Luebbers, T.</span>; <span class="NLM_string-name">Nettekoven, M.</span></span> <span> </span><span class="NLM_article-title">Indol-Amide Compounds as Beta-Amyloid Inhibitors</span>. <span class="NLM_patent">WO2014060386</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+Baumann&author=A.+Flohr&author=S.+Jolidon&author=H.+Knust&author=T.+Luebbers&author=M.+Nettekoven&title=Indol-Amide+Compounds+as+Beta-Amyloid+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DK.%26atitle%3DIndol-Amide%2520Compounds%2520as%2520Beta-Amyloid%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. Q.</span>; <span class="NLM_string-name">Leurs, R.</span>; <span class="NLM_string-name">Timmerman, H.</span></span> <span> </span><span class="NLM_article-title">Histamine H1-Receptor Antagonists</span>. In  <i>Burger’s Medicinal Chemistry an Drug Discovery</i>, <span class="NLM_edition">5</span>th ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, M. E.</span></span>, Ed.; <span class="NLM_publisher-name">Vrije Universiteit</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">1997</span>; Vol.  <span class="NLM_volume">5</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=M.+Q.+Zhang&author=R.+Leurs&author=H.+Timmermanauthor=M.+E.+Wolff&title=Burger%E2%80%99s+Medicinal+Chemistry+an+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%2BQ.%26atitle%3DHistamine%2520H1-Receptor%2520Antagonists%26btitle%3DBurger%25E2%2580%2599s%2520Medicinal%2520Chemistry%2520an%2520Drug%2520Discovery%26aulast%3DWolff%26aufirst%3DM.%2BE.%26pub%3DVrije%2520Universiteit%26date%3D1997%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prathipati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of some substituted pyrazinopyridoindoles and 3D QSAR studies along with related compounds: piperazines, piperidines, pyrazinoisoquinolines, and diphenhydramine, and its semi-rigid analogs as antihistamines (H1)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8258</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.bmc.2006.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=17010624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=8249-8258&author=M.+Saxenaauthor=S.+Gaurauthor=P.+Prathipatiauthor=A.+K.+Saxena&title=Synthesis+of+some+substituted+pyrazinopyridoindoles+and+3D+QSAR+studies+along+with+related+compounds%3A+piperazines%2C+piperidines%2C+pyrazinoisoquinolines%2C+and+diphenhydramine%2C+and+its+semi-rigid+analogs+as+antihistamines+%28H1%29&doi=10.1016%2Fj.bmc.2006.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some substituted pyrazinopyridoindoles and 3D QSAR studies along with related compounds: Piperazines, piperidines, pyrazinoisoquinolines, and diphenhydramine, and its semi-rigid analogs as antihistamines (H1)</span></div><div class="casAuthors">Saxena, Mridula; Gaur, Stuti; Prathipati, Philip; Saxena, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8249-8258</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">3D QSAR studies on the title compds. led to the development of a model with three biophoric sites and six secondary sites viz.  H-acceptor (ACC), H-donor (DON), heteroatom (presence), hydrophobic (hydrophobicity), steric (refractivity), and a ring (presence) along with total hydrophobicity and total refractivity as global properties.  The model predicted the test set of compds. reasonably well.  Three of the five newly synthesized 2-substituted octahydropyrazinopyridoindoles have shown potent antihistaminic H1 activity with less toxicity and sedation potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowk39v6uAhWLVg90H21EOLACvtfcHk0lhxcSaYnHOvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7zI&md5=ed714e960dfa30d6be42edb200dc0e5f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DM.%26aulast%3DGaur%26aufirst%3DS.%26aulast%3DPrathipati%26aufirst%3DP.%26aulast%3DSaxena%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%2520of%2520some%2520substituted%2520pyrazinopyridoindoles%2520and%25203D%2520QSAR%2520studies%2520along%2520with%2520related%2520compounds%253A%2520piperazines%252C%2520piperidines%252C%2520pyrazinoisoquinolines%252C%2520and%2520diphenhydramine%252C%2520and%2520its%2520semi-rigid%2520analogs%2520as%2520antihistamines%2520%2528H1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D8249%26epage%3D8258%26doi%3D10.1016%2Fj.bmc.2006.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriegl, J. M.</span></span> <span> </span><span class="NLM_article-title">What can we learn from molecular dynamics simulations for GPCR drug design?</span>. <i>Comput. Struct. Biotechnol. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.csbj.2014.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.csbj.2014.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=25709761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOlsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=111-121&author=C.+S.+Tautermannauthor=D.+Seeligerauthor=J.+M.+Kriegl&title=What+can+we+learn+from+molecular+dynamics+simulations+for+GPCR+drug+design%3F&doi=10.1016%2Fj.csbj.2014.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">What can we learn from molecular dynamics simulations for GPCR drug design?</span></div><div class="casAuthors">Tautermann, Christofer S.; Seeliger, Daniel; Kriegl, Jan M.</div><div class="citationInfo"><span class="NLM_cas:title">Computational and Structural Biotechnology Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-121</span>CODEN:
                <span class="NLM_cas:coden">CSBJAC</span>;
        ISSN:<span class="NLM_cas:issn">2001-0370</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent years have seen a tremendous progress in the elucidation of exptl. structural information for G-protein coupled receptors (GPCRs).  Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homol. models the steadily increasing amt. of structural information fosters the application of structure-based drug design tools for this important class of drug targets.  In this article we focus on the application of mol. dynamics (MD) simulations in GPCR drug discovery programs.  Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small mol. antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small mols. to the human muscarinic acetylcholine receptor 3 (hM3R).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0PtAwst0DrVg90H21EOLACvtfcHk0lhnmC-A9fkecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOlsb7O&md5=5dff5b6ab82b720bbd083d1f41d3664b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.csbj.2014.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.csbj.2014.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DSeeliger%26aufirst%3DD.%26aulast%3DKriegl%26aufirst%3DJ.%2BM.%26atitle%3DWhat%2520can%2520we%2520learn%2520from%2520molecular%2520dynamics%2520simulations%2520for%2520GPCR%2520drug%2520design%253F%26jtitle%3DComput.%2520Struct.%2520Biotechnol.%2520J.%26date%3D2015%26volume%3D13%26spage%3D111%26epage%3D121%26doi%3D10.1016%2Fj.csbj.2014.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span> <span> </span><span class="NLM_article-title">Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">18903</span>– <span class="NLM_lpage">18910</span>, <span class="refDoi"> DOI: 10.1021/ja207494u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja207494u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=18903-18910&author=P.+Schmidtkeauthor=F.+J.+Luqueauthor=J.+B.+Murrayauthor=X.+Barril&title=Shielded+hydrogen+bonds+as+structural+determinants+of+binding+kinetics%3A+application+in+drug+design&doi=10.1021%2Fja207494u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Shielded Hydrogen Bonds as Structural Determinants of Binding Kinetics: Application in Drug Design</span></div><div class="casAuthors">Schmidtke, Peter; Luque, F. Javier; Murray, James B.; Barril, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">18903-18910</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Time scale control of mol. interactions is an essential part of biochem. systems, but very little is known about the structural factors governing the kinetics of mol. recognition.  In drug design, the lifetime of drug-target complexes is a major determinant of pharmacol. effects but the absence of structure-kinetic relationships precludes rational optimization of this property.  Almost buried polar atoms-a common feature on protein binding sites-tend to form hydrogen bonds that are shielded from water.  Formation and rupture of this type of hydrogen bonds involves an energetically penalized transition state because it occurs asynchronously with dehydration/rehydration.  In consequence, water-shielded hydrogen bonds are exchanged at slower rates.  Occurrence of this phenomenon can be anticipated from simple structural anal., affording a novel tool to interpret and predict structure-kinetics relationships.  The validity of this principle has been investigated on two pairs of Hsp90 inhibitors for which detailed thermodn. and kinetic data has been exptl. detd.  The agreement between macroscopic observables and mol. simulations confirms the role of water-shielded hydrogen bonds as kinetic traps and illustrates how the authors' finding could be used as an aid in structure-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozQcgRgDTxL7Vg90H21EOLACvtfcHk0lhnmC-A9fkecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7zP&md5=f2a69f635c4a8083d4b7ade4c1f01030</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fja207494u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja207494u%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidtke%26aufirst%3DP.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BB.%26aulast%3DBarril%26aufirst%3DX.%26atitle%3DShielded%2520hydrogen%2520bonds%2520as%2520structural%2520determinants%2520of%2520binding%2520kinetics%253A%2520application%2520in%2520drug%2520design%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D18903%26epage%3D18910%26doi%3D10.1021%2Fja207494u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span> <span> </span><span class="NLM_article-title">Decoding the role of water dynamics in ligand-protein unbinding: CRF1R as a test case</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=1857-1866&author=A.+Bortolatoauthor=F.+Deflorianauthor=D.+R.+Weissauthor=J.+S.+Mason&title=Decoding+the+role+of+water+dynamics+in+ligand-protein+unbinding%3A+CRF1R+as+a+test+case&doi=10.1021%2Facs.jcim.5b00440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding the Role of Water Dynamics in Ligand-Protein Unbinding: CRF1R as a Test Case</span></div><div class="casAuthors">Bortolato, Andrea; Deflorian, Francesca; Weiss, Dahlia R.; Mason, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1857-1866</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The residence time of a ligand-protein complex is a crucial aspect in detg. biol. effect in vivo.  Despite its importance, the prediction of ligand koff still remains challenging for modern computational chem.  We have developed aMetaD, a fast and generally applicable computational protocol to predict ligand-protein unbinding events using a mol. dynamics (MD) method based on adiabatic-bias MD and metadynamics.  This physics-based, fully flexible, and pose-dependent ligand scoring function evaluates the max. energy (RTscore) required to move the ligand from the bound-state energy basin to the next.  Unbinding trajectories are automatically analyzed and translated into at. solvation factor (SF) values representing the water dynamics during the unbinding event.  This novel computational protocol was initially tested on two M3 muscarinic receptor and two adenosine A2A receptor antagonists and then evaluated on a test set of 12 CRF1R ligands.  The resulting RTscores were used successfully to classify ligands with different residence times.  Addnl., the SF anal. was used to detect key differences in the degree of accessibility to water mols. during the predicted ligand unbinding events.  The protocol provides actionable working hypotheses that are applicable in a drug discovery program for the rational optimization of ligand binding kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrga4-8KCm2obVg90H21EOLACvtfcHk0lhnmC-A9fkecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGjsLnO&md5=91e3e7e373526591640a239dbdf33f29</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00440%26sid%3Dliteratum%253Aachs%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DD.%2BR.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26atitle%3DDecoding%2520the%2520role%2520of%2520water%2520dynamics%2520in%2520ligand-protein%2520unbinding%253A%2520CRF1R%2520as%2520a%2520test%2520case%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D1857%26epage%3D1866%26doi%3D10.1021%2Facs.jcim.5b00440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span> <span> </span><span class="NLM_article-title">A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1111/bph.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fbph.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23713847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=101-126&author=A.+J.+Kooistraauthor=S.+Kuhneauthor=I.+J.+P.+de+Eschauthor=R.+Leursauthor=C.+de+Graaf&title=A+structural+chemogenomics+analysis+of+aminergic+GPCRs%3A+lessons+for+histamine+receptor+ligand+design&doi=10.1111%2Fbph.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design</span></div><div class="casAuthors">Kooistra, A. J.; Kuhne, S.; de Esch, I. J. P.; Leurs, R.; de Graaf, C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-126</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Chemogenomics focuses on the discovery of new connections between chem. and biol. space leading to the discovery of new protein targets and biol. active mols.  G-protein coupled receptors (GPCRs) are a particularly interesting protein family for chemogenomics studies because there is an overwhelming amt. of ligand binding affinity data available.  The increasing no. of aminergic GPCR crystal structures now for the first time allows the integration of chemogenomics studies with high-resoln. structural analyses of GPCR-ligand complexes.  Exptl. Approach In this study, we have combined ligand affinity data, receptor mutagenesis studies, and amino acid sequence analyses to high-resoln. structural analyses of (hist)aminergic GPCR-ligand interactions.  This integrated structural chemogenomics anal. is used to more accurately describe the mol. and structural determinants of ligand affinity and selectivity in different key binding regions of the crystd. aminergic GPCRs, and histamine receptors in particular.  Key Results Our investigations highlight interesting correlations and differences between ligand similarity and ligand binding site similarity of different aminergic receptors.  Apparent discrepancies can be explained by combining detailed anal. of crystd. or predicted protein-ligand binding modes, receptor mutation studies, and ligand structure-selectivity relationships that identify local differences in essential pharmacophore features in the ligand binding sites of different receptors.  Conclusions and Implications We have performed structural chemogenomics studies that identify links between (hist)aminergic receptor ligands and their binding sites and binding modes.  This knowledge can be used to identify structure-selectivity relationships that increase our understanding of ligand binding to (hist)aminergic receptors and hence can be used in future GPCR ligand discovery and design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxr6kq48O11rVg90H21EOLACvtfcHk0lhcgAprhnWpbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnE&md5=08ae55b9565885165e76d98e2db1befa</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fbph.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12248%26sid%3Dliteratum%253Aachs%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DKuhne%26aufirst%3DS.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26atitle%3DA%2520structural%2520chemogenomics%2520analysis%2520of%2520aminergic%2520GPCRs%253A%2520lessons%2520for%2520histamine%2520receptor%2520ligand%2520design%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D101%26epage%3D126%26doi%3D10.1111%2Fbph.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijtmans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Identification of ligand binding hot spots of the histamine H1 receptor following structure-based fragment optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9047</span>– <span class="NLM_lpage">9061</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00981</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00981" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFanu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9047-9061&author=S.+Kuhneauthor=A.+J.+Kooistraauthor=R.+Bosmaauthor=A.+Bortolatoauthor=M.+Wijtmansauthor=H.+F.+Vischerauthor=J.+S.+Masonauthor=C.+de+Graafauthor=I.+J.+P.+de+Eschauthor=R.+Leurs&title=Identification+of+ligand+binding+hot+spots+of+the+histamine+H1+receptor+following+structure-based+fragment+optimization&doi=10.1021%2Facs.jmedchem.6b00981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Ligand Binding Hot Spots of the Histamine H1 Receptor following Structure-Based Fragment Optimization</span></div><div class="casAuthors">Kuhne, Sebastiaan; Kooistra, Albert J.; Bosma, Reggie; Bortolato, Andrea; Wijtmans, Maikel; Vischer, Henry F.; Mason, Jonathan S.; de Graaf, Chris; de Esch, Iwan J. P.; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9047-9061</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Developments in G protein-coupled receptor (GPCR) structural biol. provide insights into GPCR-ligand binding.  Compd. I (4-(2-benzylphenoxy)piperidine) with high ligand efficiency for the histamine H1 receptor (H1R) was used to design derivs. to investigate the roles of: (1) the amine-binding region, (2) the upper and lower arom. region and (3) binding site solvation.  SAR anal. showed that the amine-binding region serves as the primary binding hot spot, preferably binding small tertiary amines.  In silico prediction of water network energetics and mutagenesis studies indicated that the displacement of a water mol. from the amine-binding region is most likely responsible for the increased affinity of the N-methylated analog of I.  Deconstruction of I showed that the lower arom. region serves as a secondary binding hot spot.  This study demonstrates that an x-ray structure in combination with tool compds., assessment of water energetics, and mutagenesis studies enables SAR exploration to map GPCR-ligand binding hot spots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot3XWIDbthErVg90H21EOLACvtfcHk0lhcgAprhnWpbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFanu7rK&md5=7e9bd27144fcaf11a3176bf717849bcd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00981%26sid%3Dliteratum%253Aachs%26aulast%3DKuhne%26aufirst%3DS.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DWijtmans%26aufirst%3DM.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520ligand%2520binding%2520hot%2520spots%2520of%2520the%2520histamine%2520H1%2520receptor%2520following%2520structure-based%2520fragment%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9047%26epage%3D9061%26doi%3D10.1021%2Facs.jmedchem.6b00981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mocking, T.</span>; <span class="NLM_string-name">Bosma, R.</span>; <span class="NLM_string-name">Rahman, S. N.</span>; <span class="NLM_string-name">Verweij, E. W. E.</span>; <span class="NLM_string-name">McNaught-Flores, D. A.</span>; <span class="NLM_string-name">Vischer, H. F.</span>; <span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Molecular Aspects of Histamine Receptors</span>. In  <i>Histamine Receptors. Preclinical and Clinical Aspects.</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandina, P.</span>, <span class="NLM_string-name">Passani, M. B.</span></span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">49</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2F978-3-319-40308-3_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-49&author=T.+Mocking&author=R.+Bosma&author=S.+N.+Rahman&author=E.+W.+E.+Verweij&author=D.+A.+McNaught-Flores&author=H.+F.+Vischer&author=R.+Leursauthor=P.+Blandina&author=M.+B.+Passani&title=Histamine+Receptors.+Preclinical+and+Clinical+Aspects."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-40308-3_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-40308-3_1%26sid%3Dliteratum%253Aachs%26aulast%3DMocking%26aufirst%3DT.%26atitle%3DMolecular%2520Aspects%2520of%2520Histamine%2520Receptors%26btitle%3DHistamine%2520Receptors.%2520Preclinical%2520and%2520Clinical%2520Aspects.%26aulast%3DBlandina%26aufirst%3DP.%26pub%3DHumana%2520Press%26date%3D2016%26spage%3D1%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, P.</span></span> <span> </span><span class="NLM_article-title">Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">449</span>, <span class="refDoi"> DOI: 10.1039/c2md00270a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1039%2Fc2md00270a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Orsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=449&author=D.+C.+Millerauthor=G.+Lunnauthor=P.+Jonesauthor=Y.+Sabnisauthor=N.+L.+Daviesauthor=P.+Driscoll&title=Investigation+of+the+effect+of+molecular+properties+on+the+binding+kinetics+of+a+ligand+to+its+biological+target&doi=10.1039%2Fc2md00270a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target</span></div><div class="casAuthors">Miller, Duncan C.; Lunn, Graham; Jones, Peter; Sabnis, Yogesh; Davies, Nichola L.; Driscoll, Paul</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-452</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A database of binding kinetic data across multiple targets has been created.  Anal. of this database provides insights into trends for the effects of physicochem. properties (mol. wt., clogP, rotatable bond count) on the dissocn. kinetics of ligands from their biol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrvjiZtiu9VLVg90H21EOLACvtfcHk0ljK6D865uwOgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Orsro%253D&md5=84c6b9d95ec6df61145fe678c78d5491</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1039%2Fc2md00270a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md00270a%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DD.%2BC.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3DDriscoll%26aufirst%3DP.%26atitle%3DInvestigation%2520of%2520the%2520effect%2520of%2520molecular%2520properties%2520on%2520the%2520binding%2520kinetics%2520of%2520a%2520ligand%2520to%2520its%2520biological%2520target%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D449%26doi%3D10.1039%2Fc2md00270a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span> <span> </span><span class="NLM_article-title">Molecular properties affecting fast dissociation from the D2 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.bmc.2011.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=21421319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=2231-2241&author=G.+Tresadernauthor=J.+M.+Bartolomeauthor=G.+J.+Macdonaldauthor=X.+Langlois&title=Molecular+properties+affecting+fast+dissociation+from+the+D2+receptor&doi=10.1016%2Fj.bmc.2011.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties affecting fast dissociation from the D2 receptor</span></div><div class="casAuthors">Tresadern, Gary; Bartolome, Jose Manuel; MacDonald, Gregor J.; Langlois, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2231-2241</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine D2 receptor antagonism is the foundation of antipsychotic treatment.  Antipsychotic agents vary in how fast they dissoc. from the D2 receptors.  It has been proposed that the liability to exhibit side effects such as extra pyramidal symptoms may be the result of a slow rate of dissocn.  Compds. with a faster rate of dissocn., while still blocking efficiently the D2 receptors, will subsequently respond better to physiol. surges in dopamine transmission.  Therefore, work in our labs. has focussed on identifying fast dissocg. and selective D2 antagonists.  Biol. screening was performed to measure the affinity and extent of dissocn. for a large dataset of over 1800 D2 antagonists.  Subsequent univariate and multivariate statistical anal. revealed the mol. properties which differentiate fast and slow dissocg. compds.  It is shown that faster dissocg. antagonists are less lipophilic and have lower mol. wt.  There was a clear and expected inverse relationship with extent of dissocn. and binding affinity with more potent compds. tending to be slower dissocg.  However, within a range of comparable affinity both fast and slow dissocg. compds. were identified.  After de-correlating affinity and dissocn. the anal. revealed the important descriptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilpQ8-EuD-LVg90H21EOLACvtfcHk0ljK6D865uwOgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D&md5=574e106853b1cff1b6975c4bba979031</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DBartolome%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DLanglois%26aufirst%3DX.%26atitle%3DMolecular%2520properties%2520affecting%2520fast%2520dissociation%2520from%2520the%2520D2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D2231%26epage%3D2241%26doi%3D10.1016%2Fj.bmc.2011.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaas, L. A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josimovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">The target residence time of antihistamines determines their antagonism of the G protein-coupled histamine H1 receptor</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">667</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.3389%2Ffphar.2017.00667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=29033838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=667&author=R.+Bosmaauthor=G.+Wittauthor=L.+A.+I.+Vaasauthor=I.+Josimovicauthor=P.+Gribbonauthor=H.+F.+Vischerauthor=S.+Gulauthor=R.+Leurs&title=The+target+residence+time+of+antihistamines+determines+their+antagonism+of+the+G+protein-coupled+histamine+H1+receptor&doi=10.3389%2Ffphar.2017.00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The target residence time of antihistamines determines their antagonism of the G protein-coupled histamine H1 receptor</span></div><div class="casAuthors">Bosma, Reggie; Witt, Gesa; Vaas, Lea A. I.; Josimovic, Ivana; Gribbon, Philip; Vischer, Henry F.; Gul, Sheraz; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667/1-667/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The pharmacodynamics of drug-candidates is often optimized by metrics that describe target binding (Kd or Ki value) or target modulation (IC50).  However, these metrics are detd. at equil. conditions, and consequently information regarding the onset and offset of target engagement and modulation is lost.  Drug-target residence time is a measure for the lifetime of the drug-target complex, which has recently been receiving considerable interest, as target residence time is shown to have prognostic value for the in vivo efficacy of several drugs.  In this study, we have investigated the relation between the increased residence time of antihistamines at the histamine H1 receptor (H1R) and the duration of effective target-inhibition by these antagonists.  Hela cells, endogenously expressing low levels of the H1R, were incubated with a series of antihistamines and dissocn. was initiated by washing away the unbound antihistamines.  Using a calcium-sensitive fluorescent dye and a label free, dynamic mass redistribution based assay, functional recovery of the H1R responsiveness was measured by stimulating the cells with histamine over time, and the recovery was quantified as the receptor recovery time.  Using these assays, we detd. that the receptor recovery time for a set of antihistamines differed more than 40-fold and was highly correlated to their H1R residence times, as detd. with competitive radioligand binding expts. to the H1R in a cell homogenate.  Thus, the receptor recovery time is proposed as a cell based and physiol. relevant metric for the lead optimization of G protein-coupled receptor antagonists, like the H1R antagonists.  Both, label-free or real-time, classical signaling assays allow an efficient and physiol. relevant detn. of kinetic properties of drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvQKLQXKACLVg90H21EOLACvtfcHk0lhWaYurKy9ukA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegsL3N&md5=916d9721ede4fd2a72cdf1878ec17e75</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00667%26sid%3Dliteratum%253Aachs%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DWitt%26aufirst%3DG.%26aulast%3DVaas%26aufirst%3DL.%2BA.%2BI.%26aulast%3DJosimovic%26aufirst%3DI.%26aulast%3DGribbon%26aufirst%3DP.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DGul%26aufirst%3DS.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DThe%2520target%2520residence%2520time%2520of%2520antihistamines%2520determines%2520their%2520antagonism%2520of%2520the%2520G%2520protein-coupled%2520histamine%2520H1%2520receptor%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D667%26doi%3D10.3389%2Ffphar.2017.00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiroishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the human histamine H1 receptor complex with doxepin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature10236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnature10236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=21697825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2011&pages=65-70&author=T.+Shimamuraauthor=M.+Shiroishiauthor=S.+Weyandauthor=H.+Tsujimotoauthor=G.+Winterauthor=V.+Katritchauthor=R.+Abagyanauthor=V.+Cherezovauthor=W.+Liuauthor=G.+W.+Hanauthor=T.+Kobayashiauthor=R.+C.+Stevensauthor=S.+Iwata&title=Structure+of+the+human+histamine+H1+receptor+complex+with+doxepin&doi=10.1038%2Fnature10236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human histamine H1 receptor complex with doxepin</span></div><div class="casAuthors">Shimamura, Tatsuro; Shiroishi, Mitsunori; Weyand, Simone; Tsujimoto, Hirokazu; Winter, Graeme; Katritch, Vsevolod; Abagyan, Ruben; Cherezov, Vadim; Liu, Wei; Han, Gye Won; Kobayashi, Takuya; Stevens, Raymond C.; Iwata, So</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">7354</span>),
    <span class="NLM_cas:pages">65-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The biogenic amine histamine is an important pharmacol. mediator involved in pathophysiol. processes such as allergies and inflammations.  Histamine H1 receptor (H1R) antagonists are very effective drugs alleviating the symptoms of allergic reactions.  Here, we show the crystal structure of the H1R complex with doxepin, a first-generation H1R antagonist.  Doxepin sits deep in the ligand-binding pocket and directly interacts with Trp 428, a highly conserved key residue in G-protein-coupled-receptor activation.  This well-conserved pocket with mostly hydrophobic nature contributes to the low selectivity of the first-generation compds.  The pocket is assocd. with an anion-binding region occupied by a phosphate ion.  Docking of various second-generation H1R antagonists reveals that the unique carboxyl group present in this class of compds. interacts with Lys 191 and/or Lys 179ECL2, both of which form part of the anion-binding region.  This region is not conserved in other aminergic receptors, demonstrating how minor differences in receptors lead to pronounced selectivity differences with small mols.  Our study sheds light on the mol. basis of H1R antagonist specificity against H1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1obci6QtYbVg90H21EOLACvtfcHk0lhWaYurKy9ukA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVekt7k%253D&md5=7116228016caa1f3afbfed11468c0154</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnature10236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10236%26sid%3Dliteratum%253Aachs%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DShiroishi%26aufirst%3DM.%26aulast%3DWeyand%26aufirst%3DS.%26aulast%3DTsujimoto%26aufirst%3DH.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DIwata%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520human%2520histamine%2520H1%2520receptor%2520complex%2520with%2520doxepin%26jtitle%3DNature%26date%3D2011%26volume%3D475%26spage%3D65%26epage%3D70%26doi%3D10.1038%2Fnature10236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stützle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Exner, T. E.</span></span> <span> </span><span class="NLM_article-title">Empirical scoring functions for advanced Protein-Ligand docking with PLANTS</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1021/ci800298z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800298z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=84-96&author=O.+Korbauthor=T.+St%C3%BCtzleauthor=T.+E.+Exner&title=Empirical+scoring+functions+for+advanced+Protein-Ligand+docking+with+PLANTS&doi=10.1021%2Fci800298z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS</span></div><div class="casAuthors">Korb, Oliver; Stuetzle, Thomas; Exner, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-96</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper we present two empirical scoring functions, PLANTSCHEMPLP and PLANTSPLP, designed for our docking algorithm PLANTS (Protein-Ligand ANT System), which is based on ant colony optimization (ACO).  They are related, regarding their functional form, to parts of already published scoring functions and force fields.  The parametrization procedure described here was able to identify several parameter settings showing an excellent performance for the task of pose prediction on two test sets comprising 298 complexes in total.  Up to 87% of the complexes of the Astex diverse set and 77% of the CCDC/Astex clean listnc (noncovalently bound complexes of the clean list) could be reproduced with root-mean-square deviations of less than 2 Å with respect to the exptl. detd. structures.  A comparison with the state-of-the-art docking tool GOLD clearly shows that this is, esp. for the druglike Astex diverse set, an improvement in pose prediction performance.  Addnl., optimized parameter settings for the search algorithm were identified, which can be used to balance pose prediction reliability and search speed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_kyR7CGk9mbVg90H21EOLACvtfcHk0lgU9Ik9F3oJ0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSquw%253D%253D&md5=fce960b75b9f8906354b7c97ff84c092</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fci800298z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800298z%26sid%3Dliteratum%253Aachs%26aulast%3DKorb%26aufirst%3DO.%26aulast%3DSt%25C3%25BCtzle%26aufirst%3DT.%26aulast%3DExner%26aufirst%3DT.%2BE.%26atitle%3DEmpirical%2520scoring%2520functions%2520for%2520advanced%2520Protein-Ligand%2520docking%2520with%2520PLANTS%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D84%26epage%3D96%26doi%3D10.1021%2Fci800298z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, D. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of antihistamines</span>. <i>Indian J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.4103/0019-5154.110832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.4103%2F0019-5154.110832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23723474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=219-224&author=M.+K.+Churchauthor=D.+S.+Church&title=Pharmacology+of+antihistamines&doi=10.4103%2F0019-5154.110832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of antihistamines</span></div><div class="casAuthors">Church Martin K; Church Diana S</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">H1-antihistamines, the mainstay of treatment for urticaria, were developed from anticholinergic drugs more than 70 years ago.  They act as inverse agonists rather than antagonists of histamine H1-receptors which are members of the G-protein family.  The older first generation H1-antihistamines penetrate readily into the brain to cause sedation, drowsiness, fatigue and impaired concentration and memory causing detrimental effects on learning and examination performance in children and on impairment of the ability of adults to work and drive.  Their use should be discouraged.  The newer second-generation H1-antihistamines are safer, cause less sedation and are more efficacious.  Three drugs widely used for symptomatic relief in urticaria, desloratadine, levocetirizine and fexofenadine are highlighted in this review.  Of these levocetirizine and fexofenadine are the most potent in humans in vivo.  However, levocetirizine may cause somnolence in susceptible individuals, whereas fexofenadine has a relatively short duration of action and may be required to be given twice daily for all round daily protection.  Although desloratadine is less potent, it has the advantages of rarely causing somnolence and having a long duration of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkA18dqept1EH3Rlp_k91zfW6udTcc2eaLxTECZcFKrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D&md5=867adc1094106d91708347063af8a9d9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4103%2F0019-5154.110832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0019-5154.110832%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26aulast%3DChurch%26aufirst%3DD.%2BS.%26atitle%3DPharmacology%2520of%2520antihistamines%26jtitle%3DIndian%2520J.%2520Dermatol.%26date%3D2013%26volume%3D58%26spage%3D219%26epage%3D224%26doi%3D10.4103%2F0019-5154.110832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttmann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1641</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01285.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fj.1476-5381.2011.01285.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=22022805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2gu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1627-1641&author=R.+J.+Slackauthor=L.+J.+Russellauthor=D.+A.+Hallauthor=M.+A.+Luttmannauthor=A.+J.+Fordauthor=K.+A.+Saundersauthor=S.+T.+Hodgsonauthor=H.+E.+Connorauthor=C.+Browningauthor=K.+L.+Clark&title=Pharmacological+characterization+of+GSK1004723%2C+a+novel%2C+long-acting+antagonist+at+histamine+H1+and+H3+receptors&doi=10.1111%2Fj.1476-5381.2011.01285.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors</span></div><div class="casAuthors">Slack, R. J.; Russell, L. J.; Hall, D. A.; Luttmann, M. A.; Ford, A. J.; Saunders, K. A.; Hodgson, S. T.; Connor, H. E.; Browning, C.; Clark, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1627-1641</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Preclin. pharmacol. characterization of GSK1004723, a novel, dual histamine H1 and H3 receptor antagonist.  Exptl. Approach GSK1004723 was characterized in vitro and in vivo using methods that included radioligand binding, intracellular calcium mobilization, cAMP prodn., GTPγS binding, superfused human bronchus and guinea pig whole body plethysmog.  Key Results In cell membranes over-expressing human recombinant H1 and H3 receptors, GSK1004723 displayed high affinity, competitive binding (H1 pKi = 10.2; H3 pKi = 10.6).  In addn., GSK1004723 demonstrated slow dissocn. from both receptors with a t1/2 of 1.2 and 1.5 h for H1 and H3 resp.  GSK1004723 specifically antagonized H1 receptor mediated increases in intracellular calcium and H3 receptor mediated increases in GTPγS binding.  The antagonism exerted was retained after cell washing, consistent with slow dissocn. from H1 and H3 receptors.  Duration of action was further evaluated using superfused human bronchus prepns.  GSK1004723 (100 nmol·L-1) reversed an established contractile response to histamine.  When GSK1004723 was removed from the perfusate, only 20% recovery of the histamine response was obsd. over 10 h.  Moreover, 21 h post-exposure to GSK1004723 there remained almost complete antagonism of responses to histamine.  In vivo pharmacol. was studied in conscious guinea pigs in which nasal congestion induced by intranasal histamine was measured indirectly (plethysmog.).  GSK1004723 (0.1 and 1 mg·mL-1 intranasal) antagonized the histamine-induced response with a duration of up to 72 h.  Conclusions and Implications GSK1004723 is a potent and selective histamine H1 and H3 receptor antagonist with a long duration of action and represents a potential novel therapy for allergic rhinitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpQi3cXynjQ7Vg90H21EOLACvtfcHk0lgU9Ik9F3oJ0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2gu73M&md5=e4201bd03c09a79a423e8874cfb78926</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01285.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01285.x%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DRussell%26aufirst%3DL.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DSaunders%26aufirst%3DK.%2BA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DConnor%26aufirst%3DH.%2BE.%26aulast%3DBrowning%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DK.%2BL.%26atitle%3DPharmacological%2520characterization%2520of%2520GSK1004723%252C%2520a%2520novel%252C%2520long-acting%2520antagonist%2520at%2520histamine%2520H1%2520and%2520H3%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1627%26epage%3D1641%26doi%3D10.1111%2Fj.1476-5381.2011.01285.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of drug-receptor binding kinetics</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.drudis.2013.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23454741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=667-673&author=A.+C.+Panauthor=D.+W.+Borhaniauthor=R.+O.+Drorauthor=D.+E.+Shaw&title=Molecular+determinants+of+drug-receptor+binding+kinetics&doi=10.1016%2Fj.drudis.2013.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of drug-receptor binding kinetics</span></div><div class="casAuthors">Pan, Albert C.; Borhani, David W.; Dror, Ron O.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">667-673</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  It is increasingly appreciated that the rates at which drugs assoc. with and dissoc. from receptors - the binding kinetics - directly impact drug efficacy and safety.  The mol. determinants of drug-receptor binding kinetics remain poorly understood, however, esp. when compared with the well-known factors that affect binding affinity.  The rational modulation of kinetics during lead optimization thus remains challenging.  We review some of the key factors thought to control drug-receptor binding kinetics at the mol. level - mol. size, conformational fluctuations, electrostatic interactions and hydrophobic effects - and discuss several possible approaches for the rational design of drugs with desired binding kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvEt3tx06Z7Vg90H21EOLACvtfcHk0ljyzruzfmeR8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyrtr0%253D&md5=df094bb86b1e280b9ddf5a90031b3f32</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DMolecular%2520determinants%2520of%2520drug-receptor%2520binding%2520kinetics%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D667%26epage%3D673%26doi%3D10.1016%2Fj.drudis.2013.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiechle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wex, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banholzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarosa, P.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8746</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/jm401219y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401219y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8746-8756&author=C.+S.+Tautermannauthor=T.+Kiechleauthor=D.+Seeligerauthor=S.+Diehlauthor=E.+Wexauthor=R.+Banholzerauthor=F.+Gantnerauthor=M.+P.+Pieperauthor=P.+Casarosa&title=Molecular+basis+for+the+long+duration+of+action+and+kinetic+selectivity+of+tiotropium+for+the+muscarinic+M3+receptor&doi=10.1021%2Fjm401219y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for the Long Duration of Action and Kinetic Selectivity of Tiotropium for the Muscarinic M3 Receptor</span></div><div class="casAuthors">Tautermann, Christofer S.; Kiechle, Tobias; Seeliger, Daniel; Diehl, Sonja; Wex, Eva; Banholzer, Rolf; Gantner, Florian; Pieper, Michael P.; Casarosa, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8746-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonizing the human M3 muscarinic receptor (hM3R) over a long time is a key feature of modern bronchodilating COPD drugs aiming at symptom relief.  The long duration of action of the antimuscarinic drug tiotropium and its kinetic subtype selectivity over hM2R are investigated by kinetic mapping of the binding site and the exit channel of hM3R.  Hence, dissocn. expts. have been performed with a set of mol. matched pairs of tiotropium on a large variety of mutated variants of hM3R.  The exceedingly long half-life of tiotropium (of more than 24 h) is attributed to interactions in the binding site; particularly a highly directed interaction of the ligands' hydroxy group with an asparagine (N5086.52) prevents rapid dissocn. via a snap-lock mechanism.  The kinetic selectivity over hM2R, however, is caused by differences in the electrostatics and in the flexibility of the extracellular vestibule.  Extensive mol. dynamics simulations (several microseconds) support exptl. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo95cclma8dobVg90H21EOLACvtfcHk0ljyzruzfmeR8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF&md5=2dd0ce91408c70ba97cf99cdab16b8b2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm401219y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401219y%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DKiechle%26aufirst%3DT.%26aulast%3DSeeliger%26aufirst%3DD.%26aulast%3DDiehl%26aufirst%3DS.%26aulast%3DWex%26aufirst%3DE.%26aulast%3DBanholzer%26aufirst%3DR.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%2BP.%26aulast%3DCasarosa%26aufirst%3DP.%26atitle%3DMolecular%2520basis%2520for%2520the%2520long%2520duration%2520of%2520action%2520and%2520kinetic%2520selectivity%2520of%2520tiotropium%2520for%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8746%26epage%3D8756%26doi%3D10.1021%2Fjm401219y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fsj.bjp.0706819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16847442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2006&pages=927-937&author=M.+R.+Dowlingauthor=S.+J.+Charlton&title=Quantifying+the+association+and+dissociation+rates+of+unlabelled+antagonists+at+the+muscarinic+M3+receptor&doi=10.1038%2Fsj.bjp.0706819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor</span></div><div class="casAuthors">Dowling, Mark R.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Slow receptor dissocn. kinetics has been implicated in the long clin. duration of action of the muscarinic receptor antagonist tiotropium.  However, despite the potential benefits of new drugs with slow dissocn. kinetics, the rate parameters of new compds. are seldom measured due to tech. difficulties and financial implications assocd. with radiolabeling multiple ligands.  Here we describe the development and optimization of a medium throughput assay which is capable of measuring the kinetic parameters of novel, unlabeled compds.  Radioligand binding studies were performed with membranes derived from CHO cells recombinantly expressing the human M3 muscarinic receptor.  Initial characterization of the radioligand [3H]-NMS yielded on and off rates of 4.1±0.2×108 M-1 min-1 and 0.015±0.0005 min-1, resp.  The specific binding of [3H]-NMS was measured over time in the presence and absence of several concns. of unlabeled competitor compds.  These data were analyzed using a competition kinetic model to provide on and off rates for the unlabeled competitor.  Comparison of the kinetically derived Kd (koff/kon) with Ki values generated at equil. showed an excellent correlation (r2=0.99), providing good validation of the method.  The on and off rates were also used in theor. computer simulations to successfully predict the effect of incubation time on apparent IC50 values.  This study demonstrates that a medium-throughput competition kinetic binding assay can be used to det. accurate on and off rates of unlabeled compds., providing the opportunity to optimize for kinetic parameters early in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwZ8YOvAS0F7Vg90H21EOLACvtfcHk0ljyzruzfmeR8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFWrurc%253D&md5=99194c7f2158c3706aa09c4ec83bfbb4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706819%26sid%3Dliteratum%253Aachs%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DQuantifying%2520the%2520association%2520and%2520dissociation%2520rates%2520of%2520unlabelled%2520antagonists%2520at%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D148%26spage%3D927%26epage%3D937%26doi%3D10.1038%2Fsj.bjp.0706819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lgN7l5SBz6Ayg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.-Q.</span></span> <i>PAINS-Remover</i>, <span class="NLM_year">2019</span>. <a href="http://www.cbligand.org/PAINS/" class="extLink">www.cbligand.org/PAINS/</a> (accessed Mar 10, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.-Q.+Xie&title=PAINS-Remover"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DX.-Q.%26jtitle%3DPAINS-Remover%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.-C.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lgN7l5SBz6Ayg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-C.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Optimizing fragment and scaffold docking by use of molecular interaction fingerprints</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1021/ci600342e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci600342e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12iurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=195-207&author=G.+Marcouauthor=D.+Rognan&title=Optimizing+fragment+and+scaffold+docking+by+use+of+molecular+interaction+fingerprints&doi=10.1021%2Fci600342e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints</span></div><div class="casAuthors">Marcou, Gilles; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-207</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein-ligand interaction fingerprints have been used to postprocess docking poses of three ligand data sets: a set of 40 low-mol.-wt. compds. from the Protein Data Bank, a collection of 40 scaffolds from pharmaceutically relevant protein ligands, and a database of 19 scaffolds extd. from true cdk2 inhibitors seeded in 2230 scaffold decoys.  Four popular docking tools (FlexX, Glide, Gold, and Surflex) were used to generate poses for ligands of the three data sets.  In all cases, scoring by the similarity of interaction fingerprints to a given ref. was statistically superior to conventional scoring functions in posing low-mol.-wt. fragments, predicting protein-bound scaffold coordinates according to the known binding mode of related ligands, and screening a scaffold library to enrich a hit list in true cdk2-targeted scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLbVKxK-BfLVg90H21EOLACvtfcHk0lhwNNzp5SooBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12iurzL&md5=0c9137a39d40fbcc83546aec17b595ba</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fci600342e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600342e%26sid%3Dliteratum%253Aachs%26aulast%3DMarcou%26aufirst%3DG.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DOptimizing%2520fragment%2520and%2520scaffold%2520docking%2520by%2520use%2520of%2520molecular%2520interaction%2520fingerprints%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D195%26epage%3D207%26doi%3D10.1021%2Fci600342e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref100':['cit100'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhiyong Wang, Reggie Bosma, Sebastiaan Kuhne, Jelle van den Bor, Wrej Garabitian, Henry F. Vischer, Maikel Wijtmans, Rob Leurs, <span class="NLM_string-name hlFld-ContribAuthor">Iwan J.P. de Esch</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the Effect of Cyclization of Histamine H1 Receptor Antagonists on Ligand Binding Kinetics. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (19)
                                     , 12755-12768. <a href="https://doi.org/10.1021/acsomega.0c06358" title="DOI URL">https://doi.org/10.1021/acsomega.0c06358</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c06358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c06358%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DExploring%252Bthe%252BEffect%252Bof%252BCyclization%252Bof%252BHistamine%252BH1%252BReceptor%252BAntagonists%252Bon%252BLigand%252BBinding%252BKinetics%26aulast%3DWang%26aufirst%3DZhiyong%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D28022021%26date%3D16042021%26date%3D07052021%26volume%3D6%26issue%3D19%26spage%3D12755%26epage%3D12768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huan-Ming Huang, Peter Bellotti, Philipp M. Pflüger, J. Luca Schwarz, Bastian Heidrich, <span class="NLM_string-name hlFld-ContribAuthor">Frank Glorius</span>. </span><span class="cited-content_cbyCitation_article-title">Three-Component, Interrupted Radical Heck/Allylic Substitution Cascade Involving Unactivated Alkyl Bromides. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (22)
                                     , 10173-10183. <a href="https://doi.org/10.1021/jacs.0c03239" title="DOI URL">https://doi.org/10.1021/jacs.0c03239</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c03239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c03239%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DThree-Component%25252C%252BInterrupted%252BRadical%252BHeck%25252FAllylic%252BSubstitution%252BCascade%252BInvolving%252BUnactivated%252BAlkyl%252BBromides%26aulast%3DHuang%26aufirst%3DHuan-Ming%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D24032020%26date%3D22052020%26date%3D07052020%26volume%3D142%26issue%3D22%26spage%3D10173%26epage%3D10183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wijnand J. C. van der Velden, Laura H. Heitman, <span class="NLM_string-name hlFld-ContribAuthor">Mette M. Rosenkilde</span>. </span><span class="cited-content_cbyCitation_article-title">Perspective: Implications of Ligand–Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2020,</strong> <em>3 </em>
                                    (2)
                                     , 179-189. <a href="https://doi.org/10.1021/acsptsci.0c00012" title="DOI URL">https://doi.org/10.1021/acsptsci.0c00012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.0c00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.0c00012%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DPerspective%25253A%252BImplications%252Bof%252BLigand%2525E2%252580%252593Receptor%252BBinding%252BKinetics%252Bfor%252BTherapeutic%252BTargeting%252Bof%252BG%252BProtein-Coupled%252BReceptors%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DWijnand%2BJ.%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16012020%26date%3D02042020%26date%3D18032020%26volume%3D3%26issue%3D2%26spage%3D179%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Puneet  Khurana</span>, <span class="hlFld-ContribAuthor ">Lisa  McWilliams</span>, <span class="hlFld-ContribAuthor ">Jonathan  Wingfield</span>, <span class="hlFld-ContribAuthor ">Derek  Barratt</span>, <span class="hlFld-ContribAuthor ">Bharath  Srinivasan</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel High-Throughput FLIPR Tetra–Based Method for Capturing Highly Confluent Kinetic Data for Structure–Kinetic Relationship Guided Early Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 684-697. <a href="https://doi.org/10.1177/24725552211000676" title="DOI URL">https://doi.org/10.1177/24725552211000676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/24725552211000676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F24725552211000676%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DA%252BNovel%252BHigh-Throughput%252BFLIPR%252BTetra%2525E2%252580%252593Based%252BMethod%252Bfor%252BCapturing%252BHighly%252BConfluent%252BKinetic%252BData%252Bfor%252BStructure%2525E2%252580%252593Kinetic%252BRelationship%252BGuided%252BEarly%252BDrug%252BDiscovery%26aulast%3DKhurana%26aufirst%3DPuneet%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D684%26epage%3D697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hayato  Akimoto</span>, <span class="hlFld-ContribAuthor ">Yoshihiro  Uesawa</span>, <span class="hlFld-ContribAuthor ">Shigeru  Hishinuma</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Determinants of the Kinetic Binding Properties of Antihistamines at the Histamine H1 Receptors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (5)
                                     , 2400. <a href="https://doi.org/10.3390/ijms22052400" title="DOI URL">https://doi.org/10.3390/ijms22052400</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22052400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22052400%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BDeterminants%252Bof%252Bthe%252BKinetic%252BBinding%252BProperties%252Bof%252BAntihistamines%252Bat%252Bthe%252BHistamine%252BH1%252BReceptors%26aulast%3DAkimoto%26aufirst%3DHayato%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D5%26spage%3D2400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pakhuri  Mehta</span>, <span class="hlFld-ContribAuthor ">Przemysław  Miszta</span>, <span class="hlFld-ContribAuthor ">Sławomir  Filipek</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling of Histamine Receptors—Recent Advances in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (6)
                                     , 1778. <a href="https://doi.org/10.3390/molecules26061778" title="DOI URL">https://doi.org/10.3390/molecules26061778</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26061778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26061778%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMolecular%252BModeling%252Bof%252BHistamine%252BReceptors%2525E2%252580%252594Recent%252BAdvances%252Bin%252BDrug%252BDiscovery%26aulast%3DMehta%26aufirst%3DPakhuri%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D6%26spage%3D1778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roopender  Kumar</span>, <span class="hlFld-ContribAuthor ">Nils J.  Flodén</span>, <span class="hlFld-ContribAuthor ">William G.  Whitehurst</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Gaunt</span>. </span><span class="cited-content_cbyCitation_article-title">A general carbonyl alkylative amination for tertiary amine synthesis. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2020,</strong> <em>581 </em>
                                    (7809)
                                     , 415-420. <a href="https://doi.org/10.1038/s41586-020-2213-0" title="DOI URL">https://doi.org/10.1038/s41586-020-2213-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41586-020-2213-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41586-020-2213-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DA%252Bgeneral%252Bcarbonyl%252Balkylative%252Bamination%252Bfor%252Btertiary%252Bamine%252Bsynthesis%26aulast%3DKumar%26aufirst%3DRoopender%26date%3D2020%26date%3D2020%26volume%3D581%26issue%3D7809%26spage%3D415%26epage%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of [<sup><b>3</b></sup>H]Levocetirizine<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Key: (a) Et<sub>2</sub>O, 0 °C to room temperature (rt), 16 h, 88 %; (b) SOCl<sub>2</sub>, dichloromethane (DCM), rt, 20 h, 95 %; (c) 2-(piperazin-1-yl)ethanol, PhMe, 80 °C, 20 h, 21 %; (d) (1) KOH, dimethylformamide (DMF), 0 °C, 90 min; (2) sodium 2-chloroacetate, DMF, 0 °C, 3 h, 57 %; (e) chiral separation; (f) T<sub>2</sub>, Pd/C (10 %), Et<sub>3</sub>N, EtOH.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the investigated H<sub>1</sub>R antagonists and synthesized structural analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Rupatadine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Key: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 18 h, 36–86%; (b) NaHB(OAc)<sub>3</sub>, dichloroethane (DCE), rt, 14 h, 64–88%; (c) NaHB(OAc)<sub>3</sub>, DCE, rt, 14 h, 52–71%; (d) NaHB(OAc)<sub>3</sub>, MeOH, DCM, AcOH, rt, 1.5 h, 60% as fumarate salt; (e) NaHB(OAc)<sub>3</sub>, AcOH, DCM, rt, 48 h, 17%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Radioligand association binding when co-incubated with rupatadine and desloratadine. A homogenate of HEK293T cells expressing the H<sub>1</sub>R was incubated with: (A) [<sup>3</sup>H]mepyramine (3.8 nM) alone, or in the presence of either rupatadine (130 nM) or desloratadine (4 nM) or (B) [<sup>3</sup>H]levocetirizine (6.6 nM) alone, or in the presence of either rupatadine (6 nM) or desloratadine (0.7 nM). Representative graphs of three experiments are shown depicting individual measurements with duplicate values per time point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Aliphatic substituents on the basic amine of desloratadine cause differential binding kinetics at the H<sub>1</sub>R. A homogenate of HEK293T cells expressing the H<sub>1</sub>R was incubated with [<sup>3</sup>H]levocetirizine and the respective ligands. Binding of [<sup>3</sup>H]levocetirizine was determined after 1 and 6 h, and the KRI value was determined as the ratio in [<sup>3</sup>H]levocetirizine binding at both time points (6/1 h). The bars depict the mean and SEM of ≥3 experiments. The top and bottom dotted lines represent the KRI of reference ligands 1 and 2, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Functional recovery of histamine-induced calcium mobilization after a preincubation with ligands that bind the H<sub>1</sub>R. HeLa cells were preincubated for 18–20 h with the respective H<sub>1</sub>R ligand, reaching stable and high (±90%) occupancy of the endogenously expressed H<sub>1</sub>R. The cells were then labeled with Fluo4 NW in the presence of the respective ligands for 1 h. All excess Fluo4 NW and unbound ligands were removed by wash steps and the cells were subsequently stimulated with histamine (10<sup>–5</sup> M) after different incubation times. Representative graphs of ≥3 experiments are shown, which depict the normalized calcium mobilization that was measured at each time point after washout. (A) Cells were preincubated with the reference H<sub>1</sub>R antagonists: rupatadine (1) and desloratadine (2). (B) Cells were preincubated with compounds having various cycloalkyl substituents on the basic amine with (<b>14</b>, <b>16</b>, <b>17</b>) or without (<b>19</b>, <b>20</b>, <b>21</b>) a one-carbon spacer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/medium/jm-2019-004475_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proposed binding modes of (A) desloratadine (yellow), (B) rupatadine (salmon), and (C, D) compound <b>19</b> (orange) in comparison to compound <b>14</b> (blue) based on docking<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(49)</a> into the crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE">3RZE</a><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(48)</a>) of the H<sub>1</sub>R in complex with doxepin [magenta; see (A)]. The clipped molecular surface of H<sub>1</sub>R highlights the limited space for growing from the amine of desloratadine due to I454<sup>7.39</sup> and Y458<sup>7.43</sup>. To highlight the fit of the substituents of rupatadine (<b>2</b>, B), <b>19</b> (C), and <b>14</b> (D) compared to desloratadine in the H<sub>1</sub>R binding pocket, they are shown as transparent surfaces.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00447/20190719/images/large/jm-2019-004475_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00447&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Biochemical mechanisms of drug action: what does it take for success?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1038/nrd1500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd1500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=15340390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=801-808&author=D.+C.+Swinney&title=Biochemical+mechanisms+of+drug+action%3A+what+does+it+take+for+success%3F&doi=10.1038%2Fnrd1500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Biochemical mechanisms of drug action: what does it take for success?</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">801-808</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Drug discovery is extremely difficult.  There are many unanticipated scientific, medical and business challenges to every drug discovery program.  It is important to increase our understanding of the fundamental properties of effective drugs so that we can anticipate potential problems in developing new agents.  This article addresses potential drug discovery and development risks assocd. with the biochem. mechanism of drug action, and proposes simple rules to minimize these risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXhyDgozFUdrVg90H21EOLACvtfcHk0lh9iRXfoicI7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCnsL4%253D&md5=b06bdc6ace3168dcb011679b43b72aed</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd1500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1500%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DBiochemical%2520mechanisms%2520of%2520drug%2520action%253A%2520what%2520does%2520it%2520take%2520for%2520success%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D801%26epage%3D808%26doi%3D10.1038%2Fnrd1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">478</span>, <span class="refDoi"> DOI: 10.2174/156802606776743093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.2174%2F156802606776743093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16719803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtV2jurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=461-478&author=D.+C.+Swinney&title=Biochemical+mechanisms+of+new+molecular+entities+%28NMEs%29+approved+by+United+States+FDA+during+2001-2004%3A+mechanisms+leading+to+optimal+efficacy+and+safety&doi=10.2174%2F156802606776743093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety</span></div><div class="casAuthors">Swinney, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">461-478</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The United States FDA approved 85 New Mol. Entities (NMEs) during the period from Jan. 2001 to Nov. 2004 of which 60 were pharmaceuticals with known mol. targets.  The majority targeted enzymes (48%) or G-protein coupled receptors (GPCRs) (33%).  Eighty percent of the NMEs interacted at the same site as endogenous effector; either as competitive inhibitor/antagonist (67%) or agonist (13%).  Three biochem. operations defined the modes of action of the NMEs: (1) mass action competition (equil.), (2) a drug stabilized conformational change in the target that is important to the response (conformational), and(or) (3) drug action is less-responsive to mass action competition with effectors due to non-equil. kinetics (non-equil. kinetic).  Approx. 80% of the NMEs elicit a response utilizing conformational and(or) non-equil. kinetic mechanisms.  The remaining 20% of NMEs find mass action competition with the endogenous substrate or ligand sufficient for therapeutic utility.  These observations indicate that for the majority of drug targets, mass action-driven equil. binding alone may not be sufficient for maximal therapeutic utility.  A key determinant of the biochem. mode of action for these NMEs was to minimize the potential for toxicity, either by providing a maximal response at a low dose to minimize off-target toxicities, or by providing a mechanism to minimize the incidence of mechanism-based toxicity while retaining a sufficiently efficacious response.  This principle appears to be independent of target class and provides insight as to intrinsic biochem. features and approaches required for a maximal therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7meEijEZ3GrVg90H21EOLACvtfcHk0lhgn4DNvN2_7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtV2jurs%253D&md5=091dc5bf90bf465ccf21160bd9140067</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F156802606776743093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606776743093%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DBiochemical%2520mechanisms%2520of%2520new%2520molecular%2520entities%2520%2528NMEs%2529%2520approved%2520by%2520United%2520States%2520FDA%2520during%25202001-2004%253A%2520mechanisms%2520leading%2520to%2520optimal%2520efficacy%2520and%2520safety%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D461%26epage%3D478%26doi%3D10.2174%2F156802606776743093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lhgn4DNvN2_7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swinney, D. C.</span></span> <span> </span><span class="NLM_article-title">Applications of binding kinetics to drug discovery</span>. <i>Pharm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1007/BF03256679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2FBF03256679" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=23-34&author=D.+C.+Swinney&title=Applications+of+binding+kinetics+to+drug+discovery&doi=10.1007%2FBF03256679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2FBF03256679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03256679%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26atitle%3DApplications%2520of%2520binding%2520kinetics%2520to%2520drug%2520discovery%26jtitle%3DPharm.%2520Med.%26date%3D2008%26volume%3D22%26spage%3D23%26epage%3D34%26doi%3D10.1007%2FBF03256679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <span> </span><span class="NLM_article-title">The drug–target residence time model: a 10-year retrospective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd.2015.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=26678621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=87-95&author=R.+A.+Copeland&title=The+drug%E2%80%93target+residence+time+model%3A+a+10-year+retrospective&doi=10.1038%2Fnrd.2015.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The drug-target residence time model: a 10-year retrospective</span></div><div class="casAuthors">Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The drug-target residence time model was first introduced in 2006 and has been broadly adopted across the chem. biol., biotechnol. and pharmaceutical communities.  While traditional in vitro methods view drug-target interactions exclusively in terms of equil. affinity, the residence time model takes into account the conformational dynamics of target macromols. that affect drug binding and dissocn.  The key tenet of this model is that the lifetime (or residence time) of the binary drug-target complex, and not the binding affinity per se, dictates much of the in vivo pharmacol. activity.  Here, this model is revisited and key applications of it over the past 10 years are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwNrhp9U8kwLVg90H21EOLACvtfcHk0ljzsu-5OWO5DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCrurnE&md5=23f4a6973d77804292ff0af6c81358c0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.18%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520drug%25E2%2580%2593target%2520residence%2520time%2520model%253A%2520a%252010-year%2520retrospective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D87%26epage%3D95%26doi%3D10.1038%2Fnrd.2015.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span> <span> </span><span class="NLM_article-title">Ligand residence time at G-protein-coupled receptors-why we should take our time to study it</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">560</span>, <span class="refDoi"> DOI: 10.1124/mol.115.099671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1124%2Fmol.115.099671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=26152198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCgs77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=552-560&author=C.+Hoffmannauthor=M.+Castroauthor=A.+Rinkenauthor=R.+Leursauthor=S.+J.+Hillauthor=H.+F.+Vischer&title=Ligand+residence+time+at+G-protein-coupled+receptors-why+we+should+take+our+time+to+study+it&doi=10.1124%2Fmol.115.099671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand residence time at G-protein-coupled receptors-why we should take our time to study it</span></div><div class="casAuthors">Hoffmann, C.; Castro, M.; Rinken, A.; Leurs, R.; Hill, S. J.; Vischer, H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">552-560</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Over the past decade the kinetics of ligand binding to a receptor have received increasing interest.  The concept of drug-target residence time is becoming an invaluable parameter for drug optimization.  It holds great promise for drug development, and its optimization is thought to reduce off-target effects.  The success of long-acting drugs like tiotropium support this hypothesis.  Nonetheless, we know surprisingly little about the dynamics and the mol. detail of the drug binding process.  Because protein dynamics and adaptation during the binding event will change the conformation of the protein, ligand binding will not be the static process that is often described.  This can cause problems because simple math. models often fail to adequately describe the dynamics of the binding process.  In this minireview we will discuss the current situation with an emphasis on G-protein-coupled receptors.  These are important membrane protein drug targets that undergo conformational changes upon agonist binding to communicate signaling information across the plasma membrane of cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulpr-SkEipLVg90H21EOLACvtfcHk0ljzsu-5OWO5DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCgs77P&md5=c675935da015aa4a590c75a4be65d01a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.099671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.099671%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DCastro%26aufirst%3DM.%26aulast%3DRinken%26aufirst%3DA.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26atitle%3DLigand%2520residence%2520time%2520at%2520G-protein-coupled%2520receptors-why%2520we%2520should%2520take%2520our%2520time%2520to%2520study%2520it%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D552%26epage%3D560%26doi%3D10.1124%2Fmol.115.099671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time-a case for G protein-coupled receptors</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/med.21307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1002%2Fmed.21307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=24549504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=856-892&author=D.+Guoauthor=J.+M.+Hillgerauthor=A.+P.+IJzermanauthor=L.+H.+Heitman&title=Drug-target+residence+time-a+case+for+G+protein-coupled+receptors&doi=10.1002%2Fmed.21307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Target Residence Time-A Case for G Protein-Coupled Receptors</span></div><div class="casAuthors">Guo, Dong; Hillger, Julia M.; Ijzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">856-892</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  A vast no. of marketed drugs act on G protein-coupled receptors (GPCRs), the most successful category of drug targets to date.  These drugs usually possess high target affinity and selectivity, and such combined features have been the driving force in the early phases of drug discovery.  However, attrition has also been high.  Many investigational new drugs eventually fail in clin. trials due to a demonstrated lack of efficacy.  A retrospective assessment of successfully launched drugs revealed that their beneficial effects in patients may be attributed to their long drug-target residence times (RTs).  Likewise, for some other GPCR drugs short RT could be beneficial to reduce the potential for on-target side effects.  Hence, the compds.' kinetics behavior might in fact be the guiding principle to obtain a desired and durable effect in vivo.  We therefore propose that drug-target RT should be taken into account as an addnl. parameter in the lead selection and optimization process.  This should ultimately lead to an increased no. of candidate drugs moving to the preclin. development phase and on to the market.  This review contains examples of the kinetics behavior of GPCR ligands with improved in vivo efficacy and summarizes methods for assessing drug-target RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN5vhWI93LMbVg90H21EOLACvtfcHk0ljzsu-5OWO5DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVagtbs%253D&md5=af48cdedf3c60ecb608d5c9ad03a0bbe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fmed.21307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21307%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHillger%26aufirst%3DJ.%2BM.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DDrug-target%2520residence%2520time-a%2520case%2520for%2520G%2520protein-coupled%2520receptors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D856%26epage%3D892%26doi%3D10.1002%2Fmed.21307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, P. J.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time: critical information for lead optimization</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2010.06.176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.cbpa.2010.06.176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=20663707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=467-474&author=H.+Luauthor=P.+J.+Tonge&title=Drug-target+residence+time%3A+critical+information+for+lead+optimization&doi=10.1016%2Fj.cbpa.2010.06.176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time: Critical information for lead optimization</span></div><div class="casAuthors">Lu, Hao; Tonge, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-474</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics.  Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug-target binding are flawed, since this approach ignores the fluctuations in drug concn. that occur in vivo.  Instead the lifetime of the drug-target complex must also be considered, since drugs only act when they are bound to their targets.  Consequently, to improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug-target residence time must be incorporated into the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodk2kN_txuMLVg90H21EOLACvtfcHk0lh6A3eeImKGTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr4%253D&md5=3189f56032106db858cfb4269d3fc11f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.176%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26atitle%3DDrug-target%2520residence%2520time%253A%2520critical%2520information%2520for%2520lead%2520optimization%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D467%26epage%3D474%26doi%3D10.1016%2Fj.cbpa.2010.06.176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fj.1476-5381.2010.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=20880390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=488-508&author=G.+Vauquelinauthor=S.+J.+Charlton&title=Long-lasting+target+binding+and+rebinding+as+mechanisms+to+prolong+in+vivo+drug+action&doi=10.1111%2Fj.1476-5381.2010.00936.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span></div><div class="casAuthors">Vauquelin, Georges; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-508</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  An increasing no. of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding.  The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent.  Simulations reveal that these latter phenomena become esp. influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy.  There is not always a direct link between slow dissocn. and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor.  Local phenomena that hinder the diffusion of free drug mols. away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concn. in the bulk phase has already dropped to insignificant levels.  The micro-anat. properties of many effect compartments are likely to intensify this phenomenon.  By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiol. relevant conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSGNmKeaTzrVg90H21EOLACvtfcHk0lh6A3eeImKGTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE&md5=bd91e09a0fd79a2de6bf9ef0cfd3443e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DLong-lasting%2520target%2520binding%2520and%2520rebinding%2520as%2520mechanisms%2520to%2520prolong%2520in%2520vivo%2520drug%2520action%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D488%26epage%3D508%26doi%3D10.1111%2Fj.1476-5381.2010.00936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folmer, R. H. A.</span></span> <span> </span><span class="NLM_article-title">Drug target residence time: a misleading concept</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.drudis.2017.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=28782685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=12-16&author=R.+H.+A.+Folmer&title=Drug+target+residence+time%3A+a+misleading+concept&doi=10.1016%2Fj.drudis.2017.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug target residence time: a misleading concept</span></div><div class="casAuthors">Folmer, Rutger H. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-16</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Since the importance of drug target residence time was first highlighted more 10 years ago, slow binding kinetics has received much attention in the drug discovery literature, and indeed within pharmaceutical research.  However, the residence concept as presented in most papers is supported by rather misleading simulations and arguments, and by examples where compds. are taken out of their pharmacokinetic context.  Moreover, fast assocn. is typically more desirable than slow, and advantages of long residence time, notably a potential disconnect between pharmacodynamics (PD) and pharmacokinetics (PK), would be partially or completely offset by slow on-rate.  Therefore, plain potency is likely a better predictor of drug development success than is residence time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5NQgx9uuufLVg90H21EOLACvtfcHk0lh6A3eeImKGTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitbjI&md5=61f68447e7f8eaf6b93c4b09fc5afeda</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DFolmer%26aufirst%3DR.%2BH.%2BA.%26atitle%3DDrug%2520target%2520residence%2520time%253A%2520a%2520misleading%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2018%26volume%3D23%26spage%3D12%26epage%3D16%26doi%3D10.1016%2Fj.drudis.2017.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akerud, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and the drug-target residence time concept</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.drudis.2013.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23500610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=697-707&author=G.+Dahlauthor=T.+Akerud&title=Pharmacokinetics+and+the+drug-target+residence+time+concept&doi=10.1016%2Fj.drudis.2013.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and the drug-target residence time concept</span></div><div class="casAuthors">Dahl, Goeran; Akerud, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of drug-target residence time has been in focus in recent drug discovery literature.  However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug.  Using a simple model that takes both PK and BK into account, we found that prolongation of binding owing to a long drug-target residence time can only occur when the binding dissocn. is slower than the PK elimination.  Data for several drugs and/or drug candidates in the literature indicate that the opposite is obsd., i.e., they have a slower elimination compared with dissocn.  These observations greatly reduce the usability of drug-target residence times for estg. the duration of effect of a drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2xZ9fJkTybVg90H21EOLACvtfcHk0lhRwVq0eZrO6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D&md5=73b190a44d359f55ee19af9099846505</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DAkerud%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520the%2520drug-target%2520residence%2520time%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.drudis.2013.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span> <span> </span><span class="NLM_article-title">In vivo target residence time and kinetic selectivity: the association rate constant as determinant</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.tips.2016.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27394919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=831-842&author=W.+E.+A.+de%0AWitteauthor=M.+Danhofauthor=P.+H.+van+der+Graafauthor=E.+C.+M.+de+Lange&title=In+vivo+target+residence+time+and+kinetic+selectivity%3A+the+association+rate+constant+as+determinant&doi=10.1016%2Fj.tips.2016.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant</span></div><div class="casAuthors">de Witte, Wilhelmus E. A.; Danhof, Meindert; van der Graaf, Piet H.; de Lange, Elizabeth C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">831-842</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">It is generally accepted that, in conjunction with pharmacokinetics, the first-order rate const. of target dissocn. is a major determinant of the time course and duration of in vivo target occupancy.  Here we show that the second-order rate const. of target assocn. can be equally important.  On the basis of the commonly used math. models for drug-target binding, it is shown that a high target assocn. rate const. can increase the (local) concn. of the drug, which decreases the rate of decline of target occupancy.  The increased drug concn. can also lead to increased off-target binding and decreased selectivity.  Therefore, the kinetics of both target assocn. and dissocn. need to be taken into account in the selection of drug candidates with optimal pharmacodynamic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri0cm4NKLv-7Vg90H21EOLACvtfcHk0lhRwVq0eZrO6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE&md5=e2c077f2c8636214e2f8a77ee5734ad4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.06.008%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DDanhof%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26atitle%3DIn%2520vivo%2520target%2520residence%2520time%2520and%2520kinetic%2520selectivity%253A%2520the%2520association%2520rate%2520constant%2520as%2520determinant%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26spage%3D831%26epage%3D842%26doi%3D10.1016%2Fj.tips.2016.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Louizos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yáñez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. M.</span></span> <span> </span><span class="NLM_article-title">Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships</span>. <i>J. Pharm. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.18433/J3GP53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.18433%2FJ3GP53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=24735761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADC%252BC2cnkt1OjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=34-91&author=C.+Louizosauthor=J.+A.+Y%C3%A1%C3%B1ezauthor=M.+L.+Forrestauthor=N.+M.+Davies&title=Understanding+the+hysteresis+loop+conundrum+in+pharmacokinetic%2Fpharmacodynamic+relationships&doi=10.18433%2FJ3GP53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships</span></div><div class="casAuthors">Louizos Christopher; Yanez Jaime A; Forrest M Laird; Davies Neal M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hysteresis loops are phenomena that sometimes are encountered in the analysis of pharmacokinetic and pharmacodynamic relationships spanning from pre-clinical to clinical studies.  When hysteresis occurs it provides insight into the complexity of drug action and disposition that can be encountered.  Hysteresis loops suggest that the relationship between drug concentration and the effect being measured is not a simple direct relationship, but may have an inherent time delay and disequilibrium, which may be the result of metabolites, the consequence of changes in pharmacodynamics or the use of a non-specific assay or may involve an indirect relationship.  Counter-clockwise hysteresis has been generally defined as the process in which effect can increase with time for a given drug concentration, while in the case of clockwise hysteresis the measured effect decreases with time for a given drug concentration.  Hysteresis loops can occur as a consequence of a number of different pharmacokinetic and pharmacodynamic mechanisms including tolerance, distributional delay, feedback regulation, input and output rate changes, agonistic or antagonistic active metabolites, uptake into active site, slow receptor kinetics, delayed or modified activity, time-dependent protein binding and the use of racemic drugs among other factors.  In this review, each of these various causes of hysteresis loops are discussed, with incorporation of relevant examples of drugs demonstrating these relationships for illustrative purposes.  Furthermore, the effect that pharmaceutical formulation has on the occurrence and potential change in direction of the hysteresis loop, and the major pharmacokinetic / pharmacodynamic modeling approaches utilized to collapse and model hysteresis are detailed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSC0uKaIdi8tLjnyZkbE8yXfW6udTcc2ebQTqHOOJ8ey7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnkt1OjsA%253D%253D&md5=7e58b87eebafb814d7ed9fe01c5218af</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.18433%2FJ3GP53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ3GP53%26sid%3Dliteratum%253Aachs%26aulast%3DLouizos%26aufirst%3DC.%26aulast%3DY%25C3%25A1%25C3%25B1ez%26aufirst%3DJ.%2BA.%26aulast%3DForrest%26aufirst%3DM.%2BL.%26aulast%3DDavies%26aufirst%3DN.%2BM.%26atitle%3DUnderstanding%2520the%2520hysteresis%2520loop%2520conundrum%2520in%2520pharmacokinetic%252Fpharmacodynamic%2520relationships%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D17%26spage%3D34%26epage%3D91%26doi%3D10.18433%2FJ3GP53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span> <span> </span><span class="NLM_article-title">Effects of target binding kinetics on in vivo drug efficacy: <i>k</i><sub>off</sub>, <i>k</i><sub>on</sub> and rebinding</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">2319</span>– <span class="NLM_lpage">2334</span>, <span class="refDoi"> DOI: 10.1111/bph.13504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fbph.13504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27129075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSiurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=2319-2334&author=G.+Vauquelin&title=Effects+of+target+binding+kinetics+on+in+vivo+drug+efficacy%3A+koff%2C+kon+and+rebinding&doi=10.1111%2Fbph.13504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of target binding kinetics on in vivo drug efficacy: koff, kon and rebinding</span></div><div class="casAuthors">Vauquelin, Georges</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2319-2334</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Optimal drug therapy often requires continuing high levels of target occupancy.  Besides the traditional pharmacokinetic contribution, target binding kinetics is increasingly considered to play an important role as well.  While most attention has been focused on the dissocn. rate of the complex, recent reports expressed doubt about the unreserved translatability of this pharmacodynamic property into clin. efficacy. 'Micro'-pharmacokinetic mechanisms like drug rebinding and partitioning into the cell membrane may constitute a potential fix.  Exptl. Approach : Simulations were based on solving differential equations.  Key Results : Based on a selected range of assocn. and dissocn. rate consts., kon and koff, and rebinding potencies of the drugs as variables, their effects on the temporal in vivo occupancy profile of their targets, after one or multiple repetitive dosings, have here been simulated.  Conclusions and Implications : Most strikingly, the simulations show that, when rebinding is also taken into account, increasing kon may produce closely the same outcome as decreasing koff when dosing is performed in accordance with the therapeutically most relevant const. [Lmax]/KD ratio paradigm.  Also, under certain conditions, rebinding may produce closely the same outcome as invoking slow diffusion of the drug between the plasma compartment and a target-contg. 'effect' compartment.  Although the present simulations should only be regarded as a 'proof of principle', these findings may help pharmacologists and medicinal chemists to devise ex vivo and in vitro binding kinetic assays that are more relevant and translatable to in vivo settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5-dbZNJetv7Vg90H21EOLACvtfcHk0lj1M5xez3V8Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSiurvI&md5=5d1b13ef5786a0c661118ce9be503d50</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fbph.13504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13504%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DEffects%2520of%2520target%2520binding%2520kinetics%2520on%2520in%2520vivo%2520drug%2520efficacy%253A%2520koff%252C%2520kon%2520and%2520rebinding%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D2319%26epage%3D2334%26doi%3D10.1111%2Fbph.13504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span> <span> </span><span class="NLM_article-title">The influence of drug distribution and drug-target binding on target occupancy: the rate-limiting step approximation</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">S83</span>– <span class="NLM_lpage">S89</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.ejps.2017.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotFyntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=S83-S89&author=W.+E.+A.+de%0AWitteauthor=G.+Vauquelinauthor=P.+H.+van+der+Graafauthor=E.+C.+M.+de+Lange&title=The+influence+of+drug+distribution+and+drug-target+binding+on+target+occupancy%3A+the+rate-limiting+step+approximation&doi=10.1016%2Fj.ejps.2017.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation</span></div><div class="casAuthors">de Witte, W. E. A.; Vauquelin, G.; van der Graaf, P. H.; de Lange, E. C. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Suppl.</span>),
    <span class="NLM_cas:pages">S83-S89</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The influence of drug-target binding kinetics on target occupancy can be influenced by drug distribution and diffusion around the target, often referred to as "rebinding" or "diffusion-limited binding".  This gives rise to a decreased decline of the drug-target complex concn. as a result of a locally higher drug concn. that arises around the target, which leads to prolonged target exposure to the drug.  This phenomenon has been approximated by the steady-state approxn., assuming a steady-state concn. around the target.  Recently, a rate-limiting step approxn. of drug distribution and drug-target binding has been published.  However, a comparison between both approaches has not been made so far.  In this study, the rate-limiting step approxn. has been rewritten into the same math. format as the steady-state approxn. in order to compare the performance of both approaches for the investigation of the influence of drug-target binding kinetics on target occupancy.  While both approxns. clearly indicated the importance of kon and high target concns., it was shown that the rate-limiting step approxn. is more accurate than the steady-state approxn., esp. when dissocn. is fast compared to assocn. and distribution out of the binding compartment.  It is therefore concluded that the new rate-limiting step approxn. is to be preferred for assessing the influence of binding kinetics on local target site concns. and target occupancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFE8powQy5Q7Vg90H21EOLACvtfcHk0lj1M5xez3V8Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotFyntLo%253D&md5=f3fdcef1a3d40690eb41e8d0e37ed71a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.05.024%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26atitle%3DThe%2520influence%2520of%2520drug%2520distribution%2520and%2520drug-target%2520binding%2520on%2520target%2520occupancy%253A%2520the%2520rate-limiting%2520step%2520approximation%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D109%26spage%3DS83%26epage%3DS89%26doi%3D10.1016%2Fj.ejps.2017.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0ljrpEY8exiGeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simons, F. E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, K. J.</span></span> <span> </span><span class="NLM_article-title">Histamine and H1-antihistamines: celebrating a century of progress</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2011.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.jaci.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=22035879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKnu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2011&pages=1139-1150&author=F.+E.+R.+Simonsauthor=K.+J.+Simons&title=Histamine+and+H1-antihistamines%3A+celebrating+a+century+of+progress&doi=10.1016%2Fj.jaci.2011.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine and H1-antihistamines: Celebrating a century of progress</span></div><div class="casAuthors">Simons, F. Estelle R.; Simons, Keith J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1139-1150.e4</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this review we celebrate a century of progress since the initial description of the physiol. and pathol. roles of histamine and 70 years of progress since the introduction of H1-antihistamines for clin. use.  We discuss histamine and clin. relevant information about the mol. mechanisms of action of H1-antihistamines as inverse agonists (not antagonists or blockers) with immunoregulatory effects.  Unlike first (old)-generation H1-antihistamines introduced from 1942 to the mid-1980s, most of the second (new)-generation H1-antihistamines introduced subsequently have been investigated extensively with regard to clin. pharmacol., efficacy, and safety; moreover, they are relatively free from adverse effects and not causally linked with fatalities after overdose.  Important advances include improved nasal and ophthalmic H1-antihistamines with rapid onset of action (in minutes) for allergic rhinitis and allergic conjunctivitis treatment, resp., and effective and safe use of high (up to 4-fold) doses of oral second-generation H1-antihistamines for chronic urticaria treatment.  New H1-antihistamines introduced for clin. use include oral formulations (bilastine and rupatadine), and ophthalmic formulations (alcaftadine and bepotastine).  Clin. studies of H3-antihistamines with enhanced decongestant effects have been conducted in patients with allergic rhinitis.  Addnl. novel compds. being studied include H4-antihistamines with anti-inflammatory effects in allergic rhinitis, atopic dermatitis, and other diseases.  Antihistamines have a storied past and a promising future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXBww6BOAHrVg90H21EOLACvtfcHk0lgoaU_42Paqag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKnu7%252FL&md5=974702e4d5d97dc67acebfcd6cb61ca7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DF.%2BE.%2BR.%26aulast%3DSimons%26aufirst%3DK.%2BJ.%26atitle%3DHistamine%2520and%2520H1-antihistamines%253A%2520celebrating%2520a%2520century%2520of%2520progress%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2011%26volume%3D128%26spage%3D1139%26epage%3D1150%26doi%3D10.1016%2Fj.jaci.2011.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoepke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span> <span> </span><span class="NLM_article-title">The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy caucasian and japanese volunteers</span>. <i>Acta Derm. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.2340/00015555-1490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.2340%2F00015555-1490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23147964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ekurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=286-293&author=N.+Schoepkeauthor=M.+Churchauthor=M.+Maurer&title=The+inhibition+by+levocetirizine+and+fexofenadine+of+the+histamine-induced+wheal+and+flare+response+in+healthy+caucasian+and+japanese+volunteers&doi=10.2340%2F00015555-1490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers</span></div><div class="casAuthors">Schoepke, Nicole; Church, Martin K.; Maurer, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-293, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">1651-2057</span>.
    
            (<span class="NLM_cas:orgname">Acta Dermato-Venereologica</span>)
        </div><div class="casAbstract">This randomized, double-blind, placebo-controlled cross-over study compared inhibition by one 5 mg dose of levocetirizine with two 60 mg doses of fexofenadine sepd. by 12 h of histamine-induced wheal and flare responses in 9 Caucasian and 9 Japanese healthy male volunteers.  Levocetirizine was more inhibitory than fexofenadine on wheal, flare and pruritus (p<0.005).  Variability, evaluated from the std. deviation of inhibition, ranged from 14% to 23.2% for levocetirizine and 65.4% to 112.4% for fexofenadine.  Levocetirizine had a faster onset of action (30-90 min vs. 2 h), shorter time to max. effect (3-4 vs. 3-6 h) and longer duration of action (at least 24 h vs. ∼12 h) than fexofenadine.  The plasma levels of levocetirizine rose more quickly, reached higher levels, were more consistent and decreased slower than those of fexofenadine.  There were no clin. significant ethnic differences in responsiveness to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU3pstGQuc8bVg90H21EOLACvtfcHk0lgoaU_42Paqag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ekurnK&md5=8b85c352f07576c8426cc80f6cb2e72c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2340%2F00015555-1490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2340%252F00015555-1490%26sid%3Dliteratum%253Aachs%26aulast%3DSchoepke%26aufirst%3DN.%26aulast%3DChurch%26aufirst%3DM.%26aulast%3DMaurer%26aufirst%3DM.%26atitle%3DThe%2520inhibition%2520by%2520levocetirizine%2520and%2520fexofenadine%2520of%2520the%2520histamine-induced%2520wheal%2520and%2520flare%2520response%2520in%2520healthy%2520caucasian%2520and%2520japanese%2520volunteers%26jtitle%3DActa%2520Derm.%2520Venereol.%26date%3D2013%26volume%3D93%26spage%3D286%26epage%3D293%26doi%3D10.2340%2F00015555-1490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Perren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moguilevsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massingham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, P.</span></span> <span> </span><span class="NLM_article-title">Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1124/mol.61.2.391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1124%2Fmol.61.2.391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=11809864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1OnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2002&pages=391-399&author=M.+Gillardauthor=C.+Van+Der+Perrenauthor=N.+Moguilevskyauthor=R.+Massinghamauthor=P.+Chatelain&title=Binding+characteristics+of+cetirizine+and+levocetirizine+to+human+H1+histamine+receptors%3A+contribution+of+Lys191+and+Thr194&doi=10.1124%2Fmol.61.2.391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Binding characteristics of cetirizine and levocetirizine to human H1 histamine receptors: contribution of Lys191 and Thr194</span></div><div class="casAuthors">Gillard, Michel; Van Der Perren, Christy; Moguilevsky, Nicole; Massingham, Roy; Chatelain, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-399</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Competition expts. with [3H]mepyramine showed that cetirizine and its enantiomers, levocetirizine and (S)-cetirizine, bound with high affinity and stereoselectivity to human H1 histamine receptors (Ki values of 6, 3, and 100 nM, resp.).  Cetirizine and levocetirizine were 600-fold more selective for H1 receptors compared with a panel of receptors and channels.  Binding results indicated that the interaction between cetirizine, its enantiomers, and histamine is compatible with a competitive behavior, in contrast with the noncompetitive profile of cetirizine and levocetirizine obsd. in isolated organs.  Binding kinetics provided a suitable explanation for this observation, because levocetirizine dissocd. from H1 receptors with a half-time of 142 min; that of (S)-cetirizine was only 6 min, implying that the former could act as a pseudo-irreversible antagonist in functional studies.  The carboxylic function of levocetirizine seemed responsible for its long dissocn. time.  Indeed, hydroxyl or Me ester analogs dissocd. more rapidly from H1 receptors, with half-times of 31 min and 7 min, resp.  The importance of the carboxylic function of levocetirizine for the interaction with the H1 receptor was further supported by the results from the mutation of Lys191 to Ala191.  This mutation decreased the dissocn. half-time of levocetirizine from 142 to 13 min and reduced its affinity from 3 to 12 nM, whereas the affinity and dissocn. kinetics of hydroxyl and Me ester analogs were hardly affected.  The mutation of Thr194 reduced the binding stereoselectivity by selectively enhancing the affinity of the distomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUA4hyZN6ibVg90H21EOLACvtfcHk0lgoaU_42Paqag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1OnsQ%253D%253D&md5=92af3601b619f4f3dc876dc9fd1ab999</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fmol.61.2.391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.61.2.391%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DVan%2BDer%2BPerren%26aufirst%3DC.%26aulast%3DMoguilevsky%26aufirst%3DN.%26aulast%3DMassingham%26aufirst%3DR.%26aulast%3DChatelain%26aufirst%3DP.%26atitle%3DBinding%2520characteristics%2520of%2520cetirizine%2520and%2520levocetirizine%2520to%2520human%2520H1%2520histamine%2520receptors%253A%2520contribution%2520of%2520Lys191%2520and%2520Thr194%26jtitle%3DMol.%2520Pharmacol.%26date%3D2002%26volume%3D61%26spage%3D391%26epage%3D399%26doi%3D10.1124%2Fmol.61.2.391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span> <span> </span><span class="NLM_article-title">Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1007/s00011-011-0373-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2Fs00011-011-0373-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=21874559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSju73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2011&pages=1107-1112&author=M.+K.+Church&title=Comparative+inhibition+by+bilastine+and+cetirizine+of+histamine-induced+wheal+and+flare+responses+in+humans&doi=10.1007%2Fs00011-011-0373-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans</span></div><div class="casAuthors">Church, Martin K.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1107-1112</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Comparison of bilastine and cetirizine in inhibiting skin wheal and flare responses over 24 h.  Twenty-one healthy male volunteers (aged 19-44 years).  Volunteers were randomized to receive single oral doses of 20 or 50 mg bilastine, 10 mg cetirizine or placebo before provocation of wheal and flare responses to 100 mg/mL histamine by skin prick 1.5, 4, 8, 12, and 24 h later.  There were no significant differences between overall inhibitions of wheal or flare by 20 mg bilastine and 10 mg cetirizine.  Bilastine was faster in onset than cetirizine, inhibitions of wheal and flare at 1.5 h being 89 vs. 44% and 85 vs. 45%, resp. (Student's t test).  At 1.5 h, both wheals and flares were inhibited by >70% in 11/12 volunteers taking bilastine and 3/11 taking cetirizine.  There were no significant differences between the drugs at later times.  Bilastine 50 mg had a longer duration of action than bilastine 20 mg.  Both 20 mg bilastine and 10 mg cetirizine are effective and of long duration in reducing histamine-induced wheal and flare responses, the major difference between the 2 drugs being the more rapid onset of action of bilastine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXAVx6mYGjXrVg90H21EOLACvtfcHk0lgFBL9PQ29Wmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSju73P&md5=c4bfdb3b3f1c3279e3c70ebd6e13b93b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00011-011-0373-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-011-0373-y%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26atitle%3DComparative%2520inhibition%2520by%2520bilastine%2520and%2520cetirizine%2520of%2520histamine-induced%2520wheal%2520and%2520flare%2520responses%2520in%2520humans%26jtitle%3DInflammation%2520Res.%26date%3D2011%26volume%3D60%26spage%3D1107%26epage%3D1112%26doi%3D10.1007%2Fs00011-011-0373-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1330</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.2010.10029.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fj.1365-2133.2010.10029.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=20819087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFGltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2010&pages=1330-1332&author=M.+K.+Church&title=Efficacy+and+tolerability+of+rupatadine+at+four+times+the+recommended+dose+against+histamine-+and+platelet-activating+factor-induced+flare+responses+and+ex+vivo+platelet+aggregation+in+healthy+males&doi=10.1111%2Fj.1365-2133.2010.10029.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males</span></div><div class="casAuthors">Church, M. K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1330-1332</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">European guidelines recommend increasing H1-antihistamine doses up to fourfold in poorly responding patients with urticaria.  To assess the efficacy and tolerability of high-dose rupatadine (40 mg) against platelet-activating factor (PAF)- and histamine-induced flare responses in human skin and to verify its anti-PAF activity by assessing its inhibition of PAF-induced platelet aggregation in the blood of subjects receiving rupatadine 40 mg.  In the flare study, six male volunteers received a single dose of rupatadine 40 mg.  Flares were induced before dosing and up to 96 h afterwards by intradermal PAF and histamine.  In the ex vivo study, four male volunteers received an oral dose of rupatadine 40 mg and blood samples were taken 4 h afterwards.  Platelet aggregation was assessed in platelet-rich plasma by incubation for 5 min with PAF.  Rupatadine 40 mg reached maximal plasma levels of 15.1 ± 4.4 ng/mL-1 at 1 h and its metabolite, desloratadine, 5.2 ± 0.9 ng/mL-1 at 2 h.  Neither was detectable at 12 h.  Inhibition of histamine- and PAF-induced flares was significant within 2 h, maximal at 6 h (87.8 ± 3.1% and 87.1 ± 2.5% inhibition, resp., P < 0.0001) and still statistically significant at 72 h.  Rupatadine 40 mg inhibited PAF-induced platelet aggregation ex vivo by 82 ± 9% (P = 0.023).  A single oral dose of rupatadine 40 mg was well tolerated with mild transient somnolence being reported.  A single dose of rupatadine at four times the recommended dose is well tolerated, highly effective for up to 72 h against PAF- and histamine-induced dermal flares and has demonstrable PAF-receptor antagonism ex vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ5Sj9vLAfyrVg90H21EOLACvtfcHk0lgFBL9PQ29Wmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFGltw%253D%253D&md5=fcfdafe8d0cf308f358d026bb7fb20df</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2010.10029.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2010.10029.x%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520rupatadine%2520at%2520four%2520times%2520the%2520recommended%2520dose%2520against%2520histamine-%2520and%2520platelet-activating%2520factor-induced%2520flare%2520responses%2520and%2520ex%2520vivo%2520platelet%2520aggregation%2520in%2520healthy%2520males%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2010%26volume%3D163%26spage%3D1330%26epage%3D1332%26doi%3D10.1111%2Fj.1365-2133.2010.10029.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span> <span> </span><span class="NLM_article-title">Development of a highly sensitive LC–MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: application to a clinical pharmacokinetic study</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2015.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.jpba.2015.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=25890211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtFSisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2015&pages=163-168&author=C.+Sunauthor=Q.+Liauthor=L.+Panauthor=B.+Liuauthor=P.+Guauthor=J.+Zhangauthor=L.+Dingauthor=C.+Wu&title=Development+of+a+highly+sensitive+LC%E2%80%93MS%2FMS+method+for+simultaneous+determination+of+rupatadine+and+its+two+active+metabolites+in+human+plasma%3A+application+to+a+clinical+pharmacokinetic+study&doi=10.1016%2Fj.jpba.2015.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study</span></div><div class="casAuthors">Sun, Chenglong; Li, Qian; Pan, Liping; Liu, Bing; Gu, Pan; Zhang, Junying; Ding, Li; Wu, Chungyong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-168</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An easy LC-ESI-MS/MS method was developed and validated for simultaneous detn. of rupatadine (RT) and its two active metabolites, namely desloratadine (DT) and 3-hydroxydesloratadine (3-OH-DT), in human plasma.  The chromatog. sepn. was carried out on a C18 column with gradient elution by using methanol and 10 mM ammonium acetate contg. 0.1% (vol./vol.) formic acid.  The lower limit of quantification (LLOQ) was 0.05, 0.035 and 0.035 ng/mL for RT, DT and 3-OH-DT, resp.  The intra- and inter-day precision of analytes were within the range of 1.0-4.7% and 2.2-12.1%, resp.  The intra- and inter-day accuracy of analytes were within the range of -7.7% to 5.2% and -4.1% to 4.8%, resp.  The method was successfully applied to a pharmacokinetic study of RT and its two metabolite DT and 3-OH-DT in healthy volunteers following single (10, 20, 40 mg) and multiple (10 mg) oral doses of rupatadine fumarate tablets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsb0tOdskDQ7Vg90H21EOLACvtfcHk0lgFBL9PQ29Wmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtFSisrc%253D&md5=0a5816dea760df564cd2cd2dd6f8c251</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2015.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2015.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DC.%26atitle%3DDevelopment%2520of%2520a%2520highly%2520sensitive%2520LC%25E2%2580%2593MS%252FMS%2520method%2520for%2520simultaneous%2520determination%2520of%2520rupatadine%2520and%2520its%2520two%2520active%2520metabolites%2520in%2520human%2520plasma%253A%2520application%2520to%2520a%2520clinical%2520pharmacokinetic%2520study%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2015%26volume%3D111%26spage%3D163%26epage%3D168%26doi%3D10.1016%2Fj.jpba.2015.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izquierdo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonijoan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peña, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbó, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbanoj, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1650</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2008.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.clinthera.2008.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=18840369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWqs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=1639-1650&author=A.+Solansauthor=I.+Izquierdoauthor=E.+Donadoauthor=R.+Antonijoanauthor=J.+Pe%C3%B1aauthor=T.+Nadalauthor=M.-L.+Carb%C3%B3author=M.+Merlosauthor=M.+Barbanoj&title=Pharmacokinetic+and+safety+profile+of+rupatadine+when+coadministered+with+azithromycin+at+steady-state+levels%3A+a+randomized%2C+open-label%2C+two-way%2C+crossover%2C+Phase+I+study&doi=10.1016%2Fj.clinthera.2008.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, phase I study</span></div><div class="casAuthors">Solans, Anna; Izquierdo, Inaki; Donado, Esther; Antonijoan, Rosa; Pena, Juana; Nadal, Teresa; Carbo, Marcel-li; Merlos, Manuel; Barbanoj, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1639-1650</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">Background: Rupatadine is an oral active antihistamine and platelet-activating factor antagonist indicated for the management of allergic rhinitis and chronic urticaria in Europe.  Objective: The purpose of this study was to describe the effect of the concomitant administration of azithromycin and rupatadine on the pharmacokinetics of rupatadine and its metabolites after repeated doses.  Methods: This was a multiple-dose, randomized, open-label, 2-way, crossover, Phase I study in which healthy male and female volunteers received rupatadine 10 mg once a day for 6 days either alone or with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6.  Treatments were administered after a fasting period of 10 h with 240 mL of water, and fasting conditions were kept until 3 h postmedication.  A washout period of at least 21 days between the 2 active periods was obsd.  Blood samples were collected and plasma concns. of rupatadine and its metabolites desloratadine and 3-hydroxydesloratadine were detd. by liq. chromatog. tandem mass spectrometry.  Tolerability was based on the recording of adverse events (AEs), phys. examn., electrocardiograms, and lab. screen controls at baseline and the final study visit.  Results: Twenty-four healthy volunteers (15 males, 9 females; mean [SD] age, 25.67 [5.58] years; wt., 65.96 [8.57] kg) completed the study.  Except for max. obsd. concn. during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on av., there were no statistically significant differences in mean plasma concns. in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone.  The Cmax,ss ratio was 111 (90% CI, 91-136) and area under the plasma concn.-time curve during a dosing interval (AUC0-*au) ratio had a value of 103 (90% CI, 91-117).  The corresponding ratios for the rupatadine metabolites were 109 (90% CI, 100-120) for Cmax,ss and 103 (90% CI, 96-110) for AUC0-*au for desloratadine and 109 (90% CI, 103-115) for Cmax,ss and 104 (90% CI, 100-108) for AUC0-*au for 3-hydroxydesloratadine.  Point ests. for Cmax,ss ratios using paired data were 111% for rupatadine, 109% for desloratadine, and 109% for 3-hydroxydesloratadine.  The 90% CIs were included in the interval 80% to 125% for desloratadine and 3-hydroxydesloratadine, whereas 90% CI for rupatadine was shifted to the right of the interval used for comparing bioavailability of the drugs.  A total of 5 subjects reported 9 AEs; 5 of these were thought to be related to the drug administration and all were categorized as mild or moderate.  The reported AEs were somnolence (1/24 in the rupatadine group and 1/24 in the rupatadine plus azithromycin group), diarrhea (1/24 in the rupatadine plus azithromycin group), and gastric discomfort (2/24 in the rupatadine plus azithromycin group).  Four AEs were considered not to be related (2 episodes of headache, 1 anemia, 1 cheilitis).  All were resolved spontaneously.  No serious AEs were reported.  Conclusions: The results of this study in these healthy volunteers found no significant differences in pharmacokinetic parameters other than Cmax,ss of 3-hydroxydesloratadine between rupatadine 10 mg administered alone or with azithromycin 500 mg on day 2 and 250 mg from day 3 to day 6.  The administration of rupatadine compared with rupatadine plus azithromycin met the regulatory definition of bioequivalence in terms of exposure and rate parameters; however, Cmax,ss of rupatadine was outside the conventional confidence interval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppr5FtFXMpCrVg90H21EOLACvtfcHk0lgTInMxwnwDsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWqs7zP&md5=f20f2743d03a0c72a03755c811ce1dab</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2008.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2008.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DSolans%26aufirst%3DA.%26aulast%3DIzquierdo%26aufirst%3DI.%26aulast%3DDonado%26aufirst%3DE.%26aulast%3DAntonijoan%26aufirst%3DR.%26aulast%3DPe%25C3%25B1a%26aufirst%3DJ.%26aulast%3DNadal%26aufirst%3DT.%26aulast%3DCarb%25C3%25B3%26aufirst%3DM.-L.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBarbanoj%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520and%2520safety%2520profile%2520of%2520rupatadine%2520when%2520coadministered%2520with%2520azithromycin%2520at%2520steady-state%2520levels%253A%2520a%2520randomized%252C%2520open-label%252C%2520two-way%252C%2520crossover%252C%2520Phase%2520I%2520study%26jtitle%3DClin.%2520Ther.%26date%3D2008%26volume%3D30%26spage%3D1639%26epage%3D1650%26doi%3D10.1016%2Fj.clinthera.2008.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anthes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrest, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. E.</span></span> <span> </span><span class="NLM_article-title">Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>449</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(02)02049-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2FS0014-2999%2802%2902049-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=12167464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVWltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2002&pages=229-237&author=J.+C.+Anthesauthor=H.+Gilchrestauthor=C.+Richardauthor=S.+Eckelauthor=D.+Heskauthor=R.+E.+Westauthor=S.+M.+Williamsauthor=S.+Greenfederauthor=M.+Billahauthor=W.+Kreutnerauthor=R.+E.+Egan&title=Biochemical+characterization+of+desloratadine%2C+a+potent+antagonist+of+the+human+histamine+H1+receptor&doi=10.1016%2FS0014-2999%2802%2902049-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor</span></div><div class="casAuthors">Anthes, John C.; Gilchrest, Helen; Richard, Christian; Eckel, Stephen; Hesk, Dave; West, Robert E.; Williams, Shirley M.; Greenfeder, Scott; Billah, Motasim; Kreutner, William; Egan, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">449</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-237</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">We have characterized desloratadine (5H-benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene), CAS 100643-71-8) as a potent antagonist of the human histamine H1 receptor.  [3H]Desloratadine bound to membranes expressing the recombinant human histamine H1 receptor in Chinese hamster ovary cells (CHO-H1) in a specific and saturable manner with a Kd of 1.1±0.2 nM, a Bmax of 7.9±2.0 pmol/mg protein, and an assocn. rate const. of 0.011 nM-1 min-1.  The Kd calcd. from the kinetic measurements was 1.5 nM.  Dissocn. of [3H]desloratadine from the human histamine H1 receptor was slow, with only 37% of the binding reversed at 6 h in the presence of 5 μM unlabeled desloratadine.  Seventeen histamine H1-receptor antagonists were evaluated in competition-binding studies.  Desloratadine had a Ki of 0.9±0.1 nM in these competition studies.  In CHO-H1 cells, histamine stimulation resulted in a concn.-dependent increase in [Ca2+]i with an EC50 of 170±30 nM.  After a 90-min preincubation with desloratadine, the histamine-stimulated increase in [Ca2+]i was shifted to the right, with a depression of the maximal response at higher concns. of antagonist.  The apparent Kb value was 0.2±0.14 nM with a slope of 1.6±0.1.  The slow dissocn. from the receptor and noncompetitive antagonism suggests that desloratadine may be a pseudoirreversible antagonist of the human histamine H1 receptor.  The mechanism of desloratadine antagonism of the human histamine H1 receptor may help to explain the high potency and 24-h duration of action obsd. in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6H8IJZE7hrbVg90H21EOLACvtfcHk0lgTInMxwnwDsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVWltbo%253D&md5=cd55fee981b04e2ec5ee45c339f4a37c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2902049-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252902049-6%26sid%3Dliteratum%253Aachs%26aulast%3DAnthes%26aufirst%3DJ.%2BC.%26aulast%3DGilchrest%26aufirst%3DH.%26aulast%3DRichard%26aufirst%3DC.%26aulast%3DEckel%26aufirst%3DS.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DWest%26aufirst%3DR.%2BE.%26aulast%3DWilliams%26aufirst%3DS.%2BM.%26aulast%3DGreenfeder%26aufirst%3DS.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DKreutner%26aufirst%3DW.%26aulast%3DEgan%26aufirst%3DR.%2BE.%26atitle%3DBiochemical%2520characterization%2520of%2520desloratadine%252C%2520a%2520potent%2520antagonist%2520of%2520the%2520human%2520histamine%2520H1%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D449%26spage%3D229%26epage%3D237%26doi%3D10.1016%2FS0014-2999%2802%2902049-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, P.</span></span> <span> </span><span class="NLM_article-title">Changes in pH differently affect the binding properties of histamine H1 receptor antagonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>530</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2005.11.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.ejphar.2005.11.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16388798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvVCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=530&publication_year=2006&pages=205-214&author=M.+Gillardauthor=P.+Chatelain&title=Changes+in+pH+differently+affect+the+binding+properties+of+histamine+H1+receptor+antagonists&doi=10.1016%2Fj.ejphar.2005.11.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in pH differently affect the binding properties of histamine H1 receptor antagonists</span></div><div class="casAuthors">Gillard, Michel; Chatelain, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">530</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors investigated the effect of acidic pH, a condition that can be encountered during inflammation accompanying allergic reaction, on the binding properties of histamine H1 receptor antagonists, including levocetirizine ((2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; Xyzal), fexofenadine (rac-2-[4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl) piperidin-1-yl]butyl]phenyl]-2-methylpropionic acid hydrochloride; Allegra) and desloratadine (8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; Clarinex).  Lowering the pH from 7.4 to 5.8 decreased the affinity of [3H]mepyramine for histamine H1 receptors from 1.7 to 7.5 nM while the opposite was obsd. with [3H]levocetirizine, whose affinity increased from 4.1 to 1.5 nM.  Competition curves with [3H]mepyramine indicated that decreasing the pH from 7.4 to 5.8 led to a 2- to 5-fold increase in the affinity of fexofenadine and levocetirizine, no change in affinity for desloratadine and a 5- to 10-fold decrease in affinity for mepyramine and histamine.  Kinetic expts. showed that the increase in affinity of levocetirizine and, to a lesser extent, fexofenadine were totally attributable to a lower dissocn. rate at acidic pH (t1/2 increasing from 77 to 266 min and from 71 to 135 min, resp.).  Although the affinity of desloratadine remained unchanged, lowering the pH caused a decrease in its dissocn. rate (t1/2 of 50 and 256 min at pH 7.5 and 5.8, resp.) accompanied by a concomitant 3.5-fold decrease in its assocn. rate const.  The loss of affinity of mepyramine at acidic pH was driven by a decrease in its assocn. rate const.  Interaction between the carboxylic moiety of levocetirizine and Lys191 is responsible for its slow dissocn. rate from the receptor.  The authors found that the magnitude of the pH effect on the dissocn. rate of levocetirizine was maintained after mutating Lys191 into alanine, suggesting that a tighter interaction of levocetirizine with Lys191 at lower pH is not the cause of its even slower dissocn. rate from the receptor.  Although these changes may seem limited in amplitude, the authors show that they may have substantial effects on receptor occupancy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FEmST1QTYbVg90H21EOLACvtfcHk0ljxBCAzLXYmCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvVCnsA%253D%253D&md5=314247a18386e3a7dc851b50c5e1044e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.11.051%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DChatelain%26aufirst%3DP.%26atitle%3DChanges%2520in%2520pH%2520differently%2520affect%2520the%2520binding%2520properties%2520of%2520histamine%2520H1%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D530%26spage%3D205%26epage%3D214%26doi%3D10.1016%2Fj.ejphar.2005.11.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span> <span> </span><span class="NLM_article-title">BRET-based β-arrestin2 recruitment to the histamine H1 receptor for investigating antihistamine binding kinetics</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.phrs.2016.07.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=27468652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=679-687&author=R.+Bosmaauthor=R.+Moritaniauthor=R.+Leursauthor=H.+F.+Vischer&title=BRET-based+%CE%B2-arrestin2+recruitment+to+the+histamine+H1+receptor+for+investigating+antihistamine+binding+kinetics&doi=10.1016%2Fj.phrs.2016.07.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">BRET-based β-arrestin 2 recruitment to the histamine H1 receptor for investigating antihistamine binding kinetics</span></div><div class="casAuthors">Bosma, Reggie; Moritani, Ryo; Leurs, Rob; Vischer, Henry F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">679-687</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ligand residence time is thought to be a crit. parameter for optimizing the in vivo efficacy of drug candidates.  For the histamine H1 receptor (H1R) and other G protein-coupled receptors, the kinetics of ligand binding are typically measured by low throughput radioligand binding expts. using homogenized cell membranes expressing the target receptor.  In this study, a real-time proximity assay between H1R and β-arrestin 2 in living cells was established to investigate the dynamics of antihistamine binding to the H1R.  No receptor reserve was found for the histamine-induced recruitment of β-arrestin 2 to the H1R and the transiently recruited β-arrestin 2 therefore reflected occupancy of the receptor by histamine.  Antihistamines displayed similar kinetic signatures on antagonizing histamine-induced β-arrestin 2 recruitment as compared to displacing radioligand binding from the H1R.  This homogeneous functional method unambiguously detd. the fifty-fold difference in the dissocn. rate const. between mepyramine and the long residence time antihistamines levocetirizine and desloratadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXXu1vQbacy7Vg90H21EOLACvtfcHk0ljxBCAzLXYmCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr%252FN&md5=e18f2dc0c4a3bd9712976c1768a7139e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DMoritani%26aufirst%3DR.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26atitle%3DBRET-based%2520%25CE%25B2-arrestin2%2520recruitment%2520to%2520the%2520histamine%2520H1%2520receptor%2520for%2520investigating%2520antihistamine%2520binding%2520kinetics%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.phrs.2016.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strolin Benedetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baltes, E.</span></span> <span> </span><span class="NLM_article-title">Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1007/s00011-005-1368-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2Fs00011-005-1368-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16273334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFOntL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=367-369&author=M.+Gillardauthor=M.+Strolin+Benedettiauthor=P.+Chatelainauthor=E.+Baltes&title=Histamine+H1+receptor+occupancy+and+pharmacodynamics+of+second+generation+H1-antihistamines&doi=10.1007%2Fs00011-005-1368-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines</span></div><div class="casAuthors">Gillard, M.; Benedetti, M. Strolin; Chatelain, P.; Baltes, E.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">367-369</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">The predictive efficacy of drugs in humans is frequently estd. from both a high affinity for their receptor as measured in vitro and a long plasmatic half-life.  This is grossly misleading since one key parameter is missing: drug concn. at the receptor site in vivo.  As a case study we compared the efficacies of three H1 antihistamines in inhibiting histamine-induced wheal and flare in humans at two different time points with the above mentioned parameters.  It is concluded that estg. in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concn., is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHk5Wn7LujrVg90H21EOLACvtfcHk0ljxBCAzLXYmCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFOntL3K&md5=7364f734d156d1d6aea8585814c9770a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00011-005-1368-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-005-1368-3%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DStrolin%2BBenedetti%26aufirst%3DM.%26aulast%3DChatelain%26aufirst%3DP.%26aulast%3DBaltes%26aufirst%3DE.%26atitle%3DHistamine%2520H1%2520receptor%2520occupancy%2520and%2520pharmacodynamics%2520of%2520second%2520generation%2520H1-antihistamines%26jtitle%3DInflammation%2520Res.%26date%3D2005%26volume%3D54%26spage%3D367%26epage%3D369%26doi%3D10.1007%2Fs00011-005-1368-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carceller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balsa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartroli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Rafanell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forn, J.</span></span> <span> </span><span class="NLM_article-title">(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2697</span>– <span class="NLM_lpage">2703</span>, <span class="refDoi"> DOI: 10.1021/jm00043a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00043a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1Cmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2697-2703&author=E.+Carcellerauthor=M.+Merlosauthor=M.+Giralauthor=D.+Balsaauthor=C.+Almansaauthor=J.+Bartroliauthor=J.+Garcia-Rafanellauthor=J.+Forn&title=%283-Pyridylalkyl%29piperidylidene%5Dbenzocycloheptapyridine+Derivatives+as+Dual+Antagonists+of+PAF+and+Histamine&doi=10.1021%2Fjm00043a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine</span></div><div class="casAuthors">Carceller, Elena; Merlos, Manuel; Giral, Marta; Balsa, Dolors; Almansa, Carmen; Bartroli, Javier; Garcia-Rafanell, Julian; Forn, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2697-703</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of [(3-pyridylalkyl)piperidylidene]- and (nicotinoylpiperidylidene)benzocycloheptapyridine derivs. were prepd. and evaluated for PAF antagonist and H1 antihistamine activity.  PAF antagonist activity was investigated by the in vitro PAF-induced platelet aggregation assay (PPA) and the in vivo PAF-induced hypotension test in rats (PH) and mortality test in mice (PM).  For the evaluation of H1 antihistamine activity, the in vitro histamine-induced contraction of the guinea-pig ileum assay (HC) and the in vivo histamine-induced hypotension test (HH) in normotensive rats were used.  The potential antiallergic activity of the compds. was evaluated using the active anaphylactic shock test in mice.  These compds. are structurally related to loratadine (1) and were generated by replacement of the ethoxycarbonyl group of 1 with substituted 3-pyridylmethyl and nicotinoyl moieties.  Both anti-PAF and H1 antihistamine activities have shown a high dependence on the exact nature and position of the substituent in the pyridine ring.  The optimum structure, incorporating a (5-methyl-3-pyridyl)methyl radical, displayed an unique dual activity inhibiting both PAF-induced effects (PPA, IC50 = 3.7 μM; PH, ID50 = 0.44 mg/kg i.v.; PM, ID50 = 1.9 mg/kg po) and histamine-induced effects (HC, IC50 = 3.9 nM; HH, ID50 = 1.4 mg/kg i.v.).  Furthermore, this compd. was highly active in the passive cutaneous anaphylactic shock in rats (ID50 = 1.2 mg/kg po) and strongly protected mice and rats from mortality induced by endotoxin (ID50 = 1.2 and 0.5 mg/kg i.v., resp.).  It showed itself to be devoid of CNS depressant effects, neither modifying spontaneous motor activity nor prolonging barbiturate-sleeping time in mice at a dose of 100 mg/kg po, and is now under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1hihmTS3DPrVg90H21EOLACvtfcHk0ljxBCAzLXYmCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1Cmu7k%253D&md5=294559c3d02dfab86deb09a8b9d52243</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm00043a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00043a009%26sid%3Dliteratum%253Aachs%26aulast%3DCarceller%26aufirst%3DE.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGiral%26aufirst%3DM.%26aulast%3DBalsa%26aufirst%3DD.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DBartroli%26aufirst%3DJ.%26aulast%3DGarcia-Rafanell%26aufirst%3DJ.%26aulast%3DForn%26aufirst%3DJ.%26atitle%3D%25283-Pyridylalkyl%2529piperidylidene%255Dbenzocycloheptapyridine%2520Derivatives%2520as%2520Dual%2520Antagonists%2520of%2520PAF%2520and%2520Histamine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2697%26epage%3D2703%26doi%3D10.1021%2Fjm00043a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dorp, E. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhoven, J. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brussee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1177/1087057112464776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1177%2F1087057112464776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23093571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Ogtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=309-320&author=D.+Guoauthor=E.+J.+H.+van+Dorpauthor=T.+Mulder-Kriegerauthor=J.+P.+D.+van+Veldhovenauthor=J.+Brusseeauthor=A.+P.+Ijzermanauthor=L.+H.+Heitman&title=Dual-point+competition+association+assay%3A+a+fast+and+high-throughput+kinetic+screening+method+for+assessing+ligand-receptor+binding+kinetics&doi=10.1177%2F1087057112464776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics</span></div><div class="casAuthors">Guo, Dong; van Dorp, Erika J. H.; Mulder-Krieger, Thea; van Veldhoven, Jacobus P. D.; Brussee, Johannes; Ijzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-320, 12</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The concept of ligand-receptor binding kinetics is emerging as an important parameter in the early phase of drug discovery.  Since the currently used kinetic assays are laborious and low throughput, we developed a method that enables fast and large format screening.  It is a so-called dual-point competition assocn. assay, which measures radioligand binding at two different time points in the absence or presence of unlabeled competitors.  Specifically, this assay yields the kinetic rate index (KRI), which is a measure for the binding kinetics of the unlabeled ligands screened.  As a prototypical drug target, the adenosine A1 receptor (A1R) was chosen for assay validation and optimization.  A screen with 35 high-affinity A1R antagonists yielded seven compds. with a KRI value above 1.0, which indicated a relatively slow dissocn. from the target.  All other compds. had a KRI value below or equal to 1.0, predicting a relatively fast dissocn. rate.  Several compds. were selected for follow-up kinetic quantifications in classical kinetic assays and were shown to have kinetic rates that corresponded to their KRI values.  The dual-point assay and KRI value may have general applicability at other G-proteincoupled receptors, as well as at drug targets from other protein families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQTc5G9SVmrVg90H21EOLACvtfcHk0litgF9tn5NN-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Ogtb%252FK&md5=8b43f2fbfdaf41ce30181acb06c12404</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F1087057112464776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057112464776%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3Dvan%2BDorp%26aufirst%3DE.%2BJ.%2BH.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3Dvan%2BVeldhoven%26aufirst%3DJ.%2BP.%2BD.%26aulast%3DBrussee%26aufirst%3DJ.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DDual-point%2520competition%2520association%2520assay%253A%2520a%2520fast%2520and%2520high-throughput%2520kinetic%2520screening%2520method%2520for%2520assessing%2520ligand-receptor%2520binding%2520kinetics%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2013%26volume%3D18%26spage%3D309%26epage%3D320%26doi%3D10.1177%2F1087057112464776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motulsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, L.</span></span> <span> </span><span class="NLM_article-title">The kinetics of competitive radioligand binding predicted by the law of mass action</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=6708928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=1-9&author=H.+Motulskyauthor=L.+Mahan&title=The+kinetics+of+competitive+radioligand+binding+predicted+by+the+law+of+mass+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of competitive radioligand binding predicted by the law of mass action</span></div><div class="casAuthors">Motulsky H J; Mahan L C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored.  The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time.  This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions.  Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments.  Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached.  Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time.  The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above.  When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI.  At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved.  When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCXDwvoK7MbN1QT_1O5WBYfW6udTcc2eZi8T_NWHPd7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D&md5=f0c09a16d7f8947fe0d72c256e2e4914</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotulsky%26aufirst%3DH.%26aulast%3DMahan%26aufirst%3DL.%26atitle%3DThe%2520kinetics%2520of%2520competitive%2520radioligand%2520binding%2520predicted%2520by%2520the%2520law%2520of%2520mass%2520action%26jtitle%3DMol.%2520Pharmacol.%26date%3D1984%26volume%3D25%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouzo-Lorenzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inkoom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briddon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Montalván, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7906</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-44025-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fs41598-019-44025-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=31133718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gt1Cksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7906&issue=1&author=R.+Bosmaauthor=L.+A.+Stoddartauthor=V.+Georgiauthor=M.+Bouzo-Lorenzoauthor=N.+Bushbyauthor=L.+Inkoomauthor=M.+J.+Waringauthor=S.+J.+Briddonauthor=H.+F.+Vischerauthor=R.+J.+Sheppardauthor=A.+Fern%C3%A1ndez-Montalv%C3%A1nauthor=S.+J.+Hillauthor=R.+Leurs&title=Probe+dependency+in+the+determination+of+ligand+binding+kinetics+at+a+prototypical+G+protein-coupled+receptor&doi=10.1038%2Fs41598-019-44025-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor</span></div><div class="casAuthors">Bosma Reggie; Inkoom Loretta; Vischer Henry F; Leurs Rob; Stoddart Leigh A; Bouzo-Lorenzo Monica; Briddon Stephen J; Hill Stephen J; Stoddart Leigh A; Bouzo-Lorenzo Monica; Briddon Stephen J; Hill Stephen J; Georgi Victoria; Fernandez-Montalvan Amaury; Bushby Nick; Waring Michael J; Waring Michael J; Sheppard Robert J; Fernandez-Montalvan Amaury</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7906</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug-target binding kinetics are suggested to be important parameters for the prediction of in vivo drug-efficacy.  For G protein-coupled receptors (GPCRs), the binding kinetics of ligands are typically determined using association binding experiments in competition with radiolabelled probes, followed by analysis with the widely used competitive binding kinetics theory developed by Motulsky and Mahan.  Despite this, the influence of the radioligand binding kinetics on the kinetic parameters derived for the ligands tested is often overlooked.  To address this, binding rate constants for a series of histamine H1 receptor (H1R) antagonists were determined using radioligands with either slow (low koff) or fast (high koff) dissociation characteristics.  A correlation was observed between the probe-specific datasets for the kinetic binding affinities, association rate constants and dissociation rate constants.  However, the magnitude and accuracy of the binding rate constant-values was highly dependent on the used radioligand probe.  Further analysis using recently developed fluorescent binding methods corroborates the finding that the Motulsky-Mahan methodology is limited by the employed assay conditions.  The presented data suggest that kinetic parameters of GPCR ligands depend largely on the characteristics of the probe used and results should therefore be viewed within the experimental context and limitations of the applied methodology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTifAO8Ecm0p0wlCcfExbvbfW6udTcc2eZi8T_NWHPd7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gt1Cksg%253D%253D&md5=718e9db4fe44af49f445fde232139bf8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44025-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44025-5%26sid%3Dliteratum%253Aachs%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DGeorgi%26aufirst%3DV.%26aulast%3DBouzo-Lorenzo%26aufirst%3DM.%26aulast%3DBushby%26aufirst%3DN.%26aulast%3DInkoom%26aufirst%3DL.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DBriddon%26aufirst%3DS.%2BJ.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DSheppard%26aufirst%3DR.%2BJ.%26aulast%3DFern%25C3%25A1ndez-Montalv%25C3%25A1n%26aufirst%3DA.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DProbe%2520dependency%2520in%2520the%2520determination%2520of%2520ligand%2520binding%2520kinetics%2520at%2520a%2520prototypical%2520G%2520protein-coupled%2520receptor%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D7906%26doi%3D10.1038%2Fs41598-019-44025-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreutner, W.</span></span> <span> </span><span class="NLM_article-title">Dual antagonists of platelet-activating factor and histamine: identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1021/jm00105a069</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00105a069" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1Ghtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=457-461&author=J.+J.+Piwinskiauthor=J.+K.+Wongauthor=M.+J.+Greenauthor=A.+K.+Gangulyauthor=M.+M.+Billahauthor=R.+E.+Westauthor=W.+Kreutner&title=Dual+antagonists+of+platelet-activating+factor+and+histamine%3A+identification+of+structural+requirements+for+dual+activity+of+N-acyl-4-%285%2C6-dihydro-11H-benzo%5B5%2C6%5Dcyclohepta%5B1%2C2-b%5Dpyridin-11-ylidene%29piperidines&doi=10.1021%2Fjm00105a069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual antagonists of platelet-activating factor and histamine.  Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines</span></div><div class="casAuthors">Piwinski, John J.; Wong, Jesse K.; Green, Michael J.; Ganguly, Ashit K.; Billah, M. Motasim; West, Robert E., Jr.; Kreutner, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">457-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title compds. I (R = H, Me, OMe, OH, Br, Cl, F; R1 = H, Cl, F; R2 = H, Me, Et, Pr, CMe3, OEt, Ph) were prepd. from the N-Me derivs. by demethylation-acylation.  I are dual antagonists of platelet activating factor (PAF) and histamine.  A no. of structural features are identified which are necessary for PAF antagonist activity.  Acylation of the piperidine N is required for appreciable activity with small acyl groups being optimal.  Less conformationally constrained analogs and those lacking either N atom exhibit little or no anti-PAF activity.  The H1-antihistamine activity can be adjusted utilizing substitution in the benzo ring.  I (R = Cl, R1 = H, R2 = Me) was selected for clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0fYNFCTXNV7Vg90H21EOLACvtfcHk0ljrh3dghu6Z-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1Ghtw%253D%253D&md5=84020e411a1008bc9ab1f9052b27d038</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm00105a069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00105a069%26sid%3Dliteratum%253Aachs%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DWong%26aufirst%3DJ.%2BK.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DGanguly%26aufirst%3DA.%2BK.%26aulast%3DBillah%26aufirst%3DM.%2BM.%26aulast%3DWest%26aufirst%3DR.%2BE.%26aulast%3DKreutner%26aufirst%3DW.%26atitle%3DDual%2520antagonists%2520of%2520platelet-activating%2520factor%2520and%2520histamine%253A%2520identification%2520of%2520structural%2520requirements%2520for%2520dual%2520activity%2520of%2520N-acyl-4-%25285%252C6-dihydro-11H-benzo%255B5%252C6%255Dcyclohepta%255B1%252C2-b%255Dpyridin-11-ylidene%2529piperidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D457%26epage%3D461%26doi%3D10.1021%2Fjm00105a069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume, H.</span></span> <span> </span><span class="NLM_article-title">HPLC-determination of loratadine and its active metabolite descarboethoxyloratadine in human plasma</span>. <i>Pharmazie</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=7816900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaK2cXmslWitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1994&pages=736-739&author=D.+Zhongauthor=H.+Blume&title=HPLC-determination+of+loratadine+and+its+active+metabolite+descarboethoxyloratadine+in+human+plasma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">HPLC-determination of loratadine and its active metabolite descarboethoxyloratadine in human plasma</span></div><div class="casAuthors">Zhong, D.; Blume, H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmazie</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">736-9</span>CODEN:
                <span class="NLM_cas:coden">PHARAT</span>;
        ISSN:<span class="NLM_cas:issn">0031-7144</span>.
    </div><div class="casAbstract">The quant. detn. of loratidine and its active metabolite descarboethoxyloratadine is described.  Because of the high difference in polarity between loratidine and descarboethoxyloratadine, the two analytes were detd. in two HPLC-systems sep.  As internal stds. propyl-4-(8-chloro-5,6-dihydro-11 H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridin-11-ylidin)-1-piperidinecarboxylate and 1-ethyl-4-(8-chloro-5,6-dihydro-11 H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridin-11-ylidin)-piperidine were used for loratidine and descarboethoxyloratadine, resp.  After extn. with org. solvents from 1 mL plasma, loratidine and descarboethoxyloratadine were re-extd. with dild. phosphoric acid from the org. phase.  Chromatog. sepn. on a RP-18 column and fluorescence detection allowed a sufficiently sensitive detn. of loratidine and descarboethoxyloratadine in plasma with a lower limit of quantitation of 0.5 ng/mL for both analytes.  The method was successfully applied to human plasma samples from 16 subjects after oral administration of 20 mg loratidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodu1qELsGm2rVg90H21EOLACvtfcHk0ljrh3dghu6Z-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmslWitr8%253D&md5=066f8eb34de0630222fa2884be6bf1b1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DD.%26aulast%3DBlume%26aufirst%3DH.%26atitle%3DHPLC-determination%2520of%2520loratadine%2520and%2520its%2520active%2520metabolite%2520descarboethoxyloratadine%2520in%2520human%2520plasma%26jtitle%3DPharmazie%26date%3D1994%26volume%3D49%26spage%3D736%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, M.</span>; <span class="NLM_string-name">Hasumi, K.</span>; <span class="NLM_string-name">Nishimoto, T.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Ishitani, K.</span>; <span class="NLM_string-name">Aotsuka, T.</span>; <span class="NLM_string-name">Kanazawa, H.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compound and H1 Receptor Antagonist</span>. <span class="NLM_patent">US20130085127</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Okada&author=K.+Hasumi&author=T.+Nishimoto&author=M.+Yoshida&author=K.+Ishitani&author=T.+Aotsuka&author=H.+Kanazawa&title=Heterocyclic+Compound+and+H1+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DM.%26atitle%3DHeterocyclic%2520Compound%2520and%2520H1%2520Receptor%2520Antagonist%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanoli, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramzan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, U.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and bioevaluation of tricyclic fused ring system as dual binding site acetylcholinesterase inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.bioorg.2018.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=30399465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2019&pages=336-347&author=S.+T.+Tanoliauthor=M.+Ramzanauthor=A.+Hassanauthor=A.+Sadiqauthor=M.+S.+Janauthor=F.+A.+Khanauthor=F.+Ullahauthor=H.+Ahmadauthor=M.+Bibiauthor=T.+Mahmoodauthor=U.+Rashid&title=Design%2C+synthesis+and+bioevaluation+of+tricyclic+fused+ring+system+as+dual+binding+site+acetylcholinesterase+inhibitors&doi=10.1016%2Fj.bioorg.2018.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and bioevaluation of tricyclic fused ring system as dual binding site acetylcholinesterase inhibitors</span></div><div class="casAuthors">Tanoli, Saba Tahir; Ramzan, Muhammad; Hassan, Abbas; Sadiq, Abdul; Jan, Muhammad Saeed; Khan, Farhan A.; Ullah, Farhat; Ahmad, Haseen; Bibi, Maria; Mahmood, Tariq; Rashid, Umer</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">336-347</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Due to recently discovered non-classical acetylcholinesterase (AChE) function, dual binding-site AChE inhibitors have acquired a paramount attention of drug designing researchers.  The unique structural arrangements of AChE peripheral anionic site (PAS) and catalytic site (CAS) joined by a narrow gorge, prompted us to design the inhibitors that can interact with dual binding sites of AChE.  Eighteen homo- and heterodimers of desloratadine and carbazole (already available tricyclic building blocks) were synthesized and tested for their inhibition potential against elec. eel acetylcholinesterase (eeAChE) and equine serum butyrylcholinesterase (eqBChE).  We identified a six-carbon tether heterodimer of desloratadine and indanedione based tricyclic dihydropyrimidine (4c) as potent and selective inhibitor of eeAChE with IC50 value of 0.09 ± 0.003 μM and 1.04 ± 0.08 μM (for eqBChE) with selectivity index of 11.1.  Binding pose anal. of potent inhibitors suggest that tricyclic ring is well accommodated into the AChE active site through hydrophobic interactions with Trp84 and Trp279.  The indanone ring of most active heterodimer 4b is stabilized into the bottom of the gorge and forms hydrogen bonding interactions with the important catalytic triad residue Ser200. bis-desloratadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ei_NOFNjZLVg90H21EOLACvtfcHk0ljKvNmqP1sv2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qt7bP&md5=73eb9e4b923302d4aa1cbd4f58a82c78</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DTanoli%26aufirst%3DS.%2BT.%26aulast%3DRamzan%26aufirst%3DM.%26aulast%3DHassan%26aufirst%3DA.%26aulast%3DSadiq%26aufirst%3DA.%26aulast%3DJan%26aufirst%3DM.%2BS.%26aulast%3DKhan%26aufirst%3DF.%2BA.%26aulast%3DUllah%26aufirst%3DF.%26aulast%3DAhmad%26aufirst%3DH.%26aulast%3DBibi%26aufirst%3DM.%26aulast%3DMahmood%26aufirst%3DT.%26aulast%3DRashid%26aufirst%3DU.%26atitle%3DDesign%252C%2520synthesis%2520and%2520bioevaluation%2520of%2520tricyclic%2520fused%2520ring%2520system%2520as%2520dual%2520binding%2520site%2520acetylcholinesterase%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D83%26spage%3D336%26epage%3D347%26doi%3D10.1016%2Fj.bioorg.2018.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span>; <span class="NLM_string-name">Flohr, A.</span>; <span class="NLM_string-name">Jolidon, S.</span>; <span class="NLM_string-name">Knust, H.</span>; <span class="NLM_string-name">Luebbers, T.</span>; <span class="NLM_string-name">Nettekoven, M.</span></span> <span> </span><span class="NLM_article-title">Indol-Amide Compounds as Beta-Amyloid Inhibitors</span>. <span class="NLM_patent">WO2014060386</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=K.+Baumann&author=A.+Flohr&author=S.+Jolidon&author=H.+Knust&author=T.+Luebbers&author=M.+Nettekoven&title=Indol-Amide+Compounds+as+Beta-Amyloid+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaumann%26aufirst%3DK.%26atitle%3DIndol-Amide%2520Compounds%2520as%2520Beta-Amyloid%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M. Q.</span>; <span class="NLM_string-name">Leurs, R.</span>; <span class="NLM_string-name">Timmerman, H.</span></span> <span> </span><span class="NLM_article-title">Histamine H1-Receptor Antagonists</span>. In  <i>Burger’s Medicinal Chemistry an Drug Discovery</i>, <span class="NLM_edition">5</span>th ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, M. E.</span></span>, Ed.; <span class="NLM_publisher-name">Vrije Universiteit</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">1997</span>; Vol.  <span class="NLM_volume">5</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=M.+Q.+Zhang&author=R.+Leurs&author=H.+Timmermanauthor=M.+E.+Wolff&title=Burger%E2%80%99s+Medicinal+Chemistry+an+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%2BQ.%26atitle%3DHistamine%2520H1-Receptor%2520Antagonists%26btitle%3DBurger%25E2%2580%2599s%2520Medicinal%2520Chemistry%2520an%2520Drug%2520Discovery%26aulast%3DWolff%26aufirst%3DM.%2BE.%26pub%3DVrije%2520Universiteit%26date%3D1997%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prathipati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxena, A. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of some substituted pyrazinopyridoindoles and 3D QSAR studies along with related compounds: piperazines, piperidines, pyrazinoisoquinolines, and diphenhydramine, and its semi-rigid analogs as antihistamines (H1)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8258</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.bmc.2006.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=17010624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=8249-8258&author=M.+Saxenaauthor=S.+Gaurauthor=P.+Prathipatiauthor=A.+K.+Saxena&title=Synthesis+of+some+substituted+pyrazinopyridoindoles+and+3D+QSAR+studies+along+with+related+compounds%3A+piperazines%2C+piperidines%2C+pyrazinoisoquinolines%2C+and+diphenhydramine%2C+and+its+semi-rigid+analogs+as+antihistamines+%28H1%29&doi=10.1016%2Fj.bmc.2006.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of some substituted pyrazinopyridoindoles and 3D QSAR studies along with related compounds: Piperazines, piperidines, pyrazinoisoquinolines, and diphenhydramine, and its semi-rigid analogs as antihistamines (H1)</span></div><div class="casAuthors">Saxena, Mridula; Gaur, Stuti; Prathipati, Philip; Saxena, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8249-8258</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">3D QSAR studies on the title compds. led to the development of a model with three biophoric sites and six secondary sites viz.  H-acceptor (ACC), H-donor (DON), heteroatom (presence), hydrophobic (hydrophobicity), steric (refractivity), and a ring (presence) along with total hydrophobicity and total refractivity as global properties.  The model predicted the test set of compds. reasonably well.  Three of the five newly synthesized 2-substituted octahydropyrazinopyridoindoles have shown potent antihistaminic H1 activity with less toxicity and sedation potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowk39v6uAhWLVg90H21EOLACvtfcHk0ljKvNmqP1sv2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOjt7zI&md5=ed714e960dfa30d6be42edb200dc0e5f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DM.%26aulast%3DGaur%26aufirst%3DS.%26aulast%3DPrathipati%26aufirst%3DP.%26aulast%3DSaxena%26aufirst%3DA.%2BK.%26atitle%3DSynthesis%2520of%2520some%2520substituted%2520pyrazinopyridoindoles%2520and%25203D%2520QSAR%2520studies%2520along%2520with%2520related%2520compounds%253A%2520piperazines%252C%2520piperidines%252C%2520pyrazinoisoquinolines%252C%2520and%2520diphenhydramine%252C%2520and%2520its%2520semi-rigid%2520analogs%2520as%2520antihistamines%2520%2528H1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D8249%26epage%3D8258%26doi%3D10.1016%2Fj.bmc.2006.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriegl, J. M.</span></span> <span> </span><span class="NLM_article-title">What can we learn from molecular dynamics simulations for GPCR drug design?</span>. <i>Comput. Struct. Biotechnol. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1016/j.csbj.2014.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.csbj.2014.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=25709761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOlsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=111-121&author=C.+S.+Tautermannauthor=D.+Seeligerauthor=J.+M.+Kriegl&title=What+can+we+learn+from+molecular+dynamics+simulations+for+GPCR+drug+design%3F&doi=10.1016%2Fj.csbj.2014.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">What can we learn from molecular dynamics simulations for GPCR drug design?</span></div><div class="casAuthors">Tautermann, Christofer S.; Seeliger, Daniel; Kriegl, Jan M.</div><div class="citationInfo"><span class="NLM_cas:title">Computational and Structural Biotechnology Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-121</span>CODEN:
                <span class="NLM_cas:coden">CSBJAC</span>;
        ISSN:<span class="NLM_cas:issn">2001-0370</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recent years have seen a tremendous progress in the elucidation of exptl. structural information for G-protein coupled receptors (GPCRs).  Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homol. models the steadily increasing amt. of structural information fosters the application of structure-based drug design tools for this important class of drug targets.  In this article we focus on the application of mol. dynamics (MD) simulations in GPCR drug discovery programs.  Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small mol. antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small mols. to the human muscarinic acetylcholine receptor 3 (hM3R).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0PtAwst0DrVg90H21EOLACvtfcHk0lhParXxNi96rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOlsb7O&md5=5dff5b6ab82b720bbd083d1f41d3664b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.csbj.2014.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.csbj.2014.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DSeeliger%26aufirst%3DD.%26aulast%3DKriegl%26aufirst%3DJ.%2BM.%26atitle%3DWhat%2520can%2520we%2520learn%2520from%2520molecular%2520dynamics%2520simulations%2520for%2520GPCR%2520drug%2520design%253F%26jtitle%3DComput.%2520Struct.%2520Biotechnol.%2520J.%26date%3D2015%26volume%3D13%26spage%3D111%26epage%3D121%26doi%3D10.1016%2Fj.csbj.2014.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span> <span> </span><span class="NLM_article-title">Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">18903</span>– <span class="NLM_lpage">18910</span>, <span class="refDoi"> DOI: 10.1021/ja207494u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja207494u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=18903-18910&author=P.+Schmidtkeauthor=F.+J.+Luqueauthor=J.+B.+Murrayauthor=X.+Barril&title=Shielded+hydrogen+bonds+as+structural+determinants+of+binding+kinetics%3A+application+in+drug+design&doi=10.1021%2Fja207494u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Shielded Hydrogen Bonds as Structural Determinants of Binding Kinetics: Application in Drug Design</span></div><div class="casAuthors">Schmidtke, Peter; Luque, F. Javier; Murray, James B.; Barril, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">18903-18910</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Time scale control of mol. interactions is an essential part of biochem. systems, but very little is known about the structural factors governing the kinetics of mol. recognition.  In drug design, the lifetime of drug-target complexes is a major determinant of pharmacol. effects but the absence of structure-kinetic relationships precludes rational optimization of this property.  Almost buried polar atoms-a common feature on protein binding sites-tend to form hydrogen bonds that are shielded from water.  Formation and rupture of this type of hydrogen bonds involves an energetically penalized transition state because it occurs asynchronously with dehydration/rehydration.  In consequence, water-shielded hydrogen bonds are exchanged at slower rates.  Occurrence of this phenomenon can be anticipated from simple structural anal., affording a novel tool to interpret and predict structure-kinetics relationships.  The validity of this principle has been investigated on two pairs of Hsp90 inhibitors for which detailed thermodn. and kinetic data has been exptl. detd.  The agreement between macroscopic observables and mol. simulations confirms the role of water-shielded hydrogen bonds as kinetic traps and illustrates how the authors' finding could be used as an aid in structure-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozQcgRgDTxL7Vg90H21EOLACvtfcHk0lhParXxNi96rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7zP&md5=f2a69f635c4a8083d4b7ade4c1f01030</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fja207494u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja207494u%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidtke%26aufirst%3DP.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BB.%26aulast%3DBarril%26aufirst%3DX.%26atitle%3DShielded%2520hydrogen%2520bonds%2520as%2520structural%2520determinants%2520of%2520binding%2520kinetics%253A%2520application%2520in%2520drug%2520design%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D18903%26epage%3D18910%26doi%3D10.1021%2Fja207494u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflorian, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span> <span> </span><span class="NLM_article-title">Decoding the role of water dynamics in ligand-protein unbinding: CRF1R as a test case</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1866</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00440</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00440" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGjsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=1857-1866&author=A.+Bortolatoauthor=F.+Deflorianauthor=D.+R.+Weissauthor=J.+S.+Mason&title=Decoding+the+role+of+water+dynamics+in+ligand-protein+unbinding%3A+CRF1R+as+a+test+case&doi=10.1021%2Facs.jcim.5b00440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Decoding the Role of Water Dynamics in Ligand-Protein Unbinding: CRF1R as a Test Case</span></div><div class="casAuthors">Bortolato, Andrea; Deflorian, Francesca; Weiss, Dahlia R.; Mason, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1857-1866</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The residence time of a ligand-protein complex is a crucial aspect in detg. biol. effect in vivo.  Despite its importance, the prediction of ligand koff still remains challenging for modern computational chem.  We have developed aMetaD, a fast and generally applicable computational protocol to predict ligand-protein unbinding events using a mol. dynamics (MD) method based on adiabatic-bias MD and metadynamics.  This physics-based, fully flexible, and pose-dependent ligand scoring function evaluates the max. energy (RTscore) required to move the ligand from the bound-state energy basin to the next.  Unbinding trajectories are automatically analyzed and translated into at. solvation factor (SF) values representing the water dynamics during the unbinding event.  This novel computational protocol was initially tested on two M3 muscarinic receptor and two adenosine A2A receptor antagonists and then evaluated on a test set of 12 CRF1R ligands.  The resulting RTscores were used successfully to classify ligands with different residence times.  Addnl., the SF anal. was used to detect key differences in the degree of accessibility to water mols. during the predicted ligand unbinding events.  The protocol provides actionable working hypotheses that are applicable in a drug discovery program for the rational optimization of ligand binding kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrga4-8KCm2obVg90H21EOLACvtfcHk0ljmv8WBD9B2ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGjsLnO&md5=91e3e7e373526591640a239dbdf33f29</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00440%26sid%3Dliteratum%253Aachs%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DDeflorian%26aufirst%3DF.%26aulast%3DWeiss%26aufirst%3DD.%2BR.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26atitle%3DDecoding%2520the%2520role%2520of%2520water%2520dynamics%2520in%2520ligand-protein%2520unbinding%253A%2520CRF1R%2520as%2520a%2520test%2520case%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D1857%26epage%3D1866%26doi%3D10.1021%2Facs.jcim.5b00440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span> <span> </span><span class="NLM_article-title">A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1111/bph.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fbph.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23713847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=101-126&author=A.+J.+Kooistraauthor=S.+Kuhneauthor=I.+J.+P.+de+Eschauthor=R.+Leursauthor=C.+de+Graaf&title=A+structural+chemogenomics+analysis+of+aminergic+GPCRs%3A+lessons+for+histamine+receptor+ligand+design&doi=10.1111%2Fbph.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design</span></div><div class="casAuthors">Kooistra, A. J.; Kuhne, S.; de Esch, I. J. P.; Leurs, R.; de Graaf, C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-126</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Chemogenomics focuses on the discovery of new connections between chem. and biol. space leading to the discovery of new protein targets and biol. active mols.  G-protein coupled receptors (GPCRs) are a particularly interesting protein family for chemogenomics studies because there is an overwhelming amt. of ligand binding affinity data available.  The increasing no. of aminergic GPCR crystal structures now for the first time allows the integration of chemogenomics studies with high-resoln. structural analyses of GPCR-ligand complexes.  Exptl. Approach In this study, we have combined ligand affinity data, receptor mutagenesis studies, and amino acid sequence analyses to high-resoln. structural analyses of (hist)aminergic GPCR-ligand interactions.  This integrated structural chemogenomics anal. is used to more accurately describe the mol. and structural determinants of ligand affinity and selectivity in different key binding regions of the crystd. aminergic GPCRs, and histamine receptors in particular.  Key Results Our investigations highlight interesting correlations and differences between ligand similarity and ligand binding site similarity of different aminergic receptors.  Apparent discrepancies can be explained by combining detailed anal. of crystd. or predicted protein-ligand binding modes, receptor mutation studies, and ligand structure-selectivity relationships that identify local differences in essential pharmacophore features in the ligand binding sites of different receptors.  Conclusions and Implications We have performed structural chemogenomics studies that identify links between (hist)aminergic receptor ligands and their binding sites and binding modes.  This knowledge can be used to identify structure-selectivity relationships that increase our understanding of ligand binding to (hist)aminergic receptors and hence can be used in future GPCR ligand discovery and design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxr6kq48O11rVg90H21EOLACvtfcHk0ljmv8WBD9B2ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtbnE&md5=08ae55b9565885165e76d98e2db1befa</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fbph.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12248%26sid%3Dliteratum%253Aachs%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DKuhne%26aufirst%3DS.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26atitle%3DA%2520structural%2520chemogenomics%2520analysis%2520of%2520aminergic%2520GPCRs%253A%2520lessons%2520for%2520histamine%2520receptor%2520ligand%2520design%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26spage%3D101%26epage%3D126%26doi%3D10.1111%2Fbph.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijtmans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Identification of ligand binding hot spots of the histamine H1 receptor following structure-based fragment optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9047</span>– <span class="NLM_lpage">9061</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00981</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00981" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFanu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9047-9061&author=S.+Kuhneauthor=A.+J.+Kooistraauthor=R.+Bosmaauthor=A.+Bortolatoauthor=M.+Wijtmansauthor=H.+F.+Vischerauthor=J.+S.+Masonauthor=C.+de+Graafauthor=I.+J.+P.+de+Eschauthor=R.+Leurs&title=Identification+of+ligand+binding+hot+spots+of+the+histamine+H1+receptor+following+structure-based+fragment+optimization&doi=10.1021%2Facs.jmedchem.6b00981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Ligand Binding Hot Spots of the Histamine H1 Receptor following Structure-Based Fragment Optimization</span></div><div class="casAuthors">Kuhne, Sebastiaan; Kooistra, Albert J.; Bosma, Reggie; Bortolato, Andrea; Wijtmans, Maikel; Vischer, Henry F.; Mason, Jonathan S.; de Graaf, Chris; de Esch, Iwan J. P.; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9047-9061</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Developments in G protein-coupled receptor (GPCR) structural biol. provide insights into GPCR-ligand binding.  Compd. I (4-(2-benzylphenoxy)piperidine) with high ligand efficiency for the histamine H1 receptor (H1R) was used to design derivs. to investigate the roles of: (1) the amine-binding region, (2) the upper and lower arom. region and (3) binding site solvation.  SAR anal. showed that the amine-binding region serves as the primary binding hot spot, preferably binding small tertiary amines.  In silico prediction of water network energetics and mutagenesis studies indicated that the displacement of a water mol. from the amine-binding region is most likely responsible for the increased affinity of the N-methylated analog of I.  Deconstruction of I showed that the lower arom. region serves as a secondary binding hot spot.  This study demonstrates that an x-ray structure in combination with tool compds., assessment of water energetics, and mutagenesis studies enables SAR exploration to map GPCR-ligand binding hot spots.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot3XWIDbthErVg90H21EOLACvtfcHk0ljmv8WBD9B2ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFanu7rK&md5=7e9bd27144fcaf11a3176bf717849bcd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00981%26sid%3Dliteratum%253Aachs%26aulast%3DKuhne%26aufirst%3DS.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DWijtmans%26aufirst%3DM.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520ligand%2520binding%2520hot%2520spots%2520of%2520the%2520histamine%2520H1%2520receptor%2520following%2520structure-based%2520fragment%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9047%26epage%3D9061%26doi%3D10.1021%2Facs.jmedchem.6b00981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mocking, T.</span>; <span class="NLM_string-name">Bosma, R.</span>; <span class="NLM_string-name">Rahman, S. N.</span>; <span class="NLM_string-name">Verweij, E. W. E.</span>; <span class="NLM_string-name">McNaught-Flores, D. A.</span>; <span class="NLM_string-name">Vischer, H. F.</span>; <span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">Molecular Aspects of Histamine Receptors</span>. In  <i>Histamine Receptors. Preclinical and Clinical Aspects.</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandina, P.</span>, <span class="NLM_string-name">Passani, M. B.</span></span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">49</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1007%2F978-3-319-40308-3_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-49&author=T.+Mocking&author=R.+Bosma&author=S.+N.+Rahman&author=E.+W.+E.+Verweij&author=D.+A.+McNaught-Flores&author=H.+F.+Vischer&author=R.+Leursauthor=P.+Blandina&author=M.+B.+Passani&title=Histamine+Receptors.+Preclinical+and+Clinical+Aspects."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-40308-3_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-40308-3_1%26sid%3Dliteratum%253Aachs%26aulast%3DMocking%26aufirst%3DT.%26atitle%3DMolecular%2520Aspects%2520of%2520Histamine%2520Receptors%26btitle%3DHistamine%2520Receptors.%2520Preclinical%2520and%2520Clinical%2520Aspects.%26aulast%3DBlandina%26aufirst%3DP.%26pub%3DHumana%2520Press%26date%3D2016%26spage%3D1%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, P.</span></span> <span> </span><span class="NLM_article-title">Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">449</span>, <span class="refDoi"> DOI: 10.1039/c2md00270a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1039%2Fc2md00270a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Orsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=449&author=D.+C.+Millerauthor=G.+Lunnauthor=P.+Jonesauthor=Y.+Sabnisauthor=N.+L.+Daviesauthor=P.+Driscoll&title=Investigation+of+the+effect+of+molecular+properties+on+the+binding+kinetics+of+a+ligand+to+its+biological+target&doi=10.1039%2Fc2md00270a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target</span></div><div class="casAuthors">Miller, Duncan C.; Lunn, Graham; Jones, Peter; Sabnis, Yogesh; Davies, Nichola L.; Driscoll, Paul</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-452</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A database of binding kinetic data across multiple targets has been created.  Anal. of this database provides insights into trends for the effects of physicochem. properties (mol. wt., clogP, rotatable bond count) on the dissocn. kinetics of ligands from their biol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrvjiZtiu9VLVg90H21EOLACvtfcHk0ljdfNVU2I2jlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Orsro%253D&md5=84c6b9d95ec6df61145fe678c78d5491</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1039%2Fc2md00270a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md00270a%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DD.%2BC.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3DDriscoll%26aufirst%3DP.%26atitle%3DInvestigation%2520of%2520the%2520effect%2520of%2520molecular%2520properties%2520on%2520the%2520binding%2520kinetics%2520of%2520a%2520ligand%2520to%2520its%2520biological%2520target%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D449%26doi%3D10.1039%2Fc2md00270a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span> <span> </span><span class="NLM_article-title">Molecular properties affecting fast dissociation from the D2 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.bmc.2011.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=21421319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=2231-2241&author=G.+Tresadernauthor=J.+M.+Bartolomeauthor=G.+J.+Macdonaldauthor=X.+Langlois&title=Molecular+properties+affecting+fast+dissociation+from+the+D2+receptor&doi=10.1016%2Fj.bmc.2011.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties affecting fast dissociation from the D2 receptor</span></div><div class="casAuthors">Tresadern, Gary; Bartolome, Jose Manuel; MacDonald, Gregor J.; Langlois, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2231-2241</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine D2 receptor antagonism is the foundation of antipsychotic treatment.  Antipsychotic agents vary in how fast they dissoc. from the D2 receptors.  It has been proposed that the liability to exhibit side effects such as extra pyramidal symptoms may be the result of a slow rate of dissocn.  Compds. with a faster rate of dissocn., while still blocking efficiently the D2 receptors, will subsequently respond better to physiol. surges in dopamine transmission.  Therefore, work in our labs. has focussed on identifying fast dissocg. and selective D2 antagonists.  Biol. screening was performed to measure the affinity and extent of dissocn. for a large dataset of over 1800 D2 antagonists.  Subsequent univariate and multivariate statistical anal. revealed the mol. properties which differentiate fast and slow dissocg. compds.  It is shown that faster dissocg. antagonists are less lipophilic and have lower mol. wt.  There was a clear and expected inverse relationship with extent of dissocn. and binding affinity with more potent compds. tending to be slower dissocg.  However, within a range of comparable affinity both fast and slow dissocg. compds. were identified.  After de-correlating affinity and dissocn. the anal. revealed the important descriptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilpQ8-EuD-LVg90H21EOLACvtfcHk0ljdfNVU2I2jlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D&md5=574e106853b1cff1b6975c4bba979031</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DBartolome%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DLanglois%26aufirst%3DX.%26atitle%3DMolecular%2520properties%2520affecting%2520fast%2520dissociation%2520from%2520the%2520D2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D2231%26epage%3D2241%26doi%3D10.1016%2Fj.bmc.2011.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaas, L. A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josimovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vischer, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span> <span> </span><span class="NLM_article-title">The target residence time of antihistamines determines their antagonism of the G protein-coupled histamine H1 receptor</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">667</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.3389%2Ffphar.2017.00667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=29033838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=667&author=R.+Bosmaauthor=G.+Wittauthor=L.+A.+I.+Vaasauthor=I.+Josimovicauthor=P.+Gribbonauthor=H.+F.+Vischerauthor=S.+Gulauthor=R.+Leurs&title=The+target+residence+time+of+antihistamines+determines+their+antagonism+of+the+G+protein-coupled+histamine+H1+receptor&doi=10.3389%2Ffphar.2017.00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The target residence time of antihistamines determines their antagonism of the G protein-coupled histamine H1 receptor</span></div><div class="casAuthors">Bosma, Reggie; Witt, Gesa; Vaas, Lea A. I.; Josimovic, Ivana; Gribbon, Philip; Vischer, Henry F.; Gul, Sheraz; Leurs, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667/1-667/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The pharmacodynamics of drug-candidates is often optimized by metrics that describe target binding (Kd or Ki value) or target modulation (IC50).  However, these metrics are detd. at equil. conditions, and consequently information regarding the onset and offset of target engagement and modulation is lost.  Drug-target residence time is a measure for the lifetime of the drug-target complex, which has recently been receiving considerable interest, as target residence time is shown to have prognostic value for the in vivo efficacy of several drugs.  In this study, we have investigated the relation between the increased residence time of antihistamines at the histamine H1 receptor (H1R) and the duration of effective target-inhibition by these antagonists.  Hela cells, endogenously expressing low levels of the H1R, were incubated with a series of antihistamines and dissocn. was initiated by washing away the unbound antihistamines.  Using a calcium-sensitive fluorescent dye and a label free, dynamic mass redistribution based assay, functional recovery of the H1R responsiveness was measured by stimulating the cells with histamine over time, and the recovery was quantified as the receptor recovery time.  Using these assays, we detd. that the receptor recovery time for a set of antihistamines differed more than 40-fold and was highly correlated to their H1R residence times, as detd. with competitive radioligand binding expts. to the H1R in a cell homogenate.  Thus, the receptor recovery time is proposed as a cell based and physiol. relevant metric for the lead optimization of G protein-coupled receptor antagonists, like the H1R antagonists.  Both, label-free or real-time, classical signaling assays allow an efficient and physiol. relevant detn. of kinetic properties of drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvQKLQXKACLVg90H21EOLACvtfcHk0lgWAFtDK7VMsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegsL3N&md5=916d9721ede4fd2a72cdf1878ec17e75</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00667%26sid%3Dliteratum%253Aachs%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DWitt%26aufirst%3DG.%26aulast%3DVaas%26aufirst%3DL.%2BA.%2BI.%26aulast%3DJosimovic%26aufirst%3DI.%26aulast%3DGribbon%26aufirst%3DP.%26aulast%3DVischer%26aufirst%3DH.%2BF.%26aulast%3DGul%26aufirst%3DS.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DThe%2520target%2520residence%2520time%2520of%2520antihistamines%2520determines%2520their%2520antagonism%2520of%2520the%2520G%2520protein-coupled%2520histamine%2520H1%2520receptor%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D667%26doi%3D10.3389%2Ffphar.2017.00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiroishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the human histamine H1 receptor complex with doxepin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature10236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fnature10236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=21697825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2011&pages=65-70&author=T.+Shimamuraauthor=M.+Shiroishiauthor=S.+Weyandauthor=H.+Tsujimotoauthor=G.+Winterauthor=V.+Katritchauthor=R.+Abagyanauthor=V.+Cherezovauthor=W.+Liuauthor=G.+W.+Hanauthor=T.+Kobayashiauthor=R.+C.+Stevensauthor=S.+Iwata&title=Structure+of+the+human+histamine+H1+receptor+complex+with+doxepin&doi=10.1038%2Fnature10236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human histamine H1 receptor complex with doxepin</span></div><div class="casAuthors">Shimamura, Tatsuro; Shiroishi, Mitsunori; Weyand, Simone; Tsujimoto, Hirokazu; Winter, Graeme; Katritch, Vsevolod; Abagyan, Ruben; Cherezov, Vadim; Liu, Wei; Han, Gye Won; Kobayashi, Takuya; Stevens, Raymond C.; Iwata, So</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">7354</span>),
    <span class="NLM_cas:pages">65-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The biogenic amine histamine is an important pharmacol. mediator involved in pathophysiol. processes such as allergies and inflammations.  Histamine H1 receptor (H1R) antagonists are very effective drugs alleviating the symptoms of allergic reactions.  Here, we show the crystal structure of the H1R complex with doxepin, a first-generation H1R antagonist.  Doxepin sits deep in the ligand-binding pocket and directly interacts with Trp 428, a highly conserved key residue in G-protein-coupled-receptor activation.  This well-conserved pocket with mostly hydrophobic nature contributes to the low selectivity of the first-generation compds.  The pocket is assocd. with an anion-binding region occupied by a phosphate ion.  Docking of various second-generation H1R antagonists reveals that the unique carboxyl group present in this class of compds. interacts with Lys 191 and/or Lys 179ECL2, both of which form part of the anion-binding region.  This region is not conserved in other aminergic receptors, demonstrating how minor differences in receptors lead to pronounced selectivity differences with small mols.  Our study sheds light on the mol. basis of H1R antagonist specificity against H1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1obci6QtYbVg90H21EOLACvtfcHk0lgWAFtDK7VMsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVekt7k%253D&md5=7116228016caa1f3afbfed11468c0154</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnature10236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10236%26sid%3Dliteratum%253Aachs%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DShiroishi%26aufirst%3DM.%26aulast%3DWeyand%26aufirst%3DS.%26aulast%3DTsujimoto%26aufirst%3DH.%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DIwata%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520human%2520histamine%2520H1%2520receptor%2520complex%2520with%2520doxepin%26jtitle%3DNature%26date%3D2011%26volume%3D475%26spage%3D65%26epage%3D70%26doi%3D10.1038%2Fnature10236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stützle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Exner, T. E.</span></span> <span> </span><span class="NLM_article-title">Empirical scoring functions for advanced Protein-Ligand docking with PLANTS</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1021/ci800298z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800298z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=84-96&author=O.+Korbauthor=T.+St%C3%BCtzleauthor=T.+E.+Exner&title=Empirical+scoring+functions+for+advanced+Protein-Ligand+docking+with+PLANTS&doi=10.1021%2Fci800298z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS</span></div><div class="casAuthors">Korb, Oliver; Stuetzle, Thomas; Exner, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-96</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper we present two empirical scoring functions, PLANTSCHEMPLP and PLANTSPLP, designed for our docking algorithm PLANTS (Protein-Ligand ANT System), which is based on ant colony optimization (ACO).  They are related, regarding their functional form, to parts of already published scoring functions and force fields.  The parametrization procedure described here was able to identify several parameter settings showing an excellent performance for the task of pose prediction on two test sets comprising 298 complexes in total.  Up to 87% of the complexes of the Astex diverse set and 77% of the CCDC/Astex clean listnc (noncovalently bound complexes of the clean list) could be reproduced with root-mean-square deviations of less than 2 Å with respect to the exptl. detd. structures.  A comparison with the state-of-the-art docking tool GOLD clearly shows that this is, esp. for the druglike Astex diverse set, an improvement in pose prediction performance.  Addnl., optimized parameter settings for the search algorithm were identified, which can be used to balance pose prediction reliability and search speed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_kyR7CGk9mbVg90H21EOLACvtfcHk0lgWAFtDK7VMsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVSquw%253D%253D&md5=fce960b75b9f8906354b7c97ff84c092</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fci800298z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800298z%26sid%3Dliteratum%253Aachs%26aulast%3DKorb%26aufirst%3DO.%26aulast%3DSt%25C3%25BCtzle%26aufirst%3DT.%26aulast%3DExner%26aufirst%3DT.%2BE.%26atitle%3DEmpirical%2520scoring%2520functions%2520for%2520advanced%2520Protein-Ligand%2520docking%2520with%2520PLANTS%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D84%26epage%3D96%26doi%3D10.1021%2Fci800298z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Church, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, D. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of antihistamines</span>. <i>Indian J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.4103/0019-5154.110832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.4103%2F0019-5154.110832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23723474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=219-224&author=M.+K.+Churchauthor=D.+S.+Church&title=Pharmacology+of+antihistamines&doi=10.4103%2F0019-5154.110832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of antihistamines</span></div><div class="casAuthors">Church Martin K; Church Diana S</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of dermatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">H1-antihistamines, the mainstay of treatment for urticaria, were developed from anticholinergic drugs more than 70 years ago.  They act as inverse agonists rather than antagonists of histamine H1-receptors which are members of the G-protein family.  The older first generation H1-antihistamines penetrate readily into the brain to cause sedation, drowsiness, fatigue and impaired concentration and memory causing detrimental effects on learning and examination performance in children and on impairment of the ability of adults to work and drive.  Their use should be discouraged.  The newer second-generation H1-antihistamines are safer, cause less sedation and are more efficacious.  Three drugs widely used for symptomatic relief in urticaria, desloratadine, levocetirizine and fexofenadine are highlighted in this review.  Of these levocetirizine and fexofenadine are the most potent in humans in vivo.  However, levocetirizine may cause somnolence in susceptible individuals, whereas fexofenadine has a relatively short duration of action and may be required to be given twice daily for all round daily protection.  Although desloratadine is less potent, it has the advantages of rarely causing somnolence and having a long duration of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkA18dqept1EH3Rlp_k91zfW6udTcc2ebcdGUUtCO52bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snotl2hsA%253D%253D&md5=867adc1094106d91708347063af8a9d9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.4103%2F0019-5154.110832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0019-5154.110832%26sid%3Dliteratum%253Aachs%26aulast%3DChurch%26aufirst%3DM.%2BK.%26aulast%3DChurch%26aufirst%3DD.%2BS.%26atitle%3DPharmacology%2520of%2520antihistamines%26jtitle%3DIndian%2520J.%2520Dermatol.%26date%3D2013%26volume%3D58%26spage%3D219%26epage%3D224%26doi%3D10.4103%2F0019-5154.110832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttmann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">1627</span>– <span class="NLM_lpage">1641</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01285.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1111%2Fj.1476-5381.2011.01285.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=22022805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2gu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1627-1641&author=R.+J.+Slackauthor=L.+J.+Russellauthor=D.+A.+Hallauthor=M.+A.+Luttmannauthor=A.+J.+Fordauthor=K.+A.+Saundersauthor=S.+T.+Hodgsonauthor=H.+E.+Connorauthor=C.+Browningauthor=K.+L.+Clark&title=Pharmacological+characterization+of+GSK1004723%2C+a+novel%2C+long-acting+antagonist+at+histamine+H1+and+H3+receptors&doi=10.1111%2Fj.1476-5381.2011.01285.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors</span></div><div class="casAuthors">Slack, R. J.; Russell, L. J.; Hall, D. A.; Luttmann, M. A.; Ford, A. J.; Saunders, K. A.; Hodgson, S. T.; Connor, H. E.; Browning, C.; Clark, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1627-1641</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Preclin. pharmacol. characterization of GSK1004723, a novel, dual histamine H1 and H3 receptor antagonist.  Exptl. Approach GSK1004723 was characterized in vitro and in vivo using methods that included radioligand binding, intracellular calcium mobilization, cAMP prodn., GTPγS binding, superfused human bronchus and guinea pig whole body plethysmog.  Key Results In cell membranes over-expressing human recombinant H1 and H3 receptors, GSK1004723 displayed high affinity, competitive binding (H1 pKi = 10.2; H3 pKi = 10.6).  In addn., GSK1004723 demonstrated slow dissocn. from both receptors with a t1/2 of 1.2 and 1.5 h for H1 and H3 resp.  GSK1004723 specifically antagonized H1 receptor mediated increases in intracellular calcium and H3 receptor mediated increases in GTPγS binding.  The antagonism exerted was retained after cell washing, consistent with slow dissocn. from H1 and H3 receptors.  Duration of action was further evaluated using superfused human bronchus prepns.  GSK1004723 (100 nmol·L-1) reversed an established contractile response to histamine.  When GSK1004723 was removed from the perfusate, only 20% recovery of the histamine response was obsd. over 10 h.  Moreover, 21 h post-exposure to GSK1004723 there remained almost complete antagonism of responses to histamine.  In vivo pharmacol. was studied in conscious guinea pigs in which nasal congestion induced by intranasal histamine was measured indirectly (plethysmog.).  GSK1004723 (0.1 and 1 mg·mL-1 intranasal) antagonized the histamine-induced response with a duration of up to 72 h.  Conclusions and Implications GSK1004723 is a potent and selective histamine H1 and H3 receptor antagonist with a long duration of action and represents a potential novel therapy for allergic rhinitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpQi3cXynjQ7Vg90H21EOLACvtfcHk0lhccD6vYx4crg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2gu73M&md5=e4201bd03c09a79a423e8874cfb78926</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01285.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01285.x%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DRussell%26aufirst%3DL.%2BJ.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DSaunders%26aufirst%3DK.%2BA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DConnor%26aufirst%3DH.%2BE.%26aulast%3DBrowning%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DK.%2BL.%26atitle%3DPharmacological%2520characterization%2520of%2520GSK1004723%252C%2520a%2520novel%252C%2520long-acting%2520antagonist%2520at%2520histamine%2520H1%2520and%2520H3%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1627%26epage%3D1641%26doi%3D10.1111%2Fj.1476-5381.2011.01285.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of drug-receptor binding kinetics</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2Fj.drudis.2013.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=23454741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=667-673&author=A.+C.+Panauthor=D.+W.+Borhaniauthor=R.+O.+Drorauthor=D.+E.+Shaw&title=Molecular+determinants+of+drug-receptor+binding+kinetics&doi=10.1016%2Fj.drudis.2013.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of drug-receptor binding kinetics</span></div><div class="casAuthors">Pan, Albert C.; Borhani, David W.; Dror, Ron O.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">667-673</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  It is increasingly appreciated that the rates at which drugs assoc. with and dissoc. from receptors - the binding kinetics - directly impact drug efficacy and safety.  The mol. determinants of drug-receptor binding kinetics remain poorly understood, however, esp. when compared with the well-known factors that affect binding affinity.  The rational modulation of kinetics during lead optimization thus remains challenging.  We review some of the key factors thought to control drug-receptor binding kinetics at the mol. level - mol. size, conformational fluctuations, electrostatic interactions and hydrophobic effects - and discuss several possible approaches for the rational design of drugs with desired binding kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvEt3tx06Z7Vg90H21EOLACvtfcHk0lhccD6vYx4crg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyrtr0%253D&md5=df094bb86b1e280b9ddf5a90031b3f32</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DMolecular%2520determinants%2520of%2520drug-receptor%2520binding%2520kinetics%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D667%26epage%3D673%26doi%3D10.1016%2Fj.drudis.2013.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiechle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wex, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banholzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarosa, P.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8746</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/jm401219y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401219y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8746-8756&author=C.+S.+Tautermannauthor=T.+Kiechleauthor=D.+Seeligerauthor=S.+Diehlauthor=E.+Wexauthor=R.+Banholzerauthor=F.+Gantnerauthor=M.+P.+Pieperauthor=P.+Casarosa&title=Molecular+basis+for+the+long+duration+of+action+and+kinetic+selectivity+of+tiotropium+for+the+muscarinic+M3+receptor&doi=10.1021%2Fjm401219y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for the Long Duration of Action and Kinetic Selectivity of Tiotropium for the Muscarinic M3 Receptor</span></div><div class="casAuthors">Tautermann, Christofer S.; Kiechle, Tobias; Seeliger, Daniel; Diehl, Sonja; Wex, Eva; Banholzer, Rolf; Gantner, Florian; Pieper, Michael P.; Casarosa, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8746-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonizing the human M3 muscarinic receptor (hM3R) over a long time is a key feature of modern bronchodilating COPD drugs aiming at symptom relief.  The long duration of action of the antimuscarinic drug tiotropium and its kinetic subtype selectivity over hM2R are investigated by kinetic mapping of the binding site and the exit channel of hM3R.  Hence, dissocn. expts. have been performed with a set of mol. matched pairs of tiotropium on a large variety of mutated variants of hM3R.  The exceedingly long half-life of tiotropium (of more than 24 h) is attributed to interactions in the binding site; particularly a highly directed interaction of the ligands' hydroxy group with an asparagine (N5086.52) prevents rapid dissocn. via a snap-lock mechanism.  The kinetic selectivity over hM2R, however, is caused by differences in the electrostatics and in the flexibility of the extracellular vestibule.  Extensive mol. dynamics simulations (several microseconds) support exptl. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo95cclma8dobVg90H21EOLACvtfcHk0lgAUjMWt6jxLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF&md5=2dd0ce91408c70ba97cf99cdab16b8b2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm401219y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401219y%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DKiechle%26aufirst%3DT.%26aulast%3DSeeliger%26aufirst%3DD.%26aulast%3DDiehl%26aufirst%3DS.%26aulast%3DWex%26aufirst%3DE.%26aulast%3DBanholzer%26aufirst%3DR.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%2BP.%26aulast%3DCasarosa%26aufirst%3DP.%26atitle%3DMolecular%2520basis%2520for%2520the%2520long%2520duration%2520of%2520action%2520and%2520kinetic%2520selectivity%2520of%2520tiotropium%2520for%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8746%26epage%3D8756%26doi%3D10.1021%2Fjm401219y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1038%2Fsj.bjp.0706819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=16847442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2006&pages=927-937&author=M.+R.+Dowlingauthor=S.+J.+Charlton&title=Quantifying+the+association+and+dissociation+rates+of+unlabelled+antagonists+at+the+muscarinic+M3+receptor&doi=10.1038%2Fsj.bjp.0706819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor</span></div><div class="casAuthors">Dowling, Mark R.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Slow receptor dissocn. kinetics has been implicated in the long clin. duration of action of the muscarinic receptor antagonist tiotropium.  However, despite the potential benefits of new drugs with slow dissocn. kinetics, the rate parameters of new compds. are seldom measured due to tech. difficulties and financial implications assocd. with radiolabeling multiple ligands.  Here we describe the development and optimization of a medium throughput assay which is capable of measuring the kinetic parameters of novel, unlabeled compds.  Radioligand binding studies were performed with membranes derived from CHO cells recombinantly expressing the human M3 muscarinic receptor.  Initial characterization of the radioligand [3H]-NMS yielded on and off rates of 4.1±0.2×108 M-1 min-1 and 0.015±0.0005 min-1, resp.  The specific binding of [3H]-NMS was measured over time in the presence and absence of several concns. of unlabeled competitor compds.  These data were analyzed using a competition kinetic model to provide on and off rates for the unlabeled competitor.  Comparison of the kinetically derived Kd (koff/kon) with Ki values generated at equil. showed an excellent correlation (r2=0.99), providing good validation of the method.  The on and off rates were also used in theor. computer simulations to successfully predict the effect of incubation time on apparent IC50 values.  This study demonstrates that a medium-throughput competition kinetic binding assay can be used to det. accurate on and off rates of unlabeled compds., providing the opportunity to optimize for kinetic parameters early in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwZ8YOvAS0F7Vg90H21EOLACvtfcHk0lgAUjMWt6jxLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFWrurc%253D&md5=99194c7f2158c3706aa09c4ec83bfbb4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706819%26sid%3Dliteratum%253Aachs%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DQuantifying%2520the%2520association%2520and%2520dissociation%2520rates%2520of%2520unlabelled%2520antagonists%2520at%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D148%26spage%3D927%26epage%3D937%26doi%3D10.1038%2Fsj.bjp.0706819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0liTsR4vCM41bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.-Q.</span></span> <i>PAINS-Remover</i>, <span class="NLM_year">2019</span>. <a href="http://www.cbligand.org/PAINS/" class="extLink">www.cbligand.org/PAINS/</a> (accessed Mar 10, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.-Q.+Xie&title=PAINS-Remover"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DX.-Q.%26jtitle%3DPAINS-Remover%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.-C.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0liTsR4vCM41bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-C.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Optimizing fragment and scaffold docking by use of molecular interaction fingerprints</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1021/ci600342e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci600342e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12iurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=195-207&author=G.+Marcouauthor=D.+Rognan&title=Optimizing+fragment+and+scaffold+docking+by+use+of+molecular+interaction+fingerprints&doi=10.1021%2Fci600342e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints</span></div><div class="casAuthors">Marcou, Gilles; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-207</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein-ligand interaction fingerprints have been used to postprocess docking poses of three ligand data sets: a set of 40 low-mol.-wt. compds. from the Protein Data Bank, a collection of 40 scaffolds from pharmaceutically relevant protein ligands, and a database of 19 scaffolds extd. from true cdk2 inhibitors seeded in 2230 scaffold decoys.  Four popular docking tools (FlexX, Glide, Gold, and Surflex) were used to generate poses for ligands of the three data sets.  In all cases, scoring by the similarity of interaction fingerprints to a given ref. was statistically superior to conventional scoring functions in posing low-mol.-wt. fragments, predicting protein-bound scaffold coordinates according to the known binding mode of related ligands, and screening a scaffold library to enrich a hit list in true cdk2-targeted scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHLbVKxK-BfLVg90H21EOLACvtfcHk0lgHGha-a6wYZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12iurzL&md5=0c9137a39d40fbcc83546aec17b595ba</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fci600342e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600342e%26sid%3Dliteratum%253Aachs%26aulast%3DMarcou%26aufirst%3DG.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DOptimizing%2520fragment%2520and%2520scaffold%2520docking%2520by%2520use%2520of%2520molecular%2520interaction%2520fingerprints%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D195%26epage%3D207%26doi%3D10.1021%2Fci600342e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RZE','PDB','3RZE'); return false;">PDB: 3RZE</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00447">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_54756"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00447">10.1021/acs.jmedchem.9b00447</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Characterization of the kinetics of binding and functional inhibition for H<sub>1</sub>R antagonists (Table S1); correlations between key physicochemical properties of rupatadine analogues (<b>1</b>–<b>24</b>) vs the respective p<i>K</i><sub>i</sub> and KRI values at the H<sub>1</sub>R (Figure S1); physicochemical properties of <b>1</b>–2<b>4</b> (Table S2); docked binding poses of <b>1</b>–<b>24</b> in the H<sub>1</sub>R binding pocket (Figures S2 and S3); and <sup>1</sup>H NMR and <sup>13</sup>C NMR spectroscopy data as well as high-resolution mass spectroscopy and LC–MS chromatograms (Figures S4–S69) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biochemical data of <b>1</b>–<b>24</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_001.pdf">jm9b00447_si_001.pdf (6.49 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00447/suppl_file/jm9b00447_si_002.csv">jm9b00447_si_002.csv (2.23 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00447&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00447%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-14%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00447" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679978a6abc3d95a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
